Pharmaceutical Benefits Scheme (PBS) | Home · Web viewA 17988 Capsule 50mg 50 0.30 GM 116 – P...
Transcript of Pharmaceutical Benefits Scheme (PBS) | Home · Web viewA 17988 Capsule 50mg 50 0.30 GM 116 – P...
35
TABLE 1
2007 COMMUNITY PRESCRIPTION NUMBERS, TOGETHER WITH
GOVERNMENT AND PATIENT COSTS FOR PBS–LISTED DRUGS
Table 1 includes an estimate of community prescription numbers for the 2007 calendar year, costs (government and patient contribution) for the items with a four digit PBS/RPBS code, together with the defined daily dose (DDD) where assigned. There is no cost information available for items with a five digit Amfac drug code. Table 1 exclude the presentation of information on any item with an estimated community use of less than 110 prescriptions in 2007.
The prescription items are arranged by ATC code on generic name, and by form and strength using either the PBS drug code (4 digit plus alpha) or, for non–PBS items, the Amfac drug code (5 digit). Note that in this edition, “Item type” has been added to distinguish between PBS drug code and non–PBS drug code, for instance, P refers to PBS drug code and A refers to Amfac drug code.
An index by 2nd level of the ATC classification follows:
AlimentAry trAct And metAbolism PAge no
A01 STOMATOLOGICAL PREPARATIONS 39
A02 DRUGS FOR ACID RELATED DISORDERS 40
A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 43
A04 ANTIEMETICS AND ANTINAUSEANTS 45
A05 BILE AND LIVER THERAPY 46
A06 LAXATIVES 47
A07 ANTIDIARRHOEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVES 49
A08 ANTIOBESITY PREPARATIONS, EXCLUDING DIET PRODUCTS 51
A09 DIGESTIVES, INCLUDING ENZYMES 52
A10 ANTIDIABETIC THERAPY 53
A11 VITAMINS 56
36
A12 MINERAL SUPPLEMENTS 57
A14 ANABOLIC AGENTS FOR SYSTEMIC USE 58
blood And blood forming orgAns 59
B01 ANTITHROMBOTIC AGENTS 59
B02 ANTIHAEMORRHAGICS 61
B03 ANTIANAEMIC PREPARATIONS 62
B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS 64
B06 OTHER HAEMATOLOGICAL AGENTS 65
cArdiovAsculAr system
C01 CARDIAC THERAPY 66
C02 ANTIHYPERTENSIVES 68
C03 DIURETICS 69
C04 PERIPHERAL VASODILATORS 71
C05 VASOPROTECTIVES 72
C07 BETA BLOCKING AGENTS 73
C08 CALCIUM CHANNEL BLOCKERS 74
C09 AGENTS ACTING ON THE RENIN–ANGIOTENSIN SYSTEM 76
C10 LIPID MODIFYING AGENTS 80
dermAtologicAls
D01 ANTIFUNGALS FOR DERMATOLOGICAL USE 82
D02 EMOLLIENTS AND PROTECTIVES 84
D03
D04
D05
PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS
ANTIPRURITICS, INCLUDING ANTIHISTAMINES, ANAESTHETICS ETC
86
85
87
D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE 88
D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS 89
D08 ANTISEPTICS AND DISINFECTANTS 91
D09 MEDICATED DRESSINGS 92
D10 ANTI–ACNE PREPARATIONS 93
D11 OTHER DERMATOLOGICAL PREPARATIONS 94
37
genitourinAry system And sex hormones
G01 GYNAECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS 95
G02 OTHER GYNAECOLOGICALS 96
G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 97
G04 UROLOGICALS 103
systemic hormonAl PrePArAtions, excluding sex hormones
H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES 105
H02 CORTICOSTEROIDS FOR SYSTEMIC USE 106
H03 THYROID THERAPY 107
H04 PANCREATIC HORMONES 108
H05 CALCIUM HOMEOSTASIS 109
generAl Antiinfectives for systemic use
J01 ANTIBACTERIALS FOR SYSTEMIC USE 110
J02 ANTIMYCOTICS FOR SYSTEMIC USE 118
J04 ANTIMYCOBACTERIALS 119
J05 ANTIVIRALS FOR SYSTEMIC USE 120
J07 VACCINES 122
AntineoPlAstic And immuno–modulAting Agents
L01 ANTINEOPLASTIC AGENTS 125
L02 ENDOCRINE THERAPY 131
L03 IMMUNOSTIMULANTS 133
L04 IMMUNO–SUPPRESSIVE AGENTS 134
musculo–skeletAl system
M01 ANTI–INFLAMMATORY AND ANTI–RHEUMATIC PRODUCTS 137
M02 TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN 141
M03 MUSCLE RELAXANTS 142
M04 ANTI–GOUT PREPARATIONS 143
M05 DRUGS FOR TREATMENT OF BONE DISEASES 144
38
nervous system
N01 ANAESTHETICS 145
N02 ANALGESICS 146
N03 ANTI–EPILEPTICS 153
N04 ANTI–PARKINSON DRUGS 156
N05 PSYCHOLEPTICS 158
N06 PSYCHOANALEPTICS 164
N07 OTHER NERVOUS SYSTEM DRUGS 169
Anti–PArAsitic Products, insecticides And rePellents
P01 ANTI–PROTOZOALS 171
P02 ANTHELMINTICS 172
P03 ECTOPARASITICIDES, INCLUDING SCABICIDES, INSECTICIDES AND REPELLENTS 173
resPirAtory system
R01 NASAL PREPARATIONS 174
R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 177
R05 COUGH AND COLD PREPARATIONS 180
R06 ANTI–HISTAMINES FOR SYSTEMIC USE 182
sensory orgAns
S01 OPHTHALMOLOGICALS 185
S02 OTOLOGICALS 190
S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS 191
vArious
V01 ALLERGENS 192
V03 ALL OTHER THERAPEUTIC PRODUCTS 193
P 2931G Lozenge 10mg 40.00
MG 148,100
1,369,716P 3306B Lozenge 10mg 40.0
0MG 4,48
040,395A01AB0
3CHLORHEXIDINEP 4161B Mouth wash 2mg per mL (0.2%) 250mL
30.00
MG 3,900
45,492A01AB0
9MICONAZOLEA 13832 Oral gel 20mg per mL (2%) 20g
0.20
GM 6,443
–A 14054 Oral gel 40mg per mL (2%) 40g
0.20
GM 4,048
–A01AB11
NYSTATINP 3033P Oral suspension 100,000 units per mL 24mL
1500.00
TE 130,704
1,265,924P 3343Y Oral suspension
100,000 units per mL 24mL1500.00
TE 776 7,366A01AB1
1POVIDINE IODINEA 10359 Gargle 1 – – 168 –
A01AB11
THYMOLA 11202 Mouth wash red 200m – – 134 –
39
A
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ALIMENTARY TRACT AND METABOLISMSTOMATOLOGICAL PREPARATIONSSTOMATOLOGICAL PREPARATIONSANTIINFECTIVES FOR LOCAL ORAL TREATMENT
A01AB04 AMPHOTERICIN
CORTICOSTEROIDS FOR LOCAL ORAL TREATMENTA01AC01 TRIAMCINOLONE ACETONIDE with PECTIN
A 11075 Paste 1% 5gm – – 22,884 –OTHER AGENTS FOR LOCAL ORAL TREATMENT
A01AD02 BENZYDAMINE HYDROCHLORIDE
P 1121B Mouth and throat rinse 22.5mg per 15mL 500mL
– – 5,659 104,336P 5385K Mouth and throat rinse
22.5mg per 15mL 500mL– – 153 3,3
27A01AD02
BENZYDAMINE with CHLORHEXIDINEA 14359 Solution 200mL – – 153 –
A01AD11
CHOLINE SALICYLATE with CETALKONIUM CHLORIDEA 12855 Gel 10g 1
– – 2,135 –A01AD11
SALIVA SUBSTITUTEP 4568K Solution 25mL – – 510 4,5
12P 4569L Solution 100mL – – 558 7,180A01AD1
1VARIOUSP 5334R Spray 10mg per mL 100mL – – 253 3,1
68
40
P 1157X
Tablet 200mg 0.80
GM 3,615
82,359P 115
8YTablet 400mg 0.8
0GM 29,2
14674,231P 115 Tablet 800mg 0.8 GM 2,24 53,3
FAMOTIDINEP 2487X Tablet 20mg 40.0
0MG 74,7
591,444,532P 2488Y Tablet 40mg 40.0 MG 76,0 1,571,
NIZATIDINEP 1504E Capsules 300mg 30 0.3
0GM 40,7
89995,491P 1505F Capsules 150mg 30 0.3 GM 77,9 1,815,
RANITIDINE HYDROCHLORIDEP 193
7YEffervescent tablet 150mg (base)
0.30
GM 49,790
988,285P 197
7CTablet 300mg (base) 0.3
0GM 275,1
555,662,047P 197
8DTablet 150mg (base) 0.3
0GM 814,4
5316,149,339P 816
2NSyrup 150mg (base) per 10mL 300mL
0.30
GM 24,145
438,946P 890
3NEffervescent tablet 150mg (base)
0.30
GM 1,525
38,699P 890
5QSyrup 150mg (base) per 10mL 300mL
0.30
GM 379
8,934
A
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ALIMENTARY TRACT AND METABOLISMDRUGS FOR ACID RELATED DISORDERSANTACIDSALUMINIUM COMPOUNDS
A02AB01 ALUMINIUM HYDROXIDEA 10038 Tablet 600mg 100 – – 1,143 –
CALCIUM COMPOUNDSA02AC10 CALCIUM CARBONATE with GLYCINE
P 4055K Tablet 420mg–180mg – – 1,006 21,071COMBS.AND COMPLEXES OF ALUMINIUM,CALCIUM AND MAGNESIUM COMPOUNDS
A02AD ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDEP 215
7MOral suspension 200mg–200mg per 5mL 500mL
– – 83,869
1,076,013P 257
6NTablet 200mg–200mg – – 43,56
6556,731P 411
8ROral suspension 400mg–400mg–30mg per 5mL
– – 2,996
58,160A02AD ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE with
SIMETHICONEA 11196 Mixture 750mL 1 – – 152 –P 4453J Tablet 400mg–400mg–40mg 200
– – 2,465
106,777A02AD ALUMINIUM HYDROXIDE with MAGNESIUM
TRISILICATE and MAGNESIUM HYDROXIDEP 2159P Oral suspension 250mg–120mg–120mg per 5mL
– – 24,704
316,888DRUGS FOR PEPTIC ULCER AND GORD
H2–RECEPTOR ANTAGONISTSA02BA01 CIMETIDINE
A02BA03
A02BA04
A02BA02
41
P 8600P
Tablet 20mg (enteric coated) 30
30.00
MG
2,751,351
102,562,218P 860
1QTablet 40mg (enteric coated) 30
30.00
MG
1,995,868
119,132,811P 888 Tablet 20mg (enteric 30.0 M 114,9 4,277,
LANSOPRAZOLEP 224
0XCapsule 30mg 30.0
0MG
28,943
1,070,324P 224
1YCapsule 30mg 30.0
0MG
768,091
31,109,773P 819
8LCapsule 15mg 30.0
0MG
20,743
489,615P 852
8WSachet for oral suspension 30mg
30.00
MG
3,111
113,538P 852
9XSachet for oral suspension 30mg
30.00
MG
18,301
705,371P 973 Sachet for oral suspension 30.0 M 89 48,9
OMEPRAZOLEP 132
6TCapsule 20mg 20.0
0MG
21,250
654,063P 132
7WCapsule 20mg 20.0
0MG
220,332
8,701,389P 833
1LTablet 20mg (as magnesium salt) 30
20.00
MG
87,548
2,986,501P 833
2MTablet 10mg (as magnesium salt) 30
20.00
MG
70,637
1,904,341P 833
3NTablet 20mg (as magnesium salt) 30
20.00
MG
2,693,250
107,007,920P 910
9KTablet 20mg (as magnesium salt) 30
20.00
MG
25,893
896,158P 911 Tablet 20mg (as magnesium 20.0 M 735,2 26,466
PANTOPRAZOLEP 800
7KTablet (enteric coated) equivalent to 40mg
40.00
MG
302,653
11,440,813P 800
8LTablet (enteric coated) equivalent to 40mg
40.00
MG
2,526,686
102,221,950P 839 Tablet (enteric coated) 40.0 M 288,3 6,333,
RABEPRAZOLEP 850
7RTablet 10mg 30 20.0
0MG
49,981
1,875,752P 850
8TTablet 20mg 30 20.0
0MG
1,630,226
65,472,016P 850
9WTablet 20mg 30 20.0
0MG
223,977
8,314,984
A
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ALIMENTARY TRACT AND METABOLISMDRUGS FOR ACID RELATED DISORDERSDRUGS FOR PEPTIC ULCER AND GORDPROSTAGLANDINSA02BB01 MISOPROSTOL
P 1648R Tablet 200ug 0.80 MG 2,229 112,980PROTON PUMP INHIBITORS
A02BC05 ESOMEPRAZOLE
A02BC03
A02BC01
A02BC02
A02BC04
COMBINATIONS FOR ERADICATION OF HELICOBACTER PYLORIA02BD06 ESOMEPRAZOLE AMOXICILAN and CLARITHROMYCIN
P 8738X Pack 14 tabs(ent coated)equiv 20mg esomeprazole – –70,225 6,695,250
A02BD05 OMEPRAZOLE and CLARITHROMYCIN and AMOXYCILLINP 8272J Pack 14 caps 20mg,14 tabs 500mg,28 caps 500mg – – 13,592 1,295,825
OTHER DRUGS FOR PEPTIC ULCER AND GORDA02BX13 SODIUM ALGINATE with CALCIUM CARBONATE and SODIUM BICARBONATE
P 2014B Oral liquid 1gm–320mg in 20mL 500mL – –127,999 1,684,860
42
A02BX02 SUCRALFATEP 2055E Tablet 1g 4.00 GM 14,343 326,425
43
A
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ALIMENTARY TRACT AND METABOLISMDRUGS FOR ACID RELATED DISORDERSANTIFLATULENTSANTIFLATULENTS
A02DA PEPPERMINT OILA 13371 Capsule 0.2mL 21 – – 385 –
A 12730
Tablet 135mg 30 0.30 GM 24,493
–A 141
30Tablet 135mg 30 0.30 GM 7,26
6–
P 4328T
Tablet 135mg 0.30 GM 68,514
1,952,662
A 17465 Tablet 6mg 30 – – 647 –A 17466 Tablet 6mg 60 – – 984 –
A 12939
Tablet 10mg 100 60.00
MG 15,234
–A 152
87Tablet 10mg 60.0
0MG 21,42
8–
P 4279F
Injection 20mg in 1mL 60.00
MG 3,634 115,193P 531
7WInjection 20mg in 1mL 60.0
0MG 1,442 87,7
21P 5318X
Injection 20mg in 1mL 60.00
MG 734 112,692
44
A
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ALIMENTARY TRACT AND METABOLISMDRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERSDRUGS FOR FUNCTIONAL BOWEL DISORDERSSYNT ANTICHOLIN,ESTERS WITH TERTIARY AMINO GROUP
A03AA04 MEBEVERINE HYDROCHLORIDE
SYNT ANTICHOLINERGICS,ESTERS,QUATER AMMONIUM COMPOUNDA03AB05 PROPANTHELINE
P 1953T Tablet 15mg 60.00MG 27,370 640,925DRUGS ACTING ON SEROTONIN RECEPTORS
A03AE02 TEGASEROD
OTHER DRUGS FOR FUNCTIONAL BOWEL DISORDERSA03AX13 SIMETHICONE
A 13445 Capsule 100mg 30 – – 266 –BELLADONNA AND DERIVATIVES PLAINBELLADONNA ALKALOIDS TERTIARY AMINES
A03BA01 ATROPINEP 1089H Injection 600ug in 1mL 1.50 MG 2,387 40,349P 3453R Injection 600ug in 1mL 1.50 MG 11,035 167,971
A03BA04 HYOSCYAMINE SULPHATE with ATROPINE SULPHATE with HYOSCINE HYDROBROMIDEA 10631 Mixture 100mL 1 1.00 MG 561 –A 10632 Drop 30mL 1 1.00 MG 319 –
A03BA KAOLIN with PECTIN with HYOSCYAMINE SULPHATE with ATROPINE SULPHATE with HYOSCINE HYDROBROMIDEA 10629 Suspension 200mL 1 – – 255 –
BELLADONNA ALKALOIDS SEMISYNT QUATER AMMONIUM COMPOUNDA03BB01 BUTYLSCOPOLAMINE
A03BB HYOSCINE HYDROBROMIDEA 10972 Ampoule 400ug 5 – – 1,662 –
DOMPERIDONEA 11309 Tablet 10mg 100 30.0
0MG 14,75
0–
P 1347X Tablet 10mg 30.0 MG 259,0 2,875,METOCLOPRAMIDE HYDROCHLORIDEA 111
38Tablet 10mg 100 30.0
0MG 5,76
3–
P 1205K
Syrup 5mg per 5mL 100mL
30.00
MG 223 1,824P 120
6LInjection 10mg in 2mL 30.0
0MG 37,78
5538,662P 120
7MTablet 10mg 30.0
0MG 768,6
725,526,064A 200
15Syrup 5mg per 5mL 100mL
30.00
MG 177 –P 347
6YInjection 10mg in 2mL 30.0
0MG 30,61
0353,645P 515
1DTablet 10mg 30.0
0MG 636 4,3
01
45
A
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ALIMENTARY TRACT AND METABOLISMDRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERSPROPULSIV
ES PROPULSIV
ES A03FA03
A03FA01
DOLASETRON MESYLATEP 592
3RTablet 200mg 0.2
0GM 387 16,3
26P 5924T
I.V. injection 100mg in 5mL 0.10
GM 938 17,390P 819
1DTablet 200mg 0.2
0GM 16,57
4927,569P 819 I.V. injection 100mg in 5mL 0.1 GM 7,40 255,
GRANISETRONP 589
8KTablet 2mg (base) 2 2.0
0MG 6,25
7320,746P 589
9LConcentrated injection 3mg (base) in 3mL
3.00
MG 8,554
227,662P 872
8JTablet 2mg (base) 2 2.0
0MG 22,17
21,476,435P 872
9KConcentrated injection 3mg (base) in 3mL
3.00
MG 25,685
1,072,617P 887 Tablet 2mg (base) 5 2.0 MG 163 36,6
ONDANSETRONP 159
4XTablet 4mg 16.0
0MG 2,59
4345,118P 159
5YTablet 8mg 16.0
0MG 3,23
6634,563P 159
6BI.V.injection 4mg/2mL 16.0
0MG 152 8,0
33P 1597C
I.V.injection 8mg in 4mL 16.00
MG 114 28,878A 160
47Suppository 16mg 5 – – 157 –
P 5967C
Tablet 4mg 16.00
MG 367 14,247P 596
8DTablet 8mg 16.0
0MG 10,27
4548,588P 596
9EWafer 4mg 4 16.0
0MG 117 6,2
15P 5970F
Wafer 8mg 4 16.00
MG 1,287
68,787P 597
2HI.V. injection 8mg in 4mL 16.0
0MG 9,02
7247,642P 822
4WTablet 4mg 16.0
0MG 10,38
9535,662P 822
5XTablet 8mg 16.0
0MG 47,04
63,329,273P 822
6YI.V. injection 4mg in 2mL 16.0
0MG 2,07
162,462P 822
7BI.V. injection 8mg in 4mL 16.0
0MG 33,07
21,591,925P 841
0PWafer 4mg 4 16.0
0MG 13,13
8595,549P 841
1QWafer 8mg 4 16.0
0MG 14,32
51,143,735P 841
2RWafer 4mg 10 16.0
0MG 4,07
9511,448P 841 Wafer 8mg 10 16.0 MG 3,66 739,
TROPISETRONP 274
5LCapsule 5mg (base) 5.0
0MG 30,07
71,851,914P 274
6MI.V. injection 5mg/5mL 5.0
0MG 17,80
9627,642P 598
6CCapsule 5mg (base) 5.0
0MG 7,48
9288,256P 598
7DI.V. injection 5mg/5mL 5.0
0MG 8,52
2170,589
46
A
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ALIMENTARY TRACT AND METABOLISMANTIEMETICS AND ANTINAUSEANTSANTIEMETICS AND ANTINAUSEANTSSEROTONIN (5HT3) ANTAGONISTS
A04AA04
A04AA02
A04AA01
A04AA03
VARIOUS ANTIEMETICSA04AD12 APREPITANT
P 5888X Pack 1 cap 125mg and 2 cap 80mg
95.00
MG 5,643
677,520P 8808N Pack 1 cap 125mg
and 2 cap 80mg95.00
MG 19,657
2,895,955
47
A
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ALIMENTARY TRACT AND METABOLISMBILE AND LIVER THERAPYBILE THERAPYBILE ACID PREPARATIONS
A05AA02 URSODEOXYCHOLIC ACID
P 8448P Capsule 250mg 100 0.75 GM 25,265 6,492,593
DOCUSATE SODIUMA 16099 Tablet 120mg 100 0.1
5GM 8,431 –
P 4200C Tablet 50mg 0.1 GM 8,329 94,2LIQUID PARAFFINA 10107 Oral suspension
vanilla 200mL15.00
GM 579 –A 10108 Oral suspension
vanilla 500mL15.00
GM 5,248 –
P 1258F
Suppositories 10mg 12
10.00
MG 1,483
25,563P 125
9GTablet 5mg 10.0
0MG 33,34
5440,173P 126
0HSuppositories 10mg 10
10.00
MG 42,574
840,474A 126
69Tablet 5mg 50 10.0
0MG 1,42
6–
P 3250C
Suppositories 10mg 10
10.00
MG 738 32,215P 530 Suppositories 10mg 10.0 MG 219 5,1
DOCUSATE SODIUM with SENNAA 12753 Tablet 30 – – 5,79
4–
P 4198Y Tablet 50mg–8mg – – 202,0 2,614,SENNA STANDARDISEDA 11880 Granules 150g 1 – – 3,17
6–
P 4455L Tablet 7.5mg – – 12,461
140,366
A 11156
Powder 500g 1 7.00
GM 793 –A 112
73Powder 500g 1 7.0
0GM 517 –
P 4285M
Sachets 3.5g 30 7.00
GM 3,524
56,867P 441
9NOral powder(orange–flavour sugar free)315g
7.00
GM 26,901
548,422P 442 Oral powder (non–flavoured) 7.0 GM 23,41 475,
STERCULIA with FRANGULA BARKP 110
4DGranules 620mg–80mg per g (62%–8) 500g
– – 84,647
1,958,743A 130
98Granules 200g 1 – – 288 –
P 3275J
Granules 620mg–80mg per g (62%–8) 500g
– – 783 25,712P 455 Granules 620mg–80mg per g – – 11,04 255,
STERCULIA, COMBINATIONSP 5322D Granules 620mg–80mg
per g (62%–8%) 500g– – 475 16,5
58P 5324F Granules 620mg–80mg per g (62%–8%) 500g
– – 120 4,571
48
A
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ALIMENTARY TRACT AND METABOLISMLAXATIVESLAXATIVESSOFTENERS EMOLLIENTS
A06AA02
A06AA01
CONTACT LAXATIVESA06AB02 BISACODYL
A06AB56
A06AB06
A06AB58 SODIUM PICOSULFATE with MAGNESIUM CARBONATEA 18511 Sachet 20g 2 – – 222 –
BULK PRODUCERSA06AC51 ISPAGHULA COMBINATIONS
P 4416K Oral Powder 440g – – 1,845 36,110A06AC01 PSYLLIUM HYDROPHILIC MUCILLOID
A06AC53
A06AC53
P 3064G
Mixture 3.34g per 5mL 500mL
6.70
GM 358,801
5,481,231P 538
7MMixture 3.34g per 5mL 500mL 1
6.70
GM 9,044
207,087P 538
8NMixture 3.34g per 5mL 500mL 1
6.70
GM 1,070
40,091
P 2091C
Enemas 3.125g–450mg–45mg in 5mL 12
– – 42,258
1,418,403P 327
4HEnemas 3.125g–450mg–45mg in 5mL 12
– – 3,812
201,697P 446
2WEnemas 3.125g–450mg–45mg in 5mL 4
– – 2,702
29,348P 533
1NEnemas 3.125g–450mg–45mg in 5mL 12
– – 976 48,698P 533
2PEnemas 3.125g–450mg–45mg in 5mL 12
– – 234 16,554
49
A
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ALIMENTARY TRACT AND METABOLISMLAXATIVESLAXATIVESOSMOTICALLY ACTING LAXATIVES
A06AD11 LACTULOSE
A06AD11 LACTULOSE with GALACTOSE with LACTOSE with EPILACTOSEA 10693 Syrup 200mL 1 6.70 GM 1,137 –
A06AD15 MACROGOLP 5389P Sachets powder 13.125g with electrolytes 30 10.00 GM 8,137
254,218P 5390Q Sachets powder 13.125g with electrolytes 30 10.00GM 1,595
56,500P 8612G Sachets powder 13.125g with electrolytes 30 10.00 GM
226,793 5,196,402A06AD SORBITOL
A 14787 Liquid 70% 500mL – – 10,258 –ENEMAS
A06AG02 BISACODYLP 1263L Enemas 10mg in 5mL 25 – – 9,731 368,774P 3263R Enemas 10mg in 5mL 25 – – 3,215 178,531P 5302C Enemas 10mg in 5mL 25 10.00MG 619 38,031
A06AG20 COMBINATION (SORBITOL/SODIUM CITRATE/SODIUM LAVRYL SULFOACETATE)
A06AG01 SODIUM PHOSPHATEA 15629 Laxative Mixt 3.3G/5mL – – 4,923 –
OTHER LAXATIVESA06AX01 GLYCEROL
P 2555L
Suppositories 700mg (for infants) 12
– – 483 6,658P 255
6MSuppositories 1.g (for children) 12
– – 628 9,404P 255
7NSuppositories 2.8g (for adults) 12
– – 8,082 123,113P 326
7YSuppositories 2.8g (for adults) 12
– – 223 6,110P 424
6LSuppositories 2.8g (for adults) 12
– – 407 6,062
NEOMYCIN SULPHATEP 232 Tablet 500mg 5.00 GM 740 16,4NYSTATINP 169
6GTablet 500,000 units 1500.
00TE 20,19
0379,826P 169
9KCapsule 500,000 units
1500.00
TE 33,467
691,590
A 11123
Tablet 2.5mg–25ug 15.00 MG 1,400
–A 162
60Tablet 2.5mg–25ug 15.00 MG 9,96
6–
P 250 Tablet 2.5mg–25ug 15.00 MG 287,3 2,407,LOPERAMIDE HYDROCHLORIDEP 1571Q Capsule 2mg 10.00 MG 285,8
523,635,516A 16133 Tablet 2mg 8 10.00 MG 160 –
50
A
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ALIMENTARY TRACT AND METABOLISMANTIDIARR. INTEST. ANTIINFL./ANTIINFECT. AGENTSINTESTINAL ANTIINFECTIVESANTIBIOTICSA07AA01
A07AA02
ELECTROLYTES WITH CARBOHYDRATESORAL REHYDRATION SALT FORMULATIONS
A07CA ELECTROLYTE REPLACEMENT (ORAL)P 3196F Sachets of powder for oral solution 4.87g 10 – – 26,445
361,059ANTIPROPULSIVESANTIPROPULSIVES
A07DA01 DIPHENOXYLATE HYDROCHLORIDE with ATROPINE SULPHATE
A07DA03
INTESTINAL ANTIINFLAMMATORY AGENTSCORTICOSTEROIDS FOR LOCAL USE
A07EA02 HYDROCORTISONE ACETATEP 1502C Rectal foam 125mg per applicator (10%) aerosol – –
14,516 522,260A07EA01 PREDNISOLONE SODIUM PHOSPHATE
P 1920C Retention enema equivalent to 20mg prednisolone
– – 6,423 831,888P 2554K Suppositories equivalent to
5mg prednisolone 10– – 6,894 299,
177
50
MESALAZINEP 161
1TTablet 250mg 1.5
0GM 73,2
6012,024,940P
P2214M2234N
Tablet 500mg (prolonged release)Oral granules(prolonged
1.50
1.5
GM
GM
581
25
113,037
71,5P 2287J
Oral granules(prolonged release)2g per sachet 60
1.50
GM 725
228,987P 859
8MOral granules 500mg per sachet 100
1.50
GM 3,126
540,855P 859
9NOral granules 1 mg per sachet 100
1.50
GM 19,723
5,822,132P 861
6LEnemas 2g in 60mL 7 1.5
0GM 2,02
1675,816P 861
7MEnemas 4g in 60mL 7 1.5
0GM 5,96
82,641,466P 873
1MTablet 500mg (enteric coated)
1.50
GM 39,636
9,596,317P 875
2PSuppositories 1gm 28 1.5
0GM 5,89
9745,938P 875
3QEnemas 1g in 100mL 7 1.5
0GM 52
5173,014P 876 Rectal foam 1g per app, 14 1.5 GM 1,19 390,
OLSALAZINE SODIUMP 1728Y Capsule 250mg 1.0
0GM 6,83
7599,476P 8086N Capsule 500mg 1.0 GM 15,7 2,153,
SULPHASALAZINEP 2093E Tablet 500mg 2.0
0GM 24,8
731,288,742P 2096H Tablet 500mg (enteric
coated)2.00
GM 198,769
11,312,226
A
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ALIMENTARY TRACT AND METABOLISMANTIDIARR. INTEST. ANTIINFL./ANTIINFECT. AGENTSINTESTINAL ANTIINFLAMMATORY AGENTSAMINOSALICYLIC ACID AND SIMILAR AGENTS
A07EC04 BALSALAZIDEP 8845M Capsule 750mg 6.75 GM 12,788 1,878,207
A07EC02
A07EC03
A07EC01
51
A 10636
Capsule 15mg 30 15.00 MG 15,756 –A 106
37Capsule 30mg 30 15.00 MG 78,275 –
A 106 Capsule 40mg 30 15.00 MG 94,875 –SIBUTRAMINEA 17447 Capsule 10mg
3010.00 MG 54,500 –
A 17448 Capsule 15mg 30
10.00 MG 74,340 –
A
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ALIMENTARY TRACT AND METABOLISMANTIOBESITY PREPARATIONS EXCL DIET PRODUCTSANTIOBESITY PREPARATIONS EXCL DIET PRODUCTSCENTRALLY ACTING ANTIOBESITY PRODUCTS
A08AA01 PHENTERMINE
A08AA10
PERIPHERALLY ACTING ANTIOBESITY PRODUCTSA08AB01 ORLISTAT
A 18494 Capsule 120mg 84
0.36 GM 3,677
–P 4570M Capsule 120mg
840.36 GM 15,01
81,913,294
52
A
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ALIMENTARY TRACT AND METABOLISMDIGESTIVES INCL ENZYMESDIGESTIVES INCL ENZYMESENZYME PREPARATIONS
A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC)P 249
5HCapsule providing >10,000 BP units lipase activity
– – 8,580
1,484,176P 802
0DCapsule (containing enteric coated microspheres)
– – 13,387
2,228,326P 802
1ECapsule (containing enteric coated microspheres)
– – 27,362
4,454,383P 836
6HCapsule providing >25,000 BP units lipase activity
– – 2,003
288,100P 855
6HCapsule (containing enteric coated microspheres)
– – 11,421
1,302,437
A10AB02
INSULIN (BEEF)P 1713E Injection 100 units per mL 10mL
40.00
IE 611
83,343A10AB0
1INSULIN (HUMAN)P 1531N Injection 100 units per mL 10mL
40.00
IE 18,259
2,278,177P 1762R Injection 100 units per
mL 3mL 540.00
IE 29,822
6,391,129A10AB0
5INSULIN ASPARTP 8435Y Injection (human) 100 units per mL 3mL 5
40.00
IE 102,424
26,393,713P 8571D Injection (human) 100
units per mL 10mL 540.00
IE 10,647
1,660,047A10AB0
6INSULIN GLULISINEP 1921D Injection (human) 100 units per mL 3mL 5
40.00
IE 481
123,049A10AB0
4INSULIN LISPROP 8084L Injection 100 units per mL 10mL
40.00
IE 8,991
1,417,076P 8212F Injection 100 units per
mL 3mL 540.00
IE 31,060
8,125,953
P 1533Q Injection 100 units per mL 10mL
40.00
IE 31,223
4,124,096P 1761Q Injection 100 units
per mL 3mL 540.00
IE 76,025
16,592,407
P 1425B
Injection 100 units per mL (50 units–50 units)
40.00
IE 1,006
134,288P 142
6CInjection 100 units per ml (30 units–70 units)
40.00
IE 15,665
2,057,978P 176
3TInjection 100 units per mL (30 units–70 units)
40.00
IE 112,240
24,687,900A 201
58Injection 100 units per mL (20 units–80 units)
40.00
IE 292
–A 201
61Injection 100 units per ml 10ml 1
40.00
IE 1,074
–P 206
2MInjection 100 units per mL (50 units–50 units)
40.00
IE 6,047
1,328,811P 800
6JInjection 100 units per mL (20 units–80 units)
40.00
IE 3,518
778,031A10AD3
0INSULIN ASPART/PROTAMINE ASPARTP 8609D Injection (human analogue) 30/70 units per mL
IE 97,887
25,400,907A10AD0
4INSULIN LISPROP 8390N Injection (human analogue) 100 units per mL 3mL 5 40.00
IE
12,339
3,232,212P 8874C Inj (human analogue) 100
units(50/50)per mL 3mL 5 40.00IE
1,411
367,806
53
A
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ALIMENTARY TRACT AND METABOLISMANTIDIABETIC THERAPYINSULINS AND ANALOGUESINSULINS AND ANALOGUES FAST–ACTING
INSULINS AND ANALOGUES INTERMEDIATE–ACTINGA10AC02 INSULIN (BEEF)
P 1711C Injection 100 units per mL 10mL 40.00 IE 851 117,050A10AC01 INSULIN (HUMAN)
INSULINS AND ANALOGUES INTERMEDIATE ACTING COMBINED WITH FAST–ACTINGA10AD01 INSULIN (HUMAN)
INSULINS AND ANALOGUES LONG–ACTINGA10AE05 INSULIN DETEMIR
P 9040T Injection 100 units per mL 3mL 5 40.00 IE 21,4329,084,785
A10AE04 INSULIN GLARGINEA 18353 Injection 100 units
per mL 10mL40.00
IE 882
–P 9039R Injection 100 units
per mL 3mL 540.00
IE 103,721
43,355,035
P 1801T
Tablet 850mg 2.00
GM
447,230
6,385,443P 243
0XTablet 500mg 2.0
0GM
1,822,646
25,313,324P 860
7BTablet 1000mg 2.0
0GM
1,060,124
21,239,882P 888
4NTablet 500mg (extended release) 90
2.00
GM
507,471
6,620,060
A10BB01
GLIBENCLAMIDEP 2939Q Tablet 5mg 10.0
0MG
159,244
1,668,314A10BB0
9GLICLAZIDEP 2449X Tablet 80mg 0.1
6GM
588,647
8,481,041P 8535F Tablet 30mg
(modified release)0.16
GM
1,051,473
15,334,024A10BB1
2GLIMEPIRIDEP 8450R Tablet 1mg 30 2.0
0MG
81,611
711,160P 8451T Tablet 2mg 30 2.0
0MG
112,696
1,336,011P 8452W Tablet 4mg 30 2.0
0MG
279,657
4,455,183P 8533D Tablet 3mg 30 2.0
0MG
41,464
569,692A10BB0
7GLIPIZIDEP 2440K Tablet 5mg 100 10.0
0MG
90,855
995,663
P 9059T
Tablet Rosiglitazone/metformin
– – 10,221
674,812P 906
0WTablet Rosiglitazone/metformin2mg(base)/1000mg 56 – – 31,99
02,238,920P 906
1XTablet Rosiglitazone/metformin4mg(base)/500mg 56 – – 8,34
6796,725P 906
2YTablet Rosiglitazone/metformin4mg(base)/1000mg 56 – – 41,94 4,168,
METFORMIN and SULFONAMIDESP 881
0QTablet Metformin 500mg/glibenclamide 2.5mg, 90
– – 45,527
750,587P 881
1RTablet Metformin 500mg/glibenclamide 5mg, 90
– – 62,974
1,125,483P 883
8ETablet Metformin 250mg/glibenclamide 1.25, 90
– – 5,048
68,613
54
A
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ALIMENTARY TRACT AND METABOLISMANTIDIABETIC THERAPYORAL BLOOD GLUCOSE LOWERING DRUGSBIGUANIDES
A10BA02 METFORMIN HYDROCHLORIDE
SULFONAMIDES UREA DERIVATIVES
BIGUANIDES AND SULFONAMIDES IN COMBINATIONA10BD03 METFORMIN and ROSIGLITAZONE
A10BD02
ALPHA GLUCOSIDASE INHIBITORSA10BF01 ACARBOSE
P 8188Y Tablet 50mg 0.30 GM 29,137
849,772P 8189B Tablet 100mg 0.30 GM 27,60
71,106,952
P 8694N
Tablet 15mg (base) 28
30.00
MG 42,694
2,633,002P 869
5PTablet 30mg (base) 28
30.00
MG 105,401
9,582,649P 869 Tablet 30mg (base) 30.0 MG 57,9 6,708,
ROSIGLITAZONEP 8689H Tablet 4mg (base)
286.00 MG 255,7
7616,018,900P 8690JTablet 8mg (base) 28 6.00 MG 222,7
7820,221,238
55
A
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ALIMENTARY TRACT AND METABOLISMANTIDIABETIC THERAPYORAL BLOOD GLUCOSE LOWERING DRUGSTHIAZOLIDINEDIONES
A10BG03 PIOGLITAZONE HYDROCHLORIDE
A10BG02
OTHER BLOOD GLUCOSE LOWERING DRUGSA10BX02 REPAGLINIDE
A 16645
Tablet 0.5mg 90 6.00 MG 110
–A 166
46Tablet 1mg 90 6.00 MG 46
3–
A 16647
Tablet 2mg 90 6.00 MG 2,213 –
56
A
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ALIMENTARY TRACT AND METABOLISMVITAMINSMULTIVITAMINS COMBINATIONSMULTIVITAMINS WITH MINERALS
A11AA03 VITAMINSA 11955 Dispersible tablet
10– – 134 –
A 16530 Tablet 60 – – 391 –VITAMIN A AND D INCL COMBINATIONS OF THE T WOVITAMIN A PLAIN
A11CA01 VITAMIN AA 12182 Capsule 50 000 units 100 50.00 TE 556 –
VITAMIN D AND ANALOGUESA11CC04 CALCITRIOL
P 2502Q Capsule 0.25ug 1.00 UG 159,5408,671,042A11CC01 ERGOCALCIFEROL
A 16060 Capsule 25ug 60 – – 291,087 –VITAMIN B1,PLAIN AND IN COMB. WITH VITAMIN B6 AND B12THIAMINE (VITAMIN B1) PLAIN
A11DA01 THIAMINE HYDROCHLORIDEP 1070H Tablet 100mg 50.00 MG 14,10
5134,438P 4043T Tablet 100mg 50.00 MG 26,26
3249,596VITAMIN B–COMPLEX INCL COMBINATIONS
VITAMIN B–COMPLEX PLAINA11EA VITAMIN B GROUP COMPLEX
P 4493L Oral liquid 200mL – – 17,839 213,605VITAMIN B–COMPLEX WITH VITAMIN C
A11EB VITAMIN B with CA 14139 Tablet 90 – – 491 –
OTHER PLAIN VITAMIN PREPARATIONSOTHER PLAIN VITAMIN PREPARATIONS
A11HA02 PYRIDOXINE HYDROCHLORIDEA 116
48Tablet 25mg 100 160.
00MG 94
6–
A 11649
Tablet 100mg 50 160.00
MG 1,494 –A 185
83Tablet 25mg 100 160.
00MG 12
0–
OTHER VITAMIN PRODUCTS COMBINATIONSVITAMINS WITH MINERALS
A11JB VITAMINS with MINERALSA 100
99Capsule 30 – – 3,746 –
A 12946
Capsule 100 – – 410
–A 129
47Capsule 100 – – 75
6–
A 20271
Tablet 600mg (as carbonate) 120
3.00
GM 6,628
–P 311
6BTablet (chewable) 500mg (as carbonate)
3.00
GM 2,440
37,597P 311
7CTablet 600mg (as carbonate) 3.0
0GM 73,33
21,098,386P 433
3CTablet (chewable) 500mg (as carbonate) 120
3.00
GM 3,599
49,609P 433 Tablet 600mg (as carbonate) 3.0 GM 54,24 702,
CALCIUM CITRATEP 4332B Tablet 250mg (as citrate)
120– – 3,91
450,272P 8560M Tablet 250mg (as citrate) – – 1,91
725,198
57
A
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ALIMENTARY TRACT AND METABOLISMMINERAL SUPPLEMENTSCALCIUMCALCIUM
A12AA20 CALCIUM (DIFFERENT SALTS IN COMBINATION)A 15690 Compound effervescent tablet equivalent to 1g 0.50 GM
409 –A12AA04 CALCIUM CARBONATE
A12AA
CALCIUM, COMBINATIONS WITH OTHER DRUGSA12AX CALCIUM CARBONATE with CHOLECALCIFEROL
A 10600 Tablet 600mg 60 3.00 10,755 –POTASSIUMPOTASSIUM
A12BA01 POTASSIUM CHLORIDEP 2642C Tablet 600mg
(sustained release)3.00
GM 326,202
3,627,729P 3012M Effervescent tabs
14mmol K,8mmol Cl ions3.00
GM 30,228
355,793OTHER MINERAL SUPPLEMENTS
ZINCA12CB01 ZINC SULPHATE
A 12264 Capsule 50mg 100 0.60 GM 271 –MAGNESIUM
A12CC05 MAGNESIUM ASPARTATEA 11226 Tablet 100 – – 5,242 –P 4321K Tablet 500mg – – 26,56
7385,746
58
A
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ALIMENTARY TRACT AND METABOLISMANABOLIC AGENTS FOR SYSTEMIC USEANABOLIC STEROIDSESTREN DERIVATIVES
A14AB01 NANDROLONE DECANOATEP 1671Y Injection 50mg in 1mL
disposable syringe2.00
MG 19,112
383,468A 18759 Injection 50mg in 1mL
disposable syringe2.00
MG 506 –
P 2209G
Tablet 2mg 7.50 MG
915,391
8,479,409P 221
1JTablet 5mg 7.50 M
G638,858
6,891,799P 284
3PTablet 1mg 7.50 M
G1,037,902
9,890,872P 284
4QTablet 3mg 7.50 M
G304,468
3,078,696
P 2816F
Inj 5,000 units (anti–Xa) in 0.2mL syringe
2.50
TE 9,525
588,796P 826
9FInj 10,000 units (anti–Xa) in 1mL syringe
2.50
TE 245 54,765P 827
1HInj 7,500 units (anti–Xa) in 0.75mL syringe
2.50
TE 360 61,656P 860
3TInj 2,500 units (anti–Xa) in 0.2mL syringe
2.50
TE 6,483
348,178P 864
1TInj 2,500 units (anti–Xa) in 0.2mL syringe
2.50
TE 537 50,505P 864
2WInj 5,000 units (anti–Xa) in 0.2mL syringe
2.50
TE 1,069
104,415P 864 Inj 7,500 units (anti–Xa) in 2.5 TE 161 26,4
ENOXAPARINP 826
2WInj 60mg (6000u anti–Xa) in 0.6mL syringe
2.00
TE 28,109
3,026,056P 826
3XInj 80mg (8000u anti–Xa) in 0.8mL syringe
2.00
TE 40,215
5,007,231P 826
4YInj 100mg (10000u anti–Xa) in 1 mL syringe
2.00
TE 39,003
5,982,007P 851
0XInj 40mg (4000u anti–Xa) in 0.4 mL syringe
2.00
TE 101,497
6,261,748P 855
8KInj 20mg (2000u anti–Xa) in 0.2mL syringe
2.00
TE 37,835
2,087,006P 863
9QInj 40mg (4000u anti–Xa) in 0.4mL syringe
2.00
TE 13,951
1,327,526P 864
0RInj 60mg (6000u anti–Xa) in 0.6mL syringe
2.00
TE 7,093
1,012,377P 871 Inj 20mg (2000u anti–Xa) in 2.0 TE 4,43 404,
HEPARIN SODIUMP 107
6PInjection 35,000 units in 35mL 12
10.00
TE 1,544
234,178P 146
3BInjection 5,000 units in 5mL 10.0
0TE 3,87
2188,855P 146
6EInjection 5,000 units in 0.2mL
10.00
TE 34,138
411,626
59
B
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
BLOOD AND BLOOD FORMING ORGANSANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTSVITAMIN K ANTAGONISTSB01AA02 PHENINDIONE
A 14975 Tablet 10mg 0.10 GM 1,150 –B01AA03 WARFARIN
HEPARIN GROUPB01AB04 DALTEPARIN
B01AB05
B01AB01
60
B01AC06 ASPIRINA 105
44Tablet 100mg 30 0.1
0GM
6,417
–A 105
99Tablet 100mg 28 0.1
0GM
20,985
–A 130
20Capsule 100mg 28 0.1
0GM
826
–P 407
6MTablet 100mg (enteric coated) 0.1
0GM
25,739
326,746P 407
7NTablet 100mg (enteric coated) 0.1
0GM
103,562
1,262,161P 407
8PCapsule 100mg (enteric coated pellets)
0.10
GM
16,007
210,005P 820 Tablet 100mg 0.1 G 1,206, 8,368,
B01AC04 CLOPIDOGRELP 4179Y Tablet 75mg (base) 28 75.0
0MG
35,457
2,911,936P 8358X Tablet 75mg 75.0 M 2,502, 205,31
B01AC07 DIPYRIDAMOLEA 13040 Tablet 100mg 100 0.4
0GM
803
–P 8335Q Capsule 200mg (sustained
release)0.40
GM
56,462
1,908,924B01AC3
0DIPYRIDAMOLE with ASPRINP 8382E Capsule 200mg (sustained release) 25mg
– – 463,749
15,550,752B01AC0
9EPOPROSTENOLP 6478Y Powder for I.V. infusion 1.5mg (base) with diluent
– – 130
542,743B01AC1
6EPTIFIBATIDEP 8683B Solution for I.V. injection 20mg (base) in 10mL
0.20
GM
344
88,780P 8684C Solution for I.V. infusion
75mg (base) in 100mL0.20
GM
338
257,308B01AC1
1ILOPROSTP 6456T Solution for inhalation 20ug (base) in 2mL, 30
0.15
MG
266
749,738B01AC0
5TICLOPIDINE HYDROCHLORIDEP 2095G Tablet 250mg 0.5
0GM
3,528
523,028B01AC1
7TIROFIBANP 8350L Solution concentrate I.V. infusion 12.5mg in 50mL
10.00
MG
1,869
769,975ENZYMES
B01AD11
TENECTEPLASEP 8527T Powder for injection 50mg with solvent
40.00
MG
234
481,878
B
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
BLOOD AND BLOOD FORMING ORGANSANTITHROMBOTIC AGENTSANTITHROMBOTIC AGENTSPLATELET AGGREGATION INHIBITORS EXCL. HEPARINB01AC13 ABCIXIMAB
P 8048N I.V.injection 10mg in 5mL 25.00MG 1,941 2,891,879
DIRECT THROMBIN INHIBITORSB01AE06 BIVALIRUDIN
P 8844L Powder for I.V. injection 250mg (base) 0.25 GM 1,348997,838
61
B
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
BLOOD AND BLOOD FORMING ORGANSANTIHAEMORRHAGICSANTIFIBRINOLYTICSAMINO ACIDS
B02AA02 TRANEXAMIC ACIDP 2180R Tablet 500mg 2.00 GM 33,087 1,652,964
VITAMIN K AND OTHER HAEMOSTATICSVITAMIN K
B02BA01 PHYTOMENADIONEA 110
80Tablet 10mg 100 20.0
0MG 696 –
A 16049
Ampoule 10mg/mL 5 20.00
MG 300 –A 166
48Ampoule 2mg/0.2mL 5 20.0
0MG 177 –
A 16996 Tablet 0.20
GM 50,901
–P 8815Y Oral liquid 30mg per
mL, 250mL0.20
GM 38,035
680,048
P 1508J
Injection 1mg in 1mL 20.00
UG 130,568
1,578,455A 201
16Injection 1mg in 1mL 2
20.00
UG 399 –P 269
5WInjection 1mg in 1mL 5
20.00
UG 45,746
1,683,910P 904
8FInjection 1mg in 1mL 3
20.00
UG 182,856
2,863,874
62
B
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
BLOOD AND BLOOD FORMING ORGANSANTIANAEMIC PREPARATIONSIRON PREPARATIONSIRON BIVALENT, ORAL PREPARATIONS
B03AA07 FERROUS SULPHATE DRIED
IRON TRIVALENT, PARENTERAL PREPARATIONSB03AC03 IRON POLYMALTOSE COMPLEX
P 2593L Injection 100mg (iron) in 2mL 0.10 GM 42,104 2,347,070B03AC02 SACCHARATED IRON OXIDE
P 8807M Concent for soln for infus 2.7g =100mg iron in 5mL 0.10 GM241 37,100
IRON IN COMBINATION WITH FOLIC ACIDB03AD02 FERROUS FUMARATE WITH FOLIC ACID
P 9011G Tablet 310mg–350ug – – 101,8271,104,225B03AD03 FERROUS SULPHATE DRIED with FOLIC ACID
A 14528 Capsule 270mg–300ug (delayed release)
– – 5,514 –A 18904 Tablet 270mg–300ug
(sustained release)– – 44,214 –
VITAMIN B12 AND FOLIC ACIDVITAMIN B12 (CYANOCOBALAMIN AND DERIVATIVES)
B03BA03 HYDROXOCOBALAMIN
FOLIC ACID AND DERIVATIVESB03BB01 FOLIC ACID
P 1437P Tablet 5mg – – 146,481
1,736,548P 2958Q Tablet 500ug 0.40 MG 60,09
2702,001
P 6320P
Injection 10ug in 0.4mL syringe 4
4.50
UG 215 42,655P 632
1QInjection 20ug in 0.5mL syringe 4
4.50
UG 2,977
1,161,307P 632
2RInjection 30ug in 0.3mL syringe 4
4.50
UG 3,186
1,720,954P 632
3TInjection 40ug in 0.4mL syringe 4
4.50
UG 9,318
6,390,910P 632
4WInjection 50ug in 0.5mL syringe 4
4.50
UG 1,239
1,003,536P 632
5XInjection 60ug in 0.3mL syringe 4
4.50
UG 4,061
4,240,931P 632
6YInjection 100ug in 0.5mL syringe
4.50
UG 2,461
4,416,100P 636
5BInjection 150ug in 0.3mL syringe
4.50
UG 821 1,880,425P 643
8WInjection 80ug in 0.4mL syringe 4
4.50
UG 1,644
2,113,132P 648
8LInjection 20ug in 0.5mL prefilled injection pen 1
4.50
UG 327 127,727P 648
9MInjection 40ug in 0.4mL prefilled injection pen 1
4.50
UG 604 369,989P 649
0NInjection 60ug in 0.3mL prefilled injection pen 1
4.50
UG 173 171,044P 649 Injection 80ug in 0.4mL 4.5 UG 112 140,
ERYTHROPOIETINP 620
5NInjection 3,000 units in 0.3mL syringe
1.00
TE 207 133,487P 620
6PInjection 4,000 units in 0.4mL syringe
1.00
TE 847 608,120P 620
7QInjection 10,000 units in 1mL syringe
1.00
TE 1,277
2,071,368P 630
2QInjection 5,000 units in 0.5mL syringe
1.00
TE 193 177,348P 630
3RInjection 6,000 units in 0.6mL syringe
1.00
TE 1,064
1,085,099P 630
5WInjection 8,000 units in 0.8mL syringe
1.00
TE 1,058
1,340,283P 633
9PInjection 40,000 units in 1mL syringe
1.00
TE 227 670,444P 643
4PInjection 20,000 units in 0.5mL syringe
1.00
TE 112 294,223P 648
2EInjection 4,000 units in 0.3mL syringe 6
1.00
TE 583 284,814P 648
4GInjection 6,000 units in 0.3mL syringe 6
1.00
TE 489 382,977P 648
5HInjection 10,000 units in 0.6mL pre–filled 6
1.00
TE 389 512,567
63
B
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
BLOOD AND BLOOD FORMING ORGANSANTIANAEMIC PREPARATIONSOTHER ANTIANAEMIC PREPARATIONSOTHER ANTIANAEMIC PREPARATIONS
B03XA02 DARBEPOETIN ALPHA
B03XA01
64
B
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
BLOOD AND BLOOD FORMING ORGANSBLOOD SUBSTITUTES AND PERFUSION SOLUTIONSBLOOD AND RELATED PRODUCTSBLOOD SUBSTITUTES AND PLASMA PROTEIN FRACTIONS
B05AA06 GELATIN SUCCINYLATEDP 8444K I.V. infusion 20g per 500mL,500mL – – 5,089
193,285I.V. SOLUTIONSSOLUTIONS FOR PARENTERAL NUTRITION
B05BA03 GLUCOSEP 2245E I.V. infusion 278mmol per l (5%) 1L – – 1,307 28,981
SOLUTIONS AFFECTING THE ELECTROLYTE BALANCEB05BB01 SODIUM CHLORIDE
A 18528
Ampoule 0.9% 10mL 50 – – 199 –P 226
0YI.V. infusion 513mmol per l (3%) 1L
– – 119 3,030P 226
4EI.V. infusion 154mmol per l (0.9% ) 1L
– – 25,152
908,220B05BB0
2SODIUM CHLORIDE with GLUCOSEP 2281C I.V. infusion 31mmol–222mmol per l (0.18%–4%) 1L
– – 4,899 116,878B05BB0
1SODIUM LACTATE COMPOUNDP 2286H I.V. infusion 1L – – 12,06
8281,019IRRIGATING SOLUTIONS
SALT SOLUTIONSB05CB01 SODIUM CHLORIDE
P 4460R Irrigation solution 9mg per mL (0 .9%) 500mL
– – 779
8,400P 4461T Irrigation solution 9mg per
mL (0 .9%) 1L– – 42
24,293I.V. SOLUTION ADDITIVES
ELECTROLYTE SOLUTIONSB05XA05 MAGNESIUM SULFATE
A 13927 Ampoule 5mL 5 – – 121 –
65
B
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
BLOOD AND BLOOD FORMING ORGANSOTHER HAEMATOLOGICAL AGENTSOTHER HAEMATOLOGICAL AGENTSENZYMES
B06AA03 HYALURONIDASEA 10985 Ampoule 1500u 5 – – 498 –
P 2923W Capsule 100mg 0.40
GM 8,091 206,534P 2924X Capsule 150mg 0.4 GM 3,711 126,
QUINIDINEA 19846 Tablet 250mg
(sustained release) 1001.20
GM 384 –
P 2875H
Injection 100mg in 5mL
3.00 GM 762 34,509P 287
6JInfusion 500mg in 5mL 3.00 GM 245 10,1
01P 347 Injection 100mg in 3.00 GM 6,810 235,MEXILETINE HYDROCHLORIDEP 1682M Capsule 50mg 0.80 GM 4,692 158,
047P 1683N Capsule 200mg 0.80 GM 3,653 218,019
P 1088G Tablet 50mg 60 0.20 GM 58,462
2,256,182P 1090JTablet 100mg 0.20 GM 94,69
14,463,080
66
C
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
CARDIOVASCULAR SYSTEMCARDIAC THERAPY
CARDIAC GLYCOSIDES
DIGITALIS GLYCOSIDES
C01AA05 DIGOXINP 132
2NTablet 250ug 0.2
5MG 175,8
461,627,775P 260
5DTablet 62.5ug 0.2
5MG 295,5
492,650,710P 316
4MOral solution for children 50ug per mL,
0.25
MG 1,151
28,197ANTIARRHYTHMICS CLASS I AND III
ANTIARRHYTHMICS CLASS IAC01BA03 DISOPYRAMIDE
C01BA01
ANTIARRHYTHMICS CLASS IBC01BB01 LIGNOCAINE HYDROCHLORIDE
C01BB02
ANTIARRHYTHMICS CLASS ICC01BC04 FLECAINIDE ACETATE
ANTIARRHYTHMICS CLASS IIIC01BD01 AMIODARONE HYDROCHLORIDE
P 2343H Tablet 200mg 0.20 GM 285,905
7,167,661P 2344JTablet 100mg 0.20 GM 117,1
011,920,699CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
ADRENERGIC AGENTSC01CA24 ADRENALINE
P 1016L
Injection 1mg in 1mL (1 in 1,000)
0.50
MG 3,387
69,455A 134
37Syrng 1/10000 1 0.5
0MG 198 –
P 3451P
Injection 1mg in 1mL (1 in 1,000)
0.50
MG 22,653
420,533P 869
7RI.M. injection 150mg in 0.3mL syringe
0.50
MG 18,949
3,380,647P 869
8TI.M. injection 300mg in 0.3mL syringe
0.50
MG 33,779
4,420,170
GLYCERYL TRINITRATEP 145
9TTablets 600ug 100 2.5
0MG 89,6
22928,797P 151
5RTd pad releasing approx. 5mg per 24 hours
5.00
MG 232,935
6,264,104P 151
6TTd pad releasing approx. 10mg per 24 hours
5.00
MG 138,255
4,660,158P 347
5XBuccal/sublingual spray (pump pack) 400ug per dose
2.50
MG 20,544
377,953P 801
0NTd patch releasing approx. 5mg per 24 hours
5.00
MG 96,734
2,599,606P 801
1PTd patch releasing approx. 10mg per 24 hours
5.00
MG 55,953
1,884,064P 802
6KTd patch releasing approx. 1mg per 24 hours
5.00
MG 20,541
692,501P 802
7LTd patch releasing approx. 5mg per 24 hours
5.00
MG 10,403
280,665P 802
8MTd patch releasing approx. 10mg per 24 hours
5.00
MG 8,459
285,723P 811
9HTd patch releasing approx. 15mg per 24 hours
5.00
MG 5,090
173,007P 817 Buccal/sublingual spray (pump 2.5 MG 313,5 5,753,
ISOSORBIDE DINITRATEP 2587E Tablet 10mg 60.0
0MG 19,8
09247,874P 2588F Sublingual tablet 5mg 20.0 MG 9,30 123,
ISOSORBIDE MONONITRATEP 1558B Tablets sustained
release 60mg 3040.00
MG 783,818
10,712,471P 8273K Tablets sustained
release 120mg 3040.00
MG 301,167
7,528,099
67
C
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
CARDIOVASCULAR SYSTEMCARDIAC THERAPYVASODILATORS USED IN CARDIC DISEASESORGANIC NITRATES
C01DA02
C01DA08
C01DA14
OTHER VASODILATORS USED IN CARDIAC DISEASESC01DX16 NICORANDIL
P 8228C Tablet 10mg 40.00 MG 150,076
3,168,105P 8229D Tablet 20mg 40.00 MG 68,58
51,894,876
CLONIDINEA 127
86Ampoule 150ug/mL 5 0.45 MG 748 –
P 3141H
Tablet 150ug 0.45 MG 31,771
1,131,245P 314 Tablet 100ug 0.45 MG 100,5 2,690,
MOXONIDINEP 9019Q Tablet 200mg 30 0.30 MG 15,21
4284,907P 9020R Tablet 400mg 30 0.30 MG 8,87
2240,929
P 1639G Tablet 50mg 0.10 GM 22,367
346,136P 1640H Tablet 25mg 0.10 GM 26,87
9366,903
68
C
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
CARDIOVASCULAR SYSTEMANTIHYPERTENSIVESANTIADRENERGIC AGENTS CENTRALLY ACTINGMETHYLDOPA
C02AB01 METHYLDOPAP 1629R Tablet 250mg 1.00 GM 156,4202,103,710
IMIDAZOLINE RECEPTOR AGONISTSC02AC01
C02AC05
ANTIADRENERGIC AGENTS PERIPHERALLY ACTINGALPHA – ADRENOCEPTOR BLOCKING AGENTS
C02CA01 PRAZOSIN HYDROCHLORIDEP 147
8TTablet 5mg (base) 5.00 MG 138,2
163,328,324P 147
9WTablet 1mg (base) 5.00 MG 297,0
803,904,696P 148
0XTablet 2mg (base) 5.00 MG 168,5
302,723,936ARTERIOLAR SMOOTH MUSCLE AGENTS ACTING ON
HYDRAZINOPHTHALAZINE DERIVATIVESC02DB02 HYDRALAZINE HYDROCHLORIDE
PYRIMIDINE DERIVATIVESC02DC01 MINOXIDIL
P 2313R Tablet 10mg 20.00MG 4,576 258,250OTHER ANTIHYPERTENSIVESOTHER ANTHIYPERTENSIVESC02KX01 BOSENTAN
P 6429JTablet 62.5mg (base) 60
250.00
MG 378
1,139,144P 6430K Tablet 125mg
(base) 60250.00
MG 4,859
15,867,362
P 2411X
Oral solution 10mg per mL 30mL
40.00
MG
2,917
47,405P 241
2YTablet 40mg 40.0
0MG
1,253,177
10,438,694P 241
3BInjection 20mg in 2mL 40.0
0MG
5,708
69,931P 241
4CTablet 20mg 40.0
0MG
231,076
1,981,223P 241
5DTablet 500mg 40.0
0MG
15,987
333,725P 346
6KInjection 20mg in 2mL 40.0
0MG
8,953
93,637
P 8879H Tablet 25mg 30 50.00 MG 4,102
467,192P 8880JTablet 50mg 30 50.00 MG 694 81,6
SPIRONOLACTONEP 2339D Tablet 25mg 75.00 MG 287,9
073,728,964P 2340E Tablet 100mg 75.00 MG 64,61
92,299,934
69
C
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
CARDIOVASCULAR SYSTEMDIURETICSLOW–CEILING DIURETICS THIAZIDESTHIAZIDES PLAIN
C03AA03 HYDROCHLOROTHIAZIDEP 1484D Tablet 25mg 25.00MG 92,372 1,788,760
LOW–CEILING DIURETICS EXCL. THIAZIDESSULFONAMIDES PLAIN
C03BA04 CHLORTHALIDONEP 1585K Tablet 25mg 25.00MG 38,638 469,312
C03BA11 INDAPAMIDEA 164
35Tablet 1.5mg 30 2.5
0MG 325 –
P 2436F
Tablet 2.5mg 90 2.50
MG 232,485
4,505,385P 853
2CTablet 1.5mg (sustained release) 90
2.50
MG 433,492
8,697,642HIGH–CEILING DIURETICS
SULFONAMIDES PLAINC03CA02 BUMETANIDE
A 17855 Tablet 1mg 1.00 MG 8,879 –C03CA01 FRUSEMIDE
ARYLOXYACETIC ACID DERIVATIVESC03CC01 ETHACRYNIC ACID
P 8748K Tablet 25mg 50.00MG 2,056 110,213POTASSIUM–SPARING AGENTSALDOSTERONE ANTAGONISTS
C03DA04 EPLERENONE
C03DA01
OTHER POTASSIUM–SPARING AGENTSC03DB01 AMILORIDE HYDROCHLORIDE
P 3109P Tablet 5mg 10.00MG 27,622 253,737
70
C
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
CARDIOVASCULAR SYSTEMDIURETICSDIURETICS AND POTASSIUM–SPARING AGENTS IN COMBLOW–CEILING DIURETICS AND POTASSIUM–SPARING AGENTS
C03EA01 HYDROCHLOROTHIAZIDE with AMILORIDE HYDROCHLORIDEP 1486F Tablet 50mg–5mg – – 176,4222,017,123
C03EA01 HYDROCHLOROTHIAZIDE with TRIAMTERENEP 1280J Tablet 25mg–50mg 100 – –
45,575 522,634
71
C
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
CARDIOVASCULAR SYSTEMPERIPHERAL VASODILATORSPERIPHERAL VASODILATORSPURINE DERIVATIVES
C04AD03 OXPENTIFYLLINEA 17632 Tablet 400mg 50 1.00 GM 2,258 –
OTHER PERIPHERAL VASODILATORSC04AX02 PHENOXYBENZAMINE HYDROCHLORIDE
P 1862B Capsule 10mg 30 30.00MG 2,648 150,504
C05AA01
HYDROCORTISONE with CINCHOCAINE HYDROCHLORIDEP 4036K Ointment 5mg–5mg per g
– 24,320
446,647C05AA0
1HYDROCORTISONE, CINCHOCAINE HYDROCHLORIDEA 14345 Ointment 5mg–5mg–10mg per g
– 16,013
–P 4038M Suppositories 5mg–5mg 12 – – 14,48
4259,811
and
CLEMIZOLE UNDECYLENATEA 14656 Ointment 1.9mg–5mg–
10mg per g(0.16–0.5%–1%) – – 11,203 –A 14657 Ointment 1.9mg–5mg–
10mg per g(0.195–0.5%–1%) – – 14,335 –A 14658 Suppositories 1.3mg–
1mg–5mg 12– – 6,863 –
A 12829 Cream 0.3%40g 1 – – 416
–A 13774 Cream 0.3% 20g – – 1,216 –HEPARINOID with HYALURONIDASEA 12830 Ointment 14g 1 – – 34
9–
A 12831 Ointment 40g 1 – – 255
–
72
C
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
CARDIOVASCULAR SYSTEMVASOPROTECTIVESAGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USECORTICOSTEROIDS
C05AA01 HYDROCORTISONE, LIGNOCAINE BASE, ALUMINIUM SUBACETATE and ZINC OXIDEA 14653 Ointment 2.5mg–50mg–35mg–180mg per g – – 2,013
–C05AA04 PREDNISOLONE HEXANOATE, CINCHOCAINE HYDROCHLORIDE
LOCAL ANESTHETICSC05AD03 ADRENALINE EPHEDRINE BENZOCAINE ZINC OXIDE
A 13134 Ointment 50g 1 – – 2,435 –MUSCLE RELAXANTS
C05AE01 GLYCERYL TRINITRATEA 16349 Ointment 0.2% 30g 1 – – 4,827 –
OTHER AGENTS FOR TREATMENT HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USEC05AX04 ZINC OXIDE
P 4039N Compound ointment 50g
– – 2,128 27,631P 4040P Compound
suppositories, 12– – 2,193 26,8
55ANTIVARICOSE THERAPYHEPARINS OR HEPARINOIDS FOR TOPICAL USEC05BA01 HEPARINOID
C05BA01
CAPILLARY STABILIZING AGENTSBIOFLAVONOIDS
C05CA02 HYDROXYETHYLRUTOSIDESA 13500 Capsule 250mg 50 – – 193 –A 16101 Capsule 250mg
100– – 594 –
P 2942W Tablet 20mg 0.16 GM 2,258
19,610P 2961W Tablet 40mg 0.16 GM 11,15 119,
PINDOLOLP 3062E Tablet 5mg 15.00 MG 26,54
6312,798P 3065H Tablet 15mg 15.00 MG 25,61 380,
PROPRANOLOL HYDROCHLORIDEP 256
5BTablet 10mg 0.16 GM 132,6
161,128,214P 256
6CTablet 40mg 0.16 GM 319,0
652,800,643P 289 Tablet 160mg 0.16 GM 31,51 300,
SOTALOL HYDROCHLORIDEP 2043M Tablet 160mg 0.16 GM 128,8
754,021,781P 8398B Tablet 80mg 60 0.16 GM 318,9
505,535,846
C07AB03
ATENOLOLP 1081X Tablet 50mg 0.0
8GM
4,281,609
45,827,654C07AB0
7BISOPROLOLP 8604W Tablet 2.5mg 10.0
0MG
88,048
5,135,957P 8605X Tablet 5mg 10.0
0MG
77,795
5,642,129P 8606Y Tablet 10mg 10.0
0MG
69,014
5,713,084C07AB0
2METOPROLOL SUCCINATEP 8732N Tablet 23.75mg (controlled release) 15
150.00
MG
10,504
344,412P 8733P Tablet 47.5mg
(controlled release) 30150.00
MG
23,899
1,808,483P 8734Q Tablet 95mg
(controlled release) 30150.00
MG
23,937
2,221,425P 8735R Tablet 190mg
(controlled release) 30P 8818D Pack 15 tabs 23.75mg, 15 tabs 47.5mg, 15
150.00
M
MG
22
18,387
20,8
2,006,625
C07AB02
METOPROLOL TARTRATEP 1324Q Tablet 50mg 150.
00MG
1,101,150
11,923,549P 1325R Tablet 100mg 150.
00MG
482,274
6,059,688
A 16540
Tablet 6.25mg 30 37.50 MG 234
–P 825
5LTablet 3.125mg 30 37.50 MG 48,4
201,411,841P 825
6MTablet 6.25mg 37.50 MG 126,4
399,230,416P 825
7NTablet 12.5mg 37.50 MG 152,4
1413,623,878P 825 Tablet 25mg 37.50 MG 260,2 29,122
LABETALOL HYDROCHLORIDEP 1566K Tablet 100mg 0.60 GM 20,0
04283,206P 1567L Tablet 200mg 0.60 GM 21,3
32458,509
73
C
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
CARDIOVASCULAR SYSTEMBETA BLOCKING AGENTSBETA BLOCKING AGENTS PLAINBETA BLOCKING AGENTS PLAIN NON–SELECTIVE
C07AA02 OXPRENOLOL HYDROCHLORIDE
C07AA03
C07AA05
C07AA07
BETA BLOCKING AGENTS PLAIN SELECTIVE
ALPHA– AND BETA– ADRENOCEPTOR BLOCKING AGENTSC07AG02 CARVEDILOL
C07AG01
P 1343Q
Tablet 5mg (base) maleate salt 30
5.00
MG
90,749
1,707,976P 134
5TTablet 10mg (base) maleate salt 30
5.00
MG
80,630
2,333,635A 201
26Tablet 10mg (base) besylate salt 30
5.00
MG
165
–P 275
1TTablet 5mg (base) besylate salt 3 0
5.00
MG
1,340,255
26,652,870P 275
2WTablet 10mg (base) besylate salt 30
5.00
MG
1,087,022
33,424,399P 498
5JTablet 5mg (base) besylate salt 3 0
5.00
MG
1,888
50,721P 498
6KTablet 10mg (base) besylate salt 30
5.00
MG
1,539
60,632P 892
3PTablet 5mg (base) besylate salt 30
5.00
MG
141,577
3,814,191P 892 Tablet 10mg (base) 5.0 M 164,3 6,538,
FELODIPINEP 236
1GTablet 2.5mg (extended release)
5.00
MG
210,279
3,171,306P 236
6MTablet 5mg (extended release)
5.00
MG
555,314
10,494,183P 236 Tablet 10mg (extended 5.0 M 664,0 20,683
LERCANIPIDINEP 495
9BTablet 20mg 30 10.0
0MG
395
16,890P 496
0CTablet 10mg 30 10.0
0MG
537
15,918P 853
4ETablet 10mg 30 10.0
0MG
894,465
20,797,311P 867
9TTablet 20mg 30 10.0
0MG
596,534
20,474,303P 893
9LTablet 10mg 30 10.0
0MG
73,421
2,086,658P 894 Tablet 20mg 30 10.0 M 70,0 2,794,
NIFEDIPINEP 169
4ETablet 10mg 60 30.0
0MG
38,690
712,167P 169
5FTablet 20mg 60 30.0
0MG
46,563
1,030,371P 190
6HTablet 30mg (controlled release) 30
30.00
MG
424,233
9,796,236P 190
7JTablet 60mg (controlled release) 30
30.00
MG
367,037
10,449,134P 861
0ETablet 20mg (controlled release) 30
30.00
MG
111,840
2,439,184P 893
8KTablet 20mg (controlled release) 30
30.00
MG
7,969
228,489
74
C
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
CARDIOVASCULAR SYSTEMCALCIUM CHANNEL BLOCKERSSELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTSDIHYDROPYRIDINE DERIVATIVESC08CA01 AmLODIPINE
C08CA02
C08CA13
C08CA05
P 1241H
Tablet 240mg (sustained release)
0.24
GM 706,490
12,990,041P 124
8QTablet 40mg 0.2
4GM 37,9
39446,258P 125
0TTablet 80mg 0.2
4GM 38,2
16642,640P 125
3YTablet 160mg 0.2
4GM 18,2
76382,114P 125
4BTablet 120mg 0.2
4GM 6,83
4150,158P 220
6DCapsule 160mg (sustained release)
0.24
GM 55,161
745,775P 220
7ECapsule 240mg (sustained release)
0.24
GM 88,175
1,615,820P 220
8FCapsule 180mg (sustained release)
0.24
GM 223,110
3,375,696P 349
4XInjection 5mg in 2mL 0.2
4GM 3,26
635,840
75
C
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
CARDIOVASCULAR SYSTEMCALCIUM CHANNEL BLOCKERSSELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTSPHENYLALKYLAMINE DERIVATIVES
C08DA01 VERAPAMIL HYDROCHLORIDE
BENZOTHIAZEPINE DERIVATIVESC08DB01 DILTIAZEM HYDROCHLORIDE
P 1312C
Capsule 180mg controlled delivery
0.24
GM 529,055
10,829,333P 131
3DCapsule 240mg controlled delivery
0.24
GM 532,797
13,665,016P 133
5GTablet 60mg 0.2
4GM 64,2
151,222,095P 848
0HCapsule 360mg controlled delivery 30
0.24
GM 300,183
9,542,134NON–SELECTIVE CALCIUM CHANNEL BLOCKERS
OTHER NON–SELECTIVE CALCIUM CHANNEL BLOCKERSC08EX02 PERHEXILINE MALEATE
P 1822X Tablet 100mg 0.20 GM 32,241 1,692,256
P 1147J
Tablet 12.5mg 50.00
MG
16,191
296,762P 114
8KTablet 25mg 50.0
0MG
36,858
893,296P 114
9LTablet 50mg 50.0
0MG
58,437
2,538,419P 876 Oral solution 5mg per 50.0 M 89 47,2
ENALAPRIL MALEATEP 136
8BTablet 10mg 10.0
0MG
238,293
4,857,739P 136
9CTablet 20mg 10.0
0MG
438,547
12,137,259P 137 Tablet 5mg 10.0 M 107,7 1,525,
FOSINOPRILP 1182F Tablet 10mg 30 15.0
0MG
166,078
2,919,184P 1183G Tablet 20mg 15.0 M 278,9 7,235,
LISINOPRILP 245
6GTablet 5mg 30 10.0
0MG
139,101
2,117,006P 245
7HTablet 10mg 30 10.0
0MG
262,673
5,358,141P 245 Tablet 20mg 30 10.0 M 451,2 11,753
PERINDOPRILA 198
89Tablet 2mg 30 4.0
0MG
1,206
–A 198
90Tablet 4mg 30 4.0
0MG
400
–A 198
91Tablet 8mg 30 4.0
0MG
460
–P 305
0MTablet 2mg 30 4.0
0MG
114,477
1,683,902P 305
1NTablet 4mg 30 4.0
0MG
181,538
4,048,799P 870
4DTablet 8mg 30 4.0
0MG
115,558
3,564,631P 900
6BTablet 2.5mg 30 4.0
0MG
1,070,651
15,673,383P 900
7CTablet 5mg 30 4.0
0MG
2,022,226
45,217,878P 900 Tablet 10mg 30 4.0 M 1,387, 42,876
QUINAPRILP 196
8NTablet 5mg 30 15.0
0MG
54,098
858,299P 196
9PTablet 10mg 30 15.0
0MG
147,339
3,011,906P 197
0QTablet 20mg 30 15.0
0MG
287,317
7,612,628A 198
73Tablet 5mg 30 15.0
0MG
135
–A 198
74Tablet 10mg 30 15.0
0MG
182
–
76
C
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
CARDIOVASCULAR SYSTEMAGENTS ACTING ON RENIN–ANGIOTENSIN SYSTEMANGIOTENSIN–CONVERTING ENZYME (ACE) INHIBITORS, PLAINCONVERTING ENZYME BLOCKERSC09AA01 CAPTOPRIL
C09AA02
C09AA09
C09AA03
C09AA04
C09AA06
RAMIPRILP 131
6GTablet 10mg 30 2.5
0MG
3,299
95,480P 194
4HCapsule 1.25mg 28 2.5
0MG
164,883
2,025,381P 194
5JCapsule 2.5mg 28 2.5
0MG
569,897
8,850,622P 194
6KCapsule 5.0mg 28 2.5
0MG
1,201,198
22,571,918A 199
83Pack 7 Tabs 2.5mg 21 tabs 5mg and 10 caps 10mg
2.50
MG
164
–P 495
3QTablet 2.5mg 30 2.5
0MG
306
8,204P 496
2ECapsule 10mg 30 2.5
0MG
1,185
37,682P 847
0TCapsule 10mg 30 2.5
0MG
1,718,000
48,340,077P 866
8FPack 7 Tabs 2.5mg 21 tabs 5mg and 10 caps 10mg
2.50
MG
4,220
106,074P 893
7JCapsule 10mg 30 2.5
0MG
12,290
394,837P 894
5TTablet 1.25mg 30 2.5
0MG
149
2,126P 894
6WTablet 2.5mg 30 2.5
0MG
628
11,394P 894
7XTablet 5mg 30 2.5
0MG
2,010
51,520P 912
0BCapsule 1.25mg 30 2.5
0MG
222
2,736P 912
1CCapsule 2.5mg 30 2.5
0MG
878
13,709P 912 Capsule 5.0mg 30 2.5 M 1,90 34,6
TRANDOLAPRILP 279
1XCapsule 500ug 2.0
0MG
35,031
476,820P 279
2YCapsule 1mg 2.0
0MG
114,172
2,126,317P 279
3BCapsule 2mg 2.0
0MG
267,706
5,627,444P 875
8YCapsule 4mg 28 2.0
0MG
139,543
4,518,990
77
C
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
CARDIOVASCULAR SYSTEMAGENTS ACTING ON RENIN–ANGIOTENSIN SYSTEMANGIOTENSIN–CONVERTING ENZYME (ACE) INHIBITORS, PLAINCONVERTING ENZYME BLOCKERS
C09AA05
C09AA10
ACE INHIBITORS, COMBINATIONSANGIOTENSIN–CONVERTING ENZYME BLOCKERS AND DIURETICS
C09BA02
ENALAPRIL and DIURETICSP 8477E Tablet 20mg–6mg – – 169,1
764,656,119C09BA0
9FOSINOPRIL and DIURETICSP 8400D Tablet 10mg–12.5mg – – 88,1
781,843,487P 8401E Tablet 20mg–12.5mg – – 475,4
7613,480,399C09BA0
4PERINDOPRIL and DIURETICSA 20124 Tablet 4mg (erbumine salt)–1.25mg 30
– – 1,879
–P 2190G Tablet 2.5mg (arginine salt)–0.625mg 30
– – 2,846
45,151P 2845R Tablet 5mg (arginine
salt)–1.25mg 30– – 941,1
9827,355,733P 8449Q Tablet 4mg (erbumine
salt)–1.25mg 30– – 893,0
0126,625,416C09BA0
6QUINAPRIL and DIURETICSP 8589C Tablet 10mg(base) / 12.5mg 30
– – 22,825
512,062P 8590D Tablet 20mg(base) /
12.5mg 30– – 101,1
212,616,613
P 2626F Tablet 2.5mg–2.5mg 30
– – 780 20,291P 2629JTablet 5mg–5mg 30 – – 5,279 174,
491
78
C
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
CARDIOVASCULAR SYSTEMAGENTS ACTING ON RENIN–ANGIOTENSIN SYSTEMACE INHIBITORS, COMBINATIONSACE INHIBITORS AND CALCIUM CHANNEL BLOCKERS
C09BB05 RAMIPRIL and FELODIPINE
C09BB10 TRANDOLAPRIL and VERAPAMILP 2857J Tablet 4mg – 240mg (sustained release) 28 – – 10,369 449,935
ANGIOTENSIN II ANTAGONISTSANGIOTENSIN II ANTAGONISTS PLAIN
C09CA06 CANDESARTANP 829
5NTablet 4mg 30 8.00 M
G268,096
5,183,903P 829
6PTablet 8mg 30 8.00 M
G785,174
18,102,437P 829
7QTablet 16mg 30 8.00 M
G905,450
26,232,370P 888
9WTablet 32mg 30 8.00 M
G206,471
9,283,015C09CA02 EPROSARTAN
P 8397Y Tablet 400mg (base) 56
0.60 GM
31,930
861,351P 8447N Tablet 600mg
(base) 280.60 G
M107,978
3,013,616C09CA04 IRBESARTAN
P 8246B
Tablet 75mg 150.00
MG
511,247
9,921,904P 824
7CTablet 150mg 150.
00MG
1,846,859
43,080,357P 824
8DTablet 300mg 150.
00MG
1,888,616
53,566,919C09CA0
1LOSARTANA 16073 Tablet 50mg 30 0.05 G
M5,631
–C09CA08
OLMESARTAN MEDOXOMILP 2147B Tablet 20mg 30 20.0
0MG
12,544
292,943P 2148C Tablet 40mg 30 20.0
0MG
7,635
247,223C09CA0
7TELMISARTANP 8355R Tablet 40mg 40.0
0MG
829,879
16,445,576P 8356T Tablet 80mg 40.0
0MG
827,361
22,299,194
79
C
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
CARDIOVASCULAR SYSTEMAGENTS ACTING ON RENIN–ANGIOTENSIN SYSTEMANGIOTENSIN II ANTAGONISTS COMBINATIONSANGIOTENSIN II ANTAGONISTS AND DIURETICS
C09DA06
CANDESARTAN and DIURETICSP 8504N Tablet 16mg–12.5mg 30 – – 982,1
3230,272,157C09DA0
2EPROSARTAN and DIURETICSP 8624X Tablet 600mg (base) –12.5mg 28
– – 101,418
2,987,315C09DA0
4IRBESARTAN and DIURETICSP 2136K Tablet 300mg–25mg 30 – – 7,48
9242,777P 8404H Tablet 150mg–12.5mg 30 – – 775,8
0319,649,742P 8405J Tablet 300mg–12.5mg
30– – 2,609,
22978,876,495C09DA0
8OLMESARTAN MEDOXOMIL AND DIURETICSP 2161R Tablet 20mg 12.5mg 30
– – 2,546
64,944P 2166B Tablet 40mg 12.5mg 30 – – 4,21
1127,817P 2170F Tablet 40mg 25mg 30 – – 5,01
5162,838C09DA0
7TELMISARTAN and DIURETICSP 8622T Tablet 40mg–12.5mg 28 – – 157,6
373,422,419P 8623W Tablet 80mg–12.5mg 28 – – 692,3
0119,821,349
80
P 8213G
Tablet 10mg 20.00
MG
1,941,812
78,534,977P 821
4HTablet 20mg 20.0
0MG
3,711,496
212,314,547P 821
5JTablet 40mg 20.0
0MG
3,454,803
270,977,008P 852 Tablet 80mg 20.0 M 1,219, 133,79
C10AA04 FLUVASTATINP 286
3QTablet 80mg (fluvastatin) (prolonged release) 28
60.00
MG
1,351
62,750P 802
3GCapsule 20mg (base) 60.0
0MG
34,508
870,971P 802 Capsule 40mg (base) 60.0 M 53,6 1,702,
C10AA03 PRAVASTATINP 283
3DTablet 10mg 30 30.0
0MG
122,251
3,335,372P 283
4ETablet 20mg 30 30.0
0MG
508,947
20,514,035P 819
7KTablet 40mg 30 30.0
0MG
1,017,978
60,925,866P 882 Tablet 80mg 30 30.0 M 135,1 11,925
C10AA07 ROSUVASTATINP 904
2XTablet 5mg 30 10.0
0MG
132,907
6,604,172P 904
3YTablet 10mg 30 10.0
0MG
626,811
43,258,295P 904
4BTablet 20mg 30 10.0
0MG
198,243
18,945,389P 904 Tablet 40mg 30 10.0 M 78,0 10,442
C10AA01 SIMVASTATINP 201
1WTablet 10mg 30.0
0MG
688,248
22,156,657P 201
2XTablet 20mg 30.0
0MG
2,097,197
92,213,498P 201
3YTablet 5mg 30.0
0MG
36,258
900,123A 201
62Tablet 5mg 30 30.0
0MG
760
–P 817
3ETablet 40mg 30.0
0MG
2,583,743
157,328,384P 831
3MTablet 80mg 30.0
0MG
679,700
57,917,214FIBRATE
C10AB05 FENOFIBRATEA 198
30Capsule 67mg 60 0.2
0GM
253
–P 902
2WTablet 48mg 60 0.2
0GM
19,021
529,356P 902
3XTablet 145mg 30 0.2
0GM
283,024
11,086,385
C
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
CARDIOVASCULAR SYSTEMLIPID MODIFYING AGENTS PLAINLIPID MODIFYING AGENTS PLAINHMG REDUCTASE INHIBITORS
C10AA05 ATORVASTATIN
C10AB04 GEMFIBROZILP 1453L Tablet 600mg 1.20 GM 278,294 10,921,785
BILE ACID SEQUESTRANTSC10AC02 COLESTIPOL HYDROCHLORIDE
P 1224K Sachets 5g 120 20.00GM 1,304 87,300C10AC01 COLESTYRAMINE
P 2967E Sachets 4.7g(equiv to 4 g cholestyramine)
14.00
GM 29,254
1,616,512P 2978R Sachets 9.4g equiv to 8
g cholestyramine)14.00
GM 6,995
385,763
81
A 19529
Tablet 20mg –10mg 30 – – 312
–P 888
1KTablet 40mg –10mg 30 – – 171,9
5421,386,193P 888
2LTablet 80mg –10mg 30 – – 144,3
2021,386,762
C
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
CARDIOVASCULAR SYSTEMLIPID MODIFYING AGENTS PLAINLIPID MODIFYING AGENTS PLAINNICOTINIC ACID AND DERIVATIVES
C10AD02 NICOTINIC ACIDA 19191 Tablet 250mg 2.00 GM 6,438 –
OTHER LIPID MODIFYING AGENTSC10AX09 EZETIMIBE
P 8757X Tablet 10mg 30 10.00MG 730,486 51,218,941LIPID MODIFYING AGENTS COMBINATIONSHMG COA REDUCTASE INHIBITORS IN COMBINATION WITH OTHER LIPID MOD AGENTS
C10BA02 SIMVASTATIN and EZETIMIBE
HMG COA REDUCTASE INHIBITORS, OTHER COMBINATIONSC10BX03 ATORVASTATIN AND AMLODIPINE
P 9049G
Tablet 10mg (base) 5mg (base) 30
– – 22,657
1,232,862P 905
0HTablet 20mg (base) 5mg (base) 30
– – 47,173
3,351,011P 905
1JTablet 40mg (base) 5mg (base) 30
– – 46,500
4,284,846P 905
2KTablet 80mg (base) 5mg (base) 30
– – 13,765
1,698,495P 905
3LTablet 10mg (base) 10mg (base) 30
– – 16,351
1,064,092P 905
4MTablet 20mg (base) 10mg (base) 30
– – 39,802
3,254,861P 905
5NTablet 40mg (base) 10mg (base) 30
– – 47,285
4,861,453P 905
6PTablet 80mg (base) 10mg (base) 30
– – 17,176
2,302,674
P 1698JCream 100,000 units per g 15g
– – 370 5,231P 4001N Cream 100,000 units
per g 15g– – 1,527 15,1
56
82
D
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
DERMATOLOGICALSANTIFUNGALS FOR DERMATOLOGICAL USEANTIFUNGALS FOR TOPICAL USEANTIBIOTICS
D01AA01 NYSTATIN
IMIDAZOLE DERIVATIVESD01AC10 BIFONAZOLE
P 4003Q Cream 10mg per g (1%) 15g
– – 3,829 63,241P 8066M Cream 10mg per g (1%)
15g 2– – 1,438 39,6
20D01AC01 CLOTRIMAZOLEP 102
7CLotion 10mg per mL (1%) 20mL 2
– – 634 11,339A 155
76Cream 10mg per g (1%) 50g – – 1,870 –
A 15786
Cream 10mg per g (1%) 50g – – 13,959
–A 165
85Cream 10mg per g (1%) 20g – – 3,973 –
A 17061
Cream (vaginal) 100 mg per g (10%)
– – 3,219 –P 400
4RCream 10mg per g (1%) 20g – – 16,78
2130,977P 400
5TLotion 10mg per mL (1%) 20mL
– – 1,929 21,302D01AC CLOTRIMAZOLE AND FLUCONAZOLE
A 20245 Cream 1% 10g tube and capsule 150mg 1
– – 330 –D01AC03
ECONAZOLE NITRATEA 15470 Cream 10 mg per g (1%) 20g
– – 2,088 –D01AC08
KETOCONAZOLEP 1574W Shampoo 20mg per mL (2%) 60mL
– – 595 11,658P 4007X Shampoo 20mg per mL
(2%) 100mL– – 318 5,8
45P 4008Y Shampoo 20mg per mL (2%) 60mL
– – 3,398 57,649P 9024Y Shampoo 20mg per g
(2%) 30g 1– – 4,210 120,
701P 9025B Shampoo 10mg per g (1%) 100mL
– – 531 9,116D01AC0
2MICONAZOLEA 14846 Ointment 15g – – 224 –A 17964 Cream 10mg per g (1%) 40g
– – 3,379 –P 4341L Tincture 20mg per mL (2%), 20mL
– – 1,249 22,916P 9026C Tincture 20mg per mL
(2%), 15mL 2– – 904 14,0
42P 9027D Cream 20mg per g (2%) 30g 1
– – 967 14,121P 9028E Cream 20mg per g (2%)
70g 1– – 655 12,1
60P 9029F Powder 20mg per g (2%) 30g 1 1
– – 347 4,965P 9030G Lotion 20mg per mL
(2%) 30g 1 1– – 366 6,8
66P 9031H Tincture 20mg per mL (2%) 30mL 1
– – 549 10,056D01AC0
2MICONAZOLE NITRATEP 4454K Cream 20mg per g (2%) 30g
– – 2,023 27,139D01AC5
2MICONAZOLE and HYDROCORTISONEA 17966 Cream 1% 1g/100g 30g – – 19,78
1–
P 1460W Tablet 125mg 0.50 GM 1,894
40,846P 2982Y Tablet 500mg 0.50 GM 86,1 1,722,
TERBINAFINEP 2804N Tablet 250mg
(base)0.25 GM 89,0
0211,907,841P 4011D Tablet 250mg
(base)0.25 GM 4,18
7565,476
83
D
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
DERMATOLOGICALSANTIFUNGALS FOR DERMATOLOGICAL USEANTIFUNGALS FOR TOPICAL USEOTHER ANTIFUNGALS FOR TOPICAL USE
D01AE16
AMOROLFINEP 4010C Nail treatment kit containing 50mg (base) per mL
– – 9,825 901,591D01AE1
4CICLOPIROXP 4106D Shampoo 15mg per g (1.5%), 60mL
– – 216 3,408D01AE1
5TERBINAFINEP 4463X Gel 10mg per g (1%) 15g – – 972 21,3
32P 4473K Cream 10mg per g (1%), 15g
– – 15,012
332,735D01AE1
8TOLNAFTATEP 4481W Spray aerosol 10mg per g (1%) 100g
– – 466 6,241ANTIFUNGALS FOR SYSTEMIC USE
ANTIFUNGALS FOR SYSTEMIC USED01BA01 GRISEOFULVIN
D01BA02
P 4551M
Cream 150mg–20mg per g (15%–2%) 600g
– – 179
3,767P 455
6TCream 150mg–20mg per g (15%–2%) 75g
– – 255
2,588
with MINERAL OIL with POLYETHYLENE GLYCOLA 10147 Ltn
250mL 1– – 237 –
84
D
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
DERMATOLOGICALSEMOLLIENTS AND PROTECTIVESEMOLLIENTS AND PROTECTIVESSILICONE PRODUCTS
D02AA DIMETHICONE and GLYCEROL
D02AA SILICONEA 10740 Cream pump 1 – – 157 –
SOFT PARAFFIN AND FAT PRODUCTSD02AC DEWAXED OIL with SOLUBLE KERATIN with LANOLIN
D02AC PARAFFINP 4041Q Ointment 100g – – 1,282 14,722
CARBAMIDE PRODUCTSD02AE01 UREA
P 4042R Cream 100mg per g (10%) 100g – – 29,289329,901
OTHER EMOLLIENTS AND PROTECTIVESD02AX BATH EMOLLIENT
P 4122Y Bath oil 500mL – – 9,235 159,151D02AX CARMELLOSE SODIUM with PECTIN and
GELATINA 14151 Paste 167mg–167mg–
– – 213 –P 4518T Paste 167mg–167mg–167mg per g
– – 274 3,349D02AX CETOMACROGOL
A 15823 Sorbolene crm 100g – – 181 –D02AX CETOMACROGOL with GLYCERINE
A 11020 Cream 100g 1 – – 167 –D02AX DEWAXED OIL with LANOLIN
P 4107E Lotion 500mL – – 5,117 81,078PROTECTIVES AGAINST UV–RADIATION
PROTECTIVES AGAINST UV–RADIATION FOR TOPICAL USED02BA SUNSCREENS
P 4543D
Solid stick 4.5g – – 1,090 11,458P 454
4ECream 100g – – 12,99
8187,906P 454
6GLotion (non–alcoholic) 125mL
– – 3,449 51,564
85
D
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
DERMATOLOGICALSPREPARATIONS FOR TREATMENT OF WOUNDS & ULCERSCICATRIZANTSOTHER CICATRIZANTS
D03AX VITAMIN AA 16106 Ointment 50g – – 1,639 –
A 12234 Gel 2% 15mL 1 – – 2,485 –A 12239 Ointment 5%15g
1– – 1,090 –
86
D
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
DERMATOLOGICALSANTIPRURITICS,INCL ANTIHIST,ANESTHET,ETC.ANTIPRURITICS,INCL ANTIHIST,ANESTHET,ETC.ANAESTHETICS FOR TOPICAL USE
D04AB01 LIGNOCAINE
D04AB01 LIGNOCAINE HYDROCHLORIDE and CARBOXYMETHYLCELLULOSEP 4308R Mucilage 20 mg–25 mg per mL (2%–2.5%), 200 mL – –
2,694 214,497OTHER ANTIPRURITICS
D04AX CROTAMITONA 12933 Cream 10%20g 1 – – 423 –
D04AX PINE TAR and TRIETHANOLAMINEP 4408B Solution 23mg–60mg per mL (2.3%–6%) 500mL
– – 2,375 44,427D04AX PINE TAR and TRIETHANOLAMINE LAURYL
SULPHATEA 12602 Ltn 100mL 1
– – 134 –
A 17059 Ointment 1.0% 50g 1
– – 587 –A 17060 Ointment 2.0%
50g 1– – 250 –
A 14883
Ointment 100gm – – 2,192
–A 158
67Cream 30g – – 2,00
9–
A 15868
Cream 100g – – 949 –A 169
79Scalp Solution 30mL 50ug/mL
– – 4,690
–P 208
0LCream 50ug per g (0.005%) 30g 1
– – 5,195
240,335P 829 Ointment 0.005%, 30gm – – 92,67 4,743,
TAZAROTENEA 19647 Cream 0.05% 30g 1 – – 1,28
7–
A 19648 Cream 0.1% 30g 1 – – 2,515
–
87
D
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
DERMATOLOGICALSANTIPSORIATICSANTIPSORIATICS FOR TOPICAL USETARS
D05AA TARSP 8864M Gel 10mg per g (1%) 100mL – – 6,393 236,328
ANTRACEN DERIVATIVESD05AC01 DITHRANOL with SALICYLIC ACID
OTHER ANTIPSORIATICS FOR TOPICAL USED05AX02 CALCIPOTRIOL
D05AX05
ANTIPSORIATICS FOR SYTEMIC USEPSORALENS FOR SYSTEMIC USE
D05BA02 METHOXSALENA 11443 Capsule 10mg 100 10.00 128 –
RETINOIDS FOR TREATMENT OF PSORIASISD05BB02 ACITRETIN
P 2019G Capsule 10mg 35.00 MG 7,750
1,583,834P 2020H Capsule 25mg 35.00 MG 7,79
33,057,484
A 13705
Ointment nasal 3g 1 – – 49,053
–P 434
8WCream 20mg (as calcium) per g (2%), 15g
– – 173,971
2,600,650P 435
0YOintment 20mg per g(2%), 15g
– – 193,587
2,886,624
A 13610
Cream 1%500g 1 – – 230 –P 199
6CCream 10mg–2mg per g (1%–0.2%) 50g
– – 30,777
510,170P 199
7DCream 10mg–2mg per g (1%–0.2%) 100g
– – 46,335
985,490ANTIVIRAL
D06BB10 IMIQUIMODA 179
90Cream 5% sachets 6 – – 34,95
7–
A 20128
Cream sachets 50mg per g (5%), 250mg 12
– – 905 –P 254
6BCream 50mg per g (5%), 250mg Sachet 12
– – 21,411
3,440,832P 455 Cream sachets 50mg per g – – 8,27 1,381,
D06BB04 PODOPHYLLOTOXINA 174
02Paint 5mg per mL (0.5%) 3mL (with applicators)
– – 1,807
–A 179
33Cream 1.5mg per g (0.15%) 5g – – 2,72
9–
P 4566H
Paint 5mg per mL (0.5%), 3.5mL (with 30 swabs)
– – 7,660
157,765
88
D
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
DERMATOLOGICALSANTIBIOTICS AND CHEMOTHER. FOR DERMATOLOGICAL USEANTIBIOTICS FOR TOPICAL USEOTHER ANTIBIOTICS FOR TOPICAL USE
D06AX01 FUSIDIC ACIDA 13926 Ointment 2% 15mg 1 – – 20,303 –
D06AX09 MUPIROCIN
D06AX POLYMIXIN B SULPHATE with NEOMYCIN with BACITRACINA 11330 Ointment 15g 1 – – 239 –
CHEMOTHERAPEUTICS FOR TOPICAL USESULFONAMIDES
D06BA51 SILVER SULPHADIAZINE with CHLORHEXIDINE GLUCONATE
OTHER CHEMOTHERAPEUTICS
D06BX01 METRONIDAZOLE
A 17694
Gel 0.75% 30g 1 – – 37,174
–P 403
0DGel 7.5mg per g (0.75%) 50g
– – 17,387
510,742P 434
0KCream 7.5mg per g (0.75%) 30g
– – 28,143
565,706
A 10542
Cream 0.5% 30g 1 – – 142 –A 107
19Cream 0.5% 30g 1 – – 2,63
8–
P 1495Q
Cream 10mg per g (1%) 50g – – 137,267
1,039,027A 161
65Cream 10mg per g (1%) 30g – – 254 –
A 16625
Cream 1%30g 1 – – 28,908
–A 166
26Cream 0.5%30g 1 – – 341 –
A 16627
Cream 1%30g 1 – – 10,120
–P 288
1PCream 10mg per g (1%) 50g – – 219,6
401,661,277P 288
2QTopical ointment 10mg per g (1%) 50g
– – 61,655
468,938P 288
7YCream 10mg per g (1%) 30g – – 101,9
10727,420P 288
8BTopical ointment 10mg per g (1%) 30g
– – 32,131
229,255
P 2117K Cream 200ug per g (0.02%) 100g
– – 289,010
3,942,595P 2118L Ointment 200ug per g
(0.02%) 100g– – 61,27
0835,702
A 10627
Ointment 30g 1 – – 40,211
–P 111
5QCream 500ug per g (0.05%) 15g
– – 364,613
3,750,010P 111
9XOintment 500ug per g (0.05%) 15g
– – 224,750
2,687,243A 128
81Cream 30g 1 – – 25,87
9–
A 15271
Cream 500ug per g (0.05%) 50g
– – 17,540
–A 152
72Ointment 500ug per g (0.05%) 50g
– – 10,590
–A 172
16Scalp lotion 500ug per mL (0.05%) 30mL
– – 538 –A 172
17Scalp lotion 500ug per mL (0.05%) 30mL
– – 25,590
–A 196
28Cream 500ug per g (0.05%) 30g
– – 801 –P 281
2BCream 200ug per g (0.02%) 100g
– – 443,067
6,597,307P 281
3CCream 500ug per g (0.05%) 15g
– – 99,139
767,356P 281
5EOintment 500ug per g (0.05%) 15g
– – 39,108
311,192P 282
0KOintment 200ug per g (0.02%) 100g
– – 83,051
1,245,003P 413
1KCream 1mg per g (0.1%) 30g – – 14,38
2343,942P 413 Ointment 1mg per g (0.1%) – – 8,73 221,
METHYLPREDNISOLONE ACEPONATEP 805
4XCream 1mg per g (0.1%) 15g – – 204,8
843,079,072P 805
5YOintment 1mg per g (0.1%) 15g
– – 111,465
1,918,360P 812
8TOintment 1mg per g (0.1%) 15g
– – 151,380
2,707,988P 861
8NLotion 1mg per g (0.1%) 20g – – 10,02
7164,468
89
D
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
DERMATOLOGICALSCORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONSCORTICOSTEROIDS, PLAINCORTICOSTEROIDS, WEAK (GROUP I)
D07AA02 HYDROCORTISONE
CORTICOSTEROIDS, MODERATELY POTENT (GROUP II)D07AB09 TRIAMCINOLONE ACETONIDE
CORTICOSTEROIDS, POTENT (GROUP III)D07AC01 BETAMETHASONE
D07AC14
90
D
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
DERMATOLOGICALSCORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONSCORTICOSTEROIDS, PLAINCORTICOSTEROIDS, POTENT (GROUP III)
D07AC13 MOMETASONEP 191
3QCream 1mg per g (0.1%) 15g
– – 519,138
7,818,487P 191
5TOintment 1mg per g (0.1%) 15g
– – 286,187
5,451,467P 434
2MCream 1mg per g (0.1%) 45g
– – 38,430
1,187,485P 434
3NOintment 1mg per g (0.1%) 45g
– – 23,555
794,183P 804
3HLotion 1mg per g (0.1% w/w) 30mL
– – 262,521
5,644,260CORTICOSTEROIDS, COMB WITH ANTISEPTICS
CORTICOSTEROIDS, WEAK, COMB WITH ANTISEPTICSD07BA04 HYDROCORTISONE and
CLIOQUINOLA 16100 Cream 1%–1%
30gm– – 9,271 –
A 17035 Cream 1%–1% 60gm
– – 5,243 –CORTICOSTEROIDS, COMB WITH ANTIBIOTICSCORTICOSTEROIDS, WEAK, COMB WITH ANTIBIOTICS
D07CA01 HYDROCORTISONE and CLOTRIMAZOLEA 13540 Cream 1%30g 1 – – 78,319 –
CORTICOSTEROIDS,MODERATELY POTENT,COMB. WITH ANTIBIOTICSD07CB01 TRIAMCINOLONE ACETONIDE with NEOMYCIN with GRAMICIDIN with NYSTATIN
A 11072 Ointment 30g 1 – – 20,690
–P 4482X Ointment 1 mg–2.5 mg
(base)–250 ug–– – 57,04
5882,012CORTICOSTEROIDS, OTHER COMBINATIONS
CORTICOSTEROIDS, WEAK, OTHER COMBINATIONSD07XA01 HYDROCORTISONE with CLOTRIMAZOLE
A 16834 Cream 1% 50g 1 – – 38,568 –CORTICOSTEROIDS, POTENT, OTHER COMBINATIONS
D07XC01 BETAMETHOSONE/CALCIPOTRIOLA 18741 Ointment 500ug per
g 15g– – 7,707 –
A 18742 Ointment 500ug per g 30g
– – 18,141 –
91
D
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
DERMATOLOGICALSANTISEPTICS AND DISINFECTANTSANTISEPTICS AND DISINFECTANTSPHENOL AND DERIVATIVES
D08AE04 TRICLOSAN with ENTSUFONA 11587 Lotion 500mL 1 – – 122 –
IODINE PRODUCTSD08AG02 POVIDONE IODINE
A 10226
Ointment 25g 1 – – 608 –A 102
30Solution 15mL 1 – – 395 –
P 4411E
Solution 100mg per mL (10%) 100mL
– – 5,444 103,769
P 4932N Tube 10g 4 – – 624 56,552P 4933P Tube 20g 2 – – 198 17,565
92
D
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
DERMATOLOGICALSMEDICATED DRESSINGSMEDICATED DRESSINGSOINTMENT DRESSINGS WITH ANTIINFECTIVES
D09AA CADEXOMER IODINE
D09AA09 POVIDONE–IODINEP 4779M Sterile sachets 22.5cm x 7.5cm 12 – – 125 3,888
ZINC BANDAGESD09AB01 BANDAGE ZINC PASTE
P 4750B Bandage 7.5cm x 6m – – 341 20,410SOFT PARAFFIN DRESSINGS
D09AX SOFT PARAFFIN DRESSINGP 4759L Sterile sachets 10cm
x 10cm 10– – 2,192 43,7
92P 4845B Sterile sachets 10cm x 10cm 10
– – 1,722 39,484
A 15680 Gel 0.1% 30G 1 – – 49,593 –A 16348 Cream 0.1% 30g
1– – 41,920 –
A 11780
Cream 0.05%20g 1 – – 17,839 –A 143
54Cream .025% 25g 1 – – 3,758 –
A 14355
Cream 0.05% 25g 1 – – 5,439 –A 143
56Cream 0.1% 25g 1 – – 3,075 –
A 14512
Cream 0.05% 50g 1 – – 20,299 –A 170
39Gel 0.01%30g 1 – – 6,580 –
A 13816
Topical solution 1% 100mL 1
– – 19,901 –A 164
22Topical solution 1% 50mL 1
– – 17,851 –A 165
20Lotion 10mg per mL 60mL
– – 2,590 –A 196
46Gel 1% 30g 1 – – 2,087 –
93
D
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
DERMATOLOGICALSANTI–ACNE PREPARATIONSANTI–ACNE PREPARATIONS FOR TOPICAL USERETINOIDS FOR TOPICAL USE IN ACNE
D10AD03 ADAPALENE
D10AD04 ISOTRETINOINA 14786 Gel 0.05% 30g – – 8,351 –
D10AD01 TRETINOIN
PEROXIDESD10AE51 CLINDAMYCIN with Benzpylperoxide
A 19649 Gel 1%–5% 25g 1 – – 37,872 –ANTIINFECTIVES FOR TREATMENT OF ACNE
D10AF01 CLINDAMYCIN
D10AF02 ERYTHROMYCINA 15129 Gel 2% 30g 1 – – 87,079 –
OTHER ANTI–ACNE PREPARATIONS FOR TOPICAL USED10AX01 ALUMINIUM CHLORIDE
A 10734 Roll–on 20%50mL 1 – – 119 –ANTI–ACNE PREPARATIONS FOR SYSTEMIC USERETINOIDS FOR TREATMENT OF ACNE
D10BA01 ISOTRETINOINP 254
9ECapsule 40mg 30 30.00 MG 86
9118,253P 259
1JCapsule 10mg 30.00 MG 8,36
8797,449P 259
2KCapsule 20mg 30.00 MG 135,1
9619,691,641
D11AC30
P 4405W Scalp cleanser 3mg–3mg–1mg–3mg–10mg per mL –SALICYLIC ACID BENZALKONIUM CHLORIDE
– 794 15,295
and POLYOXYETHYLENE ETHERSP 4445Y Scalp cleanser 20mg–2mg–130mg–216mg per mL –
– 406 6,911D11AC3
0SALICYLIC ACID WITH COAL TAR SOLUTIONP 4560B Scalp cleanser 20mg–50mg per mL (2%–5%) 200mL –
– 3,667 63,919
94
D
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
DERMATOLOGICALSOTHER DERMATOLOGICAL PREPARATIONSOTHER DERMATOLOGICAL PREPARATIONSANTIHIDROTICS
D11AA DIPHEMANIL METHYLSULPHATEP 4191N Dusting powder 20mg per g (2%) 50g – – 6,361
103,746MEDICATED SHAMPOOS
D11AC30 OTHERS
D11AC30 SALICYLIC ACID, COAL TAR SOLUTION, PINE TAR and UNDECYLENAMIDEP 4447C Scalp cleanser 20mg–10mg–10mg–10mg per mL – –
1,391 22,426D11AC03 SELENIUM SULFIDE
A 11876 Shampoo 2.5% 200m 1 – – 130 – P 4452H Shampoo 25mg per mL (2.5%) 125mL ––
1,320 17,212WART AND ANTI–CORN PREPARATIONS
D11AF PODOPHYLLUM RESIN with SALICYLIC ACIDA 11612 Ointment 10g 1 – – 1,748 –
OTHER DERMATOLOGICALSD11AX ALLANTOIN, GLYCEROL and ICHTHAMMOL
P 4280G Ointment 5mg–10mg per g(0.5%–1%–1 %), 50g
– – 386 5,623P 4281H Cream 5mg–10mg–10mg
per g(0.5%–1%–1%),50g– – 688 10,6
32D11AX CATIONIC CONDITIONER with PANTHENOLP 4519W Solution 250mL – – 405 4,9
18D11AX16
EFLORNITHINEA 19662 Cream 11.5%,30 g, 1 – – 851 –
D11AX HYDROLYZED COLLAGEN PROTEINSP 4271T Hair conditioner 250mL – – 1,02
512,225D11AX1
5PIMECROLIMUSA 18308 Cream 1% 30g,1 – – 8,92
0–
P 8802G Cream 10mg per g (1%) 15g – – 31,525
1,001,592D11AX SKIN CLEANSER
P 4549K Lotion 500mL – – 14,938
281,904D11AX ZINC OXIDE, STARCH and CHLORPHENESIN
P 4497Q Dusting powder 100g – – 728 7,981
A 15081
Vaginal cream 2% 40gm 0.10
GM 15,976
–NYSTATINP 401
2ECream pessaries 100,000 units, 15
100.00
TE 1,788 21,867P 401
3FVaginal cream 100,000 units per dose, 15 doses,
100.00
TE 8,943 110,076
95
G
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENITO URINARY SYSTEM AND SEX HORMONESGYNAECOLOGICAL ANTIINFECTIVES AND ANTISEPTICSANTIINFECTIVES/ANTISEPT.,EXCL. COMB. WITH CORTICOSTEROIDSANTIBIOTICS
G01AA10 CLINDAMYCIN
G01AA01
ORGANIC ACIDSG01AD02 RICINOLEIC ACID, ACETIC ACID and HYDROXYQUINOLINE SULPHATE
P 4434J Vaginal jelly 7mg–9.4mg–250ug per g– – 48910,052
IMIDAZOLE DERIVATIVESG01AF15 BUTOCONAZOLE
A 19783 Vaginal Cream 100mg in 5g (2%) 0.10 GM 2,607–
G01AF02 CLOTRIMAZOLEA 159
13Pessary 500mg 0.1
0GM 7,051 –
A 19063
Vaginal cream 50mg per 5g (1%) 35g
0.10
GM 1,568 –A 190
67Vaginal cream 50mg per 5g (1%) 35g
0.10
GM 166 –P 401
4GPessaries 100mg 6 0.1
0GM 7,690 117,
210P 4015H
Pessary 500mg 0.10
GM 6,506 106,366P 401
6JVaginal cream 50mg per 5g (1%) 35g
0.10
GM 32,513
483,362P 401
7KVaginal cream 100mg per 5g (2%)20g
0.10
GM 26,797
420,916G01AF2
0CLOTRIMAZOLE AND FLUCONAZOLEA 20144 Vaginal Cream 1% 10g and capsule 150mg 1
– – 354 –G01AF05
ECONAZOLE NITRATEA 12661 Foam–sol 1%10g 3 0.1
0GM 849 –
A 15473 Pessaries 150 mg, 3 0.10
GM 1,081 –G01AF04
MICONAZOLE NITRATEA 18370 Vaginal ovule 1.2g/cream(2%) 9 g, 100mg per 5g
0.10
GM 629 –P 4021P Vaginal cream 100mg per 5g (2%) 40g
0.10
GM 256 2,421
96
G
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENITO URINARY SYSTEM AND SEX HORMONESOTHER GYNAECOLOGICALSCONTRACEPTIVES FOR TOPICAL USEINTRAUTERINE CONTRACEPTIVES
G02BA03 PLASTIC IUD with PROGASTERONEP 8633J Intrauterine drug 52mg releasing 20ug per 24 hours – – 55,161 12,552,145
G02BA02 POLYETHYLENE COPPERA 13296 Intrauterine device 1 – – 833 –
OTHER GYNAECOLOGICALSPROLACTIN INHIBITORS
G02CB01
BROMOCRIPTINE MESYLATEP 1444B Tablet 2.5mg 5.00 MG 3,39
466,541G02CB0
3CABERGOLINEP 8114C Tablet 0.5mg 0.50 MG 28,15
22,552,608P 8115D Tablet 0.5mg 0.50 MG 2,15
483,907G02CB0
4QUINAGOLIDEP 8822H Tablet 75ug (base)
75.00
UG 614 41,012
97
G
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENITO URINARY SYSTEM AND SEX HORMONESSEX HORMONES AND MODULATORS OF THE GENITAL SYSTEMHORMONAL CONTRACEPTIVES FOR SYSTEMIC USEPROGESTOGENS AND ESTROGENS, FIXED COMBINATIONS
G03AA09
DESOGESTREL with ETHINYLOESTRADIOLA 14249 Tablet 28 1 150 ug/30ug – – 72,9
61–
G03AA DIENOGEST with ETHINYLOESTRADIOLA 19955 Ethinyloest30mg&Dienogest
2mg Tab2mg–– – 2,06
9–
A 19956 Tablet 2mg – 30ug + 7 inert 28x3
– – 9,325
–G03AA ETHINYLOESTRADIOL and ETONOGESTREL
A 19917 Ethinyloest 11.7mg & Etonog 2.7mg vaginal ring 1
– – 10,440
–A 19918 Ethinyloest 11.7mg & Etonog 2.7mg vaginal ring 3
– – 17,993
–G03AA12
ETHINYLOESTRADIOL with DROSPIRENONEA 17645 Tablet 3mg – 30ug 21 + 7 inert
– – 121,155
–A 17646 Tablet 3mg – 30ug 21 + 7 inert,28*3
– – 439,027
–G03AA10
ETHINYLOESTRADIOL with GESTODENEA 15082 Tablets 75ug/30ug, 21 + 7 – – 20,5
56–
G03AA07
LEVONORGESTREL with ETHINYLOESTRADIOLP 1393H Tablets 150ug – 30ug 21
– – 16,166
256,415P 1394J Tablets 150ug – 30ug 21 +
7 iner t, 28– – 1,472,
99623,483,961P 1456P Tablets 125ug – 50ug 21 +
7 iner t– – 93,6
781,494,230A 16212 Tablets 100ug – 50ug 28 – – 122,5
19–
A 16217 Tablets 100ug – 20ug + 7 inert 28
– – 29,968
–A 16970 Tablets 100ug – 20ug 21 + 7 iner t
– – 140,793
–A 17707 Tablets 100ug 20ug + 7 inert 28
– – 236
–A 17708 Tablets 100ug 20ug + 7 inert 28X3
– – 5,499
–G03AA05
NORETHISTERONE with ETHINYLOESTRADIOLP 2772X Tablets 500ug–35ug 21
– – 1,885
29,610P 2773Y Tablets 1mg–35ug, 21 – – 1,12
617,728P 2774B Tablets 500ug–35ug 21 + 7
inert 28– – 141,2
832,219,527P 2775C Pack containing 21 tablets
1mg–35ug– – 93,3
801,466,925G03AA0
5NORETHISTERONE with MESTRANOLP 3176E Tablets 1mg–50ug 21 – – 2,32
936,618P 3179H Tablets 1mg–50ug 21 + 7
inert 28– – 15,5
05244,012G03AA1
2OESTRADID with DROSPIRENONEA 19550 Tablet 1mg – 2mg 28 – – 20,2
23–
G03AB06
ETHINYLOESTRADIOL WITH GESTODENEA 18555 Tablet 30ug/75ug 28x3 – – 14,16
0–
G03AB03
LEVONORGESTREL with ETHINYLOESTRADIOLP 1392G Pack containing 6 tablets
– – 598,542
9,547,473G03AB0
4NORETHISTERONE with ETHINYLOESTRADIOLP 2776D Tablets 500/35ug
– – 8,277
129,889
A 17548
Tablet 0.75mg 2 – – 19,963
–A 191
55Tablet 0.75mg 2 – – 43,76
2–
A 19549
Tablet 0.75mg 2 – – 39,845
–A 201
37Tablet 30ug 28x4 – – 4,83
2–
P 2913H
Tablets 30ug 28 0.03 MG 122,556
1,915,325G03AC06 MEDROXYPROGESTERONE
P 3118D Injection 150mg in 1mL
1.67 MG 247,492
3,310,006G03AC01 NORETHISTERONE
P 1967M Tablets 350ug 28 – – 27,917
438,407ANDROGENS
A 16153
Cream 2%, 50g – – 1,186
–A 163
26Cream 1%, 50g – – 1,34
7–
A 17178
Cream 5%, 50g – – 1,724
–P 210
1NInjection 250mg 18.0
0MG 41,49
41,303,439P 211
4GInjection 250mg in 1mL 18.0
0MG 10,17
5318,754P 211
5HCapsule 40mg 120.
00MG 29,47
81,455,827P 267
0MInjection 100mg 18.0
0MG 6,88
8131,334P 809
8FSubcutaneous implant 100mg 18.0
0MG 2,70
2501,786P 809
9GSubcutaneous implant 200mg 18.0
0MG 3,27
4834,120P 846
0GTransdermal patch 12.2mg (2.5mg per 24 hr) 60
3.00
MG 3,767
380,004P 861
9PTransdermal patch 24.3mg (5mg per 24 hr) 30
3.00
MG 8,367
847,580P 883
0RTransdermal gel 50mg in 5mg sachet 30
50.00
MG 40,740
4,339,589P 900
4XInjection 1000 mg in 4mL 18.0
0MG 18,27
22,683,425
98
G
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENITO URINARY SYSTEM AND SEX HORMONESSEX HORMONES AND MODULATORS OF THE GENITAL SYSTEMHORMONAL CONTRACEPTIVES FOR SYSTEMIC USEPROGESTOGENS AND ESTROGENS,SEQUENTIAL PREPARATIONS
PROGESTOGENSG03AC08 ETONOGESTREL
P 8487Q Subcutaneous implant 68mg 0.07 MG 60,954 13,075,123G03AC03 LEVONORGESTREL
3–OXOANDROSTEN (4) DERIVATIVESG03BA03 TESTOSTERONE
5–ANDROSTANON (3) DERIVATIVESG03BB01 MESTEROLONE
A 11642 Tablet 25mg 50 50.00MG 793 –
A 16209
Tablet 1mg 28 2.00
MG 6,529
–A 162
10Tablet 2mg 28 2.0
0MG 13,18
3–
P 1742Q
Vaginal tablets 25ug 0.03
MG 429,013
8,871,450P 174
3RTransdermal patches 2mg 8 0.0
5MG 66,71
31,091,017P 174
4TTransdermal patches 4mg 8 0.0
5MG 85,61
01,399,413P 174
5WTransdermal patches 8mg 8 0.0
5MG 25,40
0474,580A 189
85Transdermal patches 5.7mg(rel 75ug/24hrs)
0.05
MG 134 –A 202
78Transdermal patches 3.28mg (rel 37.5ug/24hrs)
0.05
MG 902 –A 202
79Transdermal patches 4.33mg (rel 50ug/24hrs)8
0.05
MG 833 –A 202
80Transdermal patches 6.57mg (rel 75ug/24hrs)8
0.05
MG 375 –A 202
81Transdermal patches 8.66mg (rel 100ug/24hrs)8
0.05
MG 125 –P 801
2QTransdermal patches 3.28mg 0.0
5MG 18,59
9302,284P 801
3RTransdermal patches 4.33mg(rel 50ug/24hrs)
0.05
MG 16,034
260,846P 801
4TTransdermal patches 6.57mg(rel 50ug/24hrs)
0.05
MG 7,809
144,677P 804
1FTransdermal patches 8.66mg(rel 100ug/24hrs)
0.05
MG 6,854
130,242P 812
5PTransdermal patches 3.9mg(rel 50ug/24hrs)
0.05
MG 54,192
885,398P 812
6QTransdermal patches 7.8mg(rel 100ug/24hrs)
0.05
MG 20,269
385,994P 814
0KTransdermal patches 1.5mg(rel 50ug/24hrs)
0.05
MG 22,323
365,150P 828
6DTransdermal gel 1mg in 1g sachet 28
1.00
MG 84,880
1,475,736P 831
1KTransdermal pat 750ug (rel 25ug/24 hrs)
0.05
MG 11,906
194,519P 831
2LTransdermal patch 3mg (rel 100ug/24 hrs)
0.05
MG 8,964
169,020P 848
5NTransdermal patches 2mg(rel 25ug/24hrs)
0.05
MG 25,965
423,595P 848
6PTransdermal patches 5.7mg(rel 75ug/24hrs)
0.05
MG 8,466
158,172P 864
5BNasal spray 150 ug per actuation, 60 actuat, 4.2mL
0.30
MG 20,290
450,100P 876
1DTransdermal patches 3.9mg(rel 25ug/24hrs)
0.05
MG 9,255
150,873P 876
2ETransdermal patches 5.85mg(rel 37.5ug/24hrs)
0.05
MG 17,043
279,800P 876
3FTransdermal patches 7.8mg(rel 500ug/24hrs)
0.05
MG 31,616
516,167P 876
4GTransdermal patches 1.17mg(rel 75ug/24hrs)
0.05
MG 14,267
265,294P 876 Transdermal patches 0.0 MG 12,76 240,
OESTRADIOL VALERATEP 166
3MTablets 1mg 28 2.0
0MG 46,16
2494,793P 166
4NTablets 2mg 28 2.0
0MG 72,82
2976,100A 196
26Injection 10mg in 1mL 1.0
0MG 179 –
P 4365R
Implant 50mg 1 – – 1,398
48,896P 436
6TImplant 100mg 1 – – 5,24
7592,509P 827 Tablets 2mg 56 2.0 MG 4,47 58,1
OESTRIOLP 177
1FPessaries 500ug 15 0.2
0MG 59,75
61,163,008P 178
1RVaginal cream 1mg per g (0.1%), 15g
0.20
MG 293,309
4,945,089A 197
32Tablets 1mg 30 2.0
0MG 3,78
6–
99
G
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENITO URINARY SYSTEM AND SEX HORMONESSEX HORMONES AND MODULATORS OF THE GENITAL SYSTEMESTROGENSNATURAL AND SEMISYNTHETIC ESTROGENS, PLAIN
G03CA03 OESTRADIOL
G03CA03
G03CA04
100
P 1733F Tablets 300ug 28
0.63 MG 199,826
2,573,122P 1734G Tablets 625ug 0.63 MG 339,5 4,549,
OESTRONEA 114
13Tablet 625ug 100 1.00 MG 176 –
P 1777M
Tablet 730ug 1.00 MG 68,183
731,633P 177
8NTablet 1.46mg 1.00 MG 69,00
8902,461
A 14247
Tablet 2.5mg 5.00
MG 1,949
–P 231
9CInjection 50 mg in 1 mL 7.0
0MG 495 5,6
99P 2321E
Tablet 10mg 5.00
MG 43,494
659,958P 232
3GTablet 5mg 56 5.0
0MG 124,7
201,729,681P 272 Tablet 10mg 5.0 MG 16,96 521,
PROGESTERONEA 153
28Cream 3.2% 50g – – 1,25
3–
A 16638
Cream 10% 50g – – 406 –A 187
49Pessaries 100mg 15 90.0
0MG 215 –
A 18750
Pessaries 200mg 15 90.00
MG 323 –P 636
6CGel Vaginal (prolonged release) 90mg single dose
90.00
MG 390 –
G
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENITO URINARY SYSTEM AND SEX HORMONESSEX HORMONES AND MODULATORS OF THE GENITAL SYSTEMESTROGENSNATURAL AND SEMISYNTHETIC ESTROGENS, PLAIN
G03CA57 OESTROGENS CONJUGATED
G03CA07
OTHER ESTROGENSG03CX01 TIBOLONE
A 16835 Tablet 2.5mg 28 2.50 MG 277,577 –A 20242 Tablet 2.5mg 28 2.50 MG 17
0–
PROGESTOGENSPREGNEN (4) DERIVATIVES
G03DA02 MEDROXYPROGESTERONE
G03DA04
PREGNADIEN DERIVATIVESG03DB01 DYDROGESTERONE
P 1350C Tablet 10mg 10.00MG 12,207 182,550ESTREN DERIVATIVES
G03DC02 NORETHISTERONEP 2993M Tablet 5mg 5.00 MG 144,9674,985,523
101
P 8168X Tablet 625ug 2.5mg 28
0.63
MG 143,881
2,339,362P 8169Y Tablet 625ug 5mg 28 0.6 MG 213,4 3,474,
NORETHISTERONE AND ESTROGENP 8081H Pack containing 28
tablets 2mg–1mg2.00
MG 136,106
2,218,593P 8353P Tablets 1mg–500ug, 28 – – 201,2
553,270,577
G03GA08
CHORIOGONADOTROPIN ALFAP 9606N Powder for injection 250ug withsolvent 1
0.25
MG 139 –G03GA05
FOLLITROPIN ALFAP 8713N Injection 300i.u. in 0.5mL multi–dose cartridge
75.00
IE 580 306,768P 8714P Injection 450i.u. in
0.75mL multi–dose cartridge75.00
IE 349 261,740P 8715Q Injection 900i.u. in 1.5mL
multi–dose cartridge75.00
IE 923 1,062,310G03GA0
6FOLLITROPIN BETAP 8565T Soln for injection 300iu in 0.36mL mulit–dose cart
75.00
IE 1,148
581,993P 8566W Soln for injection 600iu in
0.75mL mulit–dose cart75.00
IE 1,639
1,175,861P 8871X Soln for injection 900iu in
1.08mL mulit–dose cart75.00
IE 564 603,024G03GA0
1HUMAN CHORIONIC GONADOTROPHINP 1579D Ampoules pdr for inj. 500units 1ml solvent 3/3
250.00
IE 645 44,496P 1581F Ampoules pdr for inj.
1500units 1ml solvent 3/3250.00
IE 5,856
329,286P 6181H Ampoules pdr for inj.
5000units 1ml solvent 3/3250.00
IE 453 –
G
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENITO URINARY SYSTEM AND SEX HORMONESSEX HORMONES AND MODULATORS OF THE GENITAL SYSTEMPROGESTOGENS AND ESTROGENS IN COMBINATIONPROGESTOGENS AND ESTROGENS,FIXED COMBINATIONS
G03FA12 MEDROXYPROGESTERONE AND ESTROGEN
G03FA01
PROGESTOGENS AND ESTROGENS,SEQUENTIAL PREPARATIONSG03FB08
DYDROGESTERONE AND ESTROGENP 8244X tabs estradiol 2mg+est/dydro 2mg/10mg,28mg(14/14)2.00
MG 8,285
134,362G03FB0
6MEDROXYPROGESTERONE AND ESTROGENA 19194 Pack 14 tablets oestrogens 625ug 0.63
MG 564 –G03FB05
OESTRADIOL with NORETHISTERONE ACETATEP 176
4WTablets sequential pack 2mg–1mg
2.00
MG 100,479
1,636,592P 802
9NPack containing 4 transdermal patches oestradiol
0.05
MG 12,553
232,538P 842
5KTransdermal patch 4 4.33mg, 4 620ug/2.7mg
0.05
MG 13,694
254,414P 842
6LTransdermal patch 4 4.33mg, 4 510ug/4.8mg
0.05
MG 10,236
188,200P 842
7MTransdermal patch 620ug/2.7mg, 8
0.05
MG 63,682
1,177,186P 842
8NTransdermal patch 510ug/4.8mg, 8
0.05
MG 27,101
499,996GONADOTROPHINS AND OTHER OVULATION STIMULANTS
GONADOTROPHINS
OVULATION STIMULANTS, SYNTHETIC
G03GB02 CLOMIPHENE CITRATEP 1211R Tablet 50mg 9.00 MG 38,729 1,523,269
P 1269T
Tablet 50mg 0.10 GM 22,125
1,783,189P 127
0WTablet 50mg 0.10 GM 13,6
333,638,009P 801
9CTablet 100mg 0.10 GM 37,9
8511,150,222
P 1285P Capsule 100mg 0.60 GM 656 37,749P 1287R Capsule 200mg 0.60 GM 1,863 163,
772
102
G
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENITO URINARY SYSTEM AND SEX HORMONESSEX HORMONES AND MODULATORS OF THE GENITAL SYSTEMANTIANDROGENSANTIANDROGENS, PLAIN PREPARATIONS
G03HA01 CYPROTERONE ACETATE
ANTIANDROGENS AND ESTROGENSG03HB01 CYPROTERONE and OESTROGEN
A 14126
Tablet 35ug/2mg 28 1 – – 23,071 –A 141
27Tablet 35ug/2mg 28 3 – – 133,794 –
A 15418
Tablet 28 1 – – 11,116 –A 154
19Tablet 28 3 – – 74,822 –
A 17090
Tablet 28 1 – – 17,229 –A 170
91Tablet 28 3 – – 130,274 –
A 18070
Tablet 35ug/2mg 28 1 – – 25,634 –A 180
71Tablet 35ug/2mg 28 3 – – 241,066 –
A 19849
Tablet 2mg 11 / 2mg + 1mg 1
– – 581
–OTHER SEX HORM. & MODULATORS OF THE GENITAL SYSTEMANTIGONADOTROPINS AND SIMILAR AGENTS
G03XA01 DANAZOL
G03XA02 GESTRINONEP 8015W Capsule 2.5mg 0.70 MG 368 28,553
ANTIGONADOTROPINS AND SIMILAR AGENTSG03XC01 RALOXIFENE
P 8363E Tablet 60mg 28 60.00MG 327,606 18,924,321
A 19785 Tablet modified release 7.5 mg (H B r salt) 28
7.50
MG 1,498
–A 19786 Tablet modified release 7.5 MG 432 –OXYBUTYNINA 20073 Transdermal patch
3.9mg per 24hrs 83.90
MG 266 –P 8039D Tablet 5mg 15.0 MG 233,3 3,568,SOLIFENACINA 19781 Tablet 5mg 30 5.0
0MG 46,54
7–
A 19782 Tablet 10mg 30 5.0 MG 14,34 –TOLTERODINEA 18891 Tablet 1mg 56 4.0
0MG 4,49
7–
A 18892 Tablet 2mg 56 4.00
MG 14,856
–
P 4579B Intracavernosal injection 10ug in single syringe
0.02
MG 8,905
723,052P 4580C Intracavernosal injection 0.0 MG 16,5 1,697,
SILDENAFILP 458
4GTablet 25mg 4 50.0
0MG 3,00
31,032,264P 458
5HTablet 50mg 4 50.0
0MG 60,5
595,422,103P 458
6JTablet 100mg 4 50.0
0MG 353,1
6227,083,612P 960 Tablet 20mg 90 50.0 MG 54 506,
TADALAFILA 188
63Tablet 20mg 8 10.0
0MG 45,2
67–
P 4596X
Tablet 10mg 4 10.00
MG 18,053
1,272,569P 459 Tablet 20mg 4 10.0 MG 267,6 20,322
VARDENAFILA 179
60Tablet 10mg 2 10.0
0MG 26
4–
A 17961
Tablet 10mg 4 10.00
MG 9,405
–A 179
62Tablet 20mg 2 10.0
0MG 76
5–
A 17963
Tablet 20mg 2 10.00
MG 57,243
–
103
G
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENITO URINARY SYSTEM AND SEX HORMONESUROLOGICALSOTHER UROLOGICALS, INCL. ANTISPASMODICSURINARY ANTISPASMODICSG04BD10 DARIFENACIN
G04BD04
G04BD08
G04BD07
DRUGS USED IN ERECTILE DYSFUNCTIONG04BE01 ALPROSTADIL
G04BE03
G04BE08
G04BE09
OTHER UROLOGICALSG04BX SODIUM BICARBONATE
P 4458P Capsule 840 mg – – 15,734
204,008G04BX SODIUM CITRO–TARTRATE
A 19768 Sachets cont. oral effervescent powder 4g 28
– – 239 –P 4049D Sachets cont. oral effervescent powder 4g 28
– – 29,757
366,997
P 4396J
Starter pack 7 tablets 1mg and 7 tablets 2mg
5.00
MG 157 2,863P 439
7KTablet 2mg 5.0
0MG 1,882 80,1
78P 4398L
Tablet 5mg 5.00
MG 2,962 174,681P 439
9MTablet 10mg 5.0
0MG 927 78,6
91
104
G
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENITO URINARY SYSTEM AND SEX HORMONESUROLOGICALSDRUGS USED IN BENIGN PROSTATIC HYPERTROPHYALPHA–ADRENORECEPTOR ANTAGONISTS
G04CA02 TAMSULOSINA 19574 Capsule 400ug (modified release) 0.40 MG
184,938 –G04CA03 TERAZOSIN
TESTOSTERONE–5–ALPHA REDUCTASE INHIBITORSG04CB01 FINASTERIDE
A 16113 Tablet 1mg 28 – – 73,836
–P 4233T Tablet 5mg 5.00 MG 55,04
15,943,097
P 6423C
Injection 60mg (base) single dose syringe
3.00
MG 324 464,313P 642
4DInjection 90mg (base) single dose syringe
3.00
MG 173 333,978P 642 Injection 120mg (base) single 3.0 MG 321 733,
OCTREOTIDEP 622
8TInjection 100ug in 1mL ampoule 5
0.70
MG 234 185,844P 642
6FInj(mod release) 10mg(base) vial + diluent syringe
0.70
MG 142 226,665P 642
7GInj(mod release) 20mg(base) vial + diluent syringe
0.70
MG 751 1,627,489P 642
8HInj(mod release) 30mg(base) vial + diluent syringe
0.70
MG 1,010
2,984,364
105
H
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
SYSTEMIC HORMONAL PREP EXCL.SEX HORMONESPITUITARY, HYPOTHALAMIC HORMONES AND ANALOGUESANTERIOR PITUITARY LOBE HORMONES AND ANALOGUESACTH
H01AA02 TETRACOSACTRINP 2832C Injection 1mg in 1mL 0.25 MG 372 25,463
THYROTROPHINH01AB01 THYROTROPIN
P 2700D Powder for injection 0.9mg 2 – – 163 310,286SOMATROPIN AND ANALOGUES
H01AC01 SOMATROPINP 6266T Injection 4mg vial with 3.5mL diluent 2.00 IE 209 –
POSTERIOR PITUITARY LOBE HORMONESVASOPRESSIN AND ANALOGUESH01BA02 DESMOPRESSIN
P 2129C
Intranasal solution 100ug per mL 2.5mL
25.00
UG 3,446
574,055P 866
2XTablet 200mg 90 400.
00UG 4,30
3685,982P 866
3YTablet 200mg 30 400.
00UG 13,03
5945,827P 871
1LNasal spray (pump pack) 10ug per mL 5, 60 act
6mL 25.00
UG 13,378
2,243,222P 871
2MNasal spray (pump pack) 10ug per mL 5, 60 act
6mL 25.00
UG 34,827
3,178,983HYPOTHALAMIC HORMONES
GONADOTROPHIN–RELEASING HORMONESH01CA02 NAFARELIN
P 2962X Nasal spray (pump pack) 200 ug base per dose 60 0.40 MG3,319 314,855
ANTIGROWTH HORMONEH01CB03 LANREOTIDE
H01CB02
106
H
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
SYSTEMIC HORMONAL PREP EXCL.SEX HORMONESCORTICOSTEROIDS FOR SYSTEMIC USECORTICOSTEROIDS FOR SYSTEMIC USE, PLAINMINERALOCORTICOIDS
H02AA02 FLUDROCORTISONE ACETATEP 1433K Tablet 100ug 0.10 MG 25,720 420,633
GLUCOCORTICOIDSH02AB01
BETAMETHASONEP 2694T Injection 3mg–3.9mg (equiv.to 5.7 mg) in 1ml
1.50
MG 62,168
1,523,122H02AB1
6BUDESONIDEA 16037 Capsule 3mg 50 9.0
0MG 135 –
A 16038 Capsule 3mg 90 9.00
MG 3,203
–H02AB10
CORTISONEP 1246N Tablet 5mg 37.5
0MG 10,16
8204,201P 1247P Tablet 25mg 37.5
0MG 32,29
8493,074H02AB0
2DEXAMETHASONEP 1291Y Injection 8mg in 2mL 1.5
0MG 10,82
3283,664P 1292B Tablet 500ug 1.5
0MG 27,37
5208,595P 2507Y Tablet 4mg 1.5
0MG 90,26
5935,206P 2509C Injection 4mg in 1mL 1.5
0MG 7,89
6134,880P 3472R Injection 4mg in 1mL 1.5
0MG 8,33
5131,156H02AB0
9HYDROCORTISONEP 1499X Tablet 4mg 30.0
0MG 21,73
7278,640P 1500Y Tablet 20mg 30.0
0MG 16,20
3219,373P 1501B Injection equivalent to
100mg with 2ml solvent30.00
MG 3,343
53,156P 1510L Injection equivalent to
100mg with 2ml solvent30.00
MG 10,335
373,408P 1511M Injection equivalent to
250mg with 2ml solvent30.00
MG 388 23,685P 3096Y Injection equivalent to
250mg with 2ml solvent30.00
MG 576 8,588P 3470P Injection equivalent to
100mg with 2ml solvent30.00
MG 10,689
161,313P 3471Q Injection equivalent to
250mg with 2ml solvent30.00
MG 8,611
126,826H02AB0
4METHYLPREDNISOLONEP 1928L Injection 40mg in 1mL 20.0
0MG 48,53
31,124,991P 2981X Injection equiv to 40mg
methylprednisolone20.00
MG 4,454
290,930P 8834Y Injection equiv to 1g
methylprednisolone = diluent20.00
MG 1,803
347,892H02AB0
6PREDNISOLONEP 1916W Tablet 25mg 10.0
0MG 508,5
635,153,408P 1917X Tablet 5mg 10.0
0MG 677,5
335,435,961P 3152X Tablet 1mg 10.0
0MG 209,5
821,616,254P 8285C Oral solution equiv to 5mg
prednisolone per mL10.00
MG 337,304
4,552,420H02AB0
7PREDNISONEP 1934T Tablet 1mg 10.0
0MG 104,1
15803,726P 1935W Tablet 5mg 10.0
0MG 325,5
072,618,264P 1936X Tablet 25mg 10.0
0MG 229,7
702,339,078H02AB0
8TRIAMCINOLONE ACETONIDEA 11073 Ampoule 40mg per ml 5 7.5
0MG 1,05
0–
107
P 2990J Injection 10mg in 1mL 7.50
MG 25,632
628,695
P 2173J
Tablet equivalent to 200ug anhydrous
0.15
MG 66,885
1,760,872P 217
4KTablet equivalent to 50ug anhydrous
0.15
MG 573,112
11,499,339P 217
5LTablet equivalent to 100ug anhydrous
0.15
MG 557,938
11,782,561
108
H
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
SYSTEMIC HORMONAL PREP EXCL.SEX HORMONESTHYROID THERAPYTHYROID PREPARATIONSTHYROID HORMONES
H03AA01 LEVOTHYROXINE SODIUM
H03AA02 LIOTHYRONINEP 2318B Tablet 20ug 60.00UG 10,931 913,396
ANTITHYROID PREPARATIONSTHIOURACILS
H03BA02 PROPYLTHIOURACILP 1955X Tablet 50mg 0.10 GM 16,306 742,752
SULPHUR–CONTAINING IMIDAZOLE DERIVATIVESH03BB01 CARBIMAZOLE
P 1153Q Tablet 5mg 15.00MG 72,598 2,041,505
109
H
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
SYSTEMIC HORMONAL PREP EXCL.SEX HORMONESPANCREATIC HORMONESGLYCOGENOLYTIC HORMONESGLYCOGENOLYTIC HORMONES
H04AA01 GLUCAGON HYDROCHLORIDEP 1449G Injection set
containing 1mg (1 i.u.)1.00
MG 28,829
1,188,153P 3467L Injection set
containing 1mg (1 i.u.)1.00
MG 16,346
663,202
110
H
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
SYSTEMIC HORMONAL PREP EXCL.SEX HORMONESCALCIUM HOMEOSTASISANTI–PARATHYROID AGENTSCALCITONIN PREPARATIONS
H05BA01 CALCITONIN (SALMON SYNTHETIC)
P 2997R Injection (salmon) 100iu in 1mL ampoule 100.00 IE253 58,371
110
A 18808
Capsule 100mg 21 0.10
GM 489 –A 188
11Capsule 50mg 25 0.1
0GM 436 –
P 2702F
Tablet 100mg (HCl salt after 1 Oct 2007) 28
0.10
GM 80,802
1,253,634P 270
3GCapsule 100mg (as HCl salt after 1 Oct 2007)
0.10
GM 58,515
920,204P 270
7LCapsule 50mg (as HCl salt after 1 Oct 2007)
0.10
GM 275,334
2,769,343P 270
8MCapsule 100mg (as HCl salt after 1 Oct 2007)
0.10
GM 288,826
2,333,396P 270
9NTablet 100mg (as HCl salt after 1 Oct 2007)
0.10
GM 378,781
3,098,252P 271
1QTablet 50mg (as HCl salt after 1 Oct 2007) 25
0.10
GM 403,129
4,042,687P 271
4WTablet 100mg (as HCl salt after 1 Oct 2007) 21
0.10
GM 61,244
786,963P 271
5XCapsule 100mg (as HCl salt after 1 Oct 2007)
0.10
GM 46,135
599,749P 332
1TTablet 100mg 0.1
0GM 4,36
034,349P 332
2WCapsule 100mg 0.1
0GM 1,61
912,816P 508
2LTablet 100mg (monohydrate) 7
0.10
GM 205 1,653P 910
5FTablet 100mg (monohydrate) 7
0.10
GM 30,014
240,455P 910
6GTablet 50mg (as monohydrate) 25
0.10
GM 52,897
531,200P 910
7HTablet 100mg (monohydrate) 28
0.10
GM 5,764
90,632P 910 Tablet 100mg (as 0.1 GM 3,10 40,0
MINOCYCLINEP 1616C Tablet 50mg 0.2
0GM 426,5
137,178,352P 3037W Capsule 100mg 0.2
0GM 3,29
831,871
J
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USEANTIBACTERIALS FOR SYSTEMIC USETETRACYCLINESTETRACYCLINES
J01AA02 DOXYCYCLINE
J01AA08
111
P 1878W
Sachet containing oral powder 3g
1.00
GM
16,853
162,565P 188
3DChewable tablet 250mg 1.0
0GM
91,396
813,980P 188
4ECapsule 250mg 1.0
0GM
378,891
3,061,729P 188
6GPowder for syrup 125mg per 5mL 100mL
1.00
GM
557,918
5,729,532P 188
7HPowder for syrup 250mg per 5mL 100mL
1.00
GM
903,836
10,276,464P 188
8JPowder paediatric oral drops 100mg per mL 20mL
1.00
GM
156,248
1,856,170P 188
9KCapsule 500mg 1.0
0GM
2,806,862
30,517,241A 197
39Powder for syrup 250mg per 5mL 100mL
1.00
GM
560
–A 199
85Capsule 250mg 1.0
0GM
422
–A 199
87Powder for syrup 125mg per 5mL 100mL
1.00
GM
394
–P 330
0QCapsule 500mg 1.0
0GM
485,213
5,138,028P 330
1RCapsule 250mg 1.0
0GM
74,944
599,847P 330
2TPowder for syrup 125mg per 5mL 100 mL
1.00
GM
11,972
122,787P 330
3WChewable tablet 250mg 1.0
0GM
1,682
14,920P 330
9ESachet containing oral powder 3g
1.00
GM
33,686
294,067P 339
3NPowder for syrup 250mg per 5mL 100mL
1.00
GM
7,788
87,938P 522
5BPowder for oral suspension 500mg per 5mL 100mL
1.00
GM
183
2,555P 858
1PTablet 1g 14 1.0
0GM
330,392
3,606,149P 870
5EPowder for oral suspension 500mg per 5mL 100mL
1.00
GM
43,292
609,155P 971 Powder paediatric oral drops 1.0 G 39 2,8
AMPICILLINP 239
0TInjection 500mg (solvent required)
2.00
GM
280
3,256P 267
1NCapsule 500mg 2.0
0GM
2,130
28,880P 297
7QInjection 1g (solvent required) 2.0
0GM
8,472
160,458
J
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USEANTIBACTERIALS FOR SYSTEMIC USEBETA–LACTAM ANTIBACTERIALS,PENICILLINSPENICILLINS WITH EXTENDED SPECTRUM
J01CA04 AMOXYCILLIN
J01CA01
P 8167W
Injection 900mg in 2mL cartridge–needle unit
3.60
GM 235 11,594P 874
3EInjection 900mg in 2mL cartridge–needle unit
3.60
GM 196 10,374P 900
2TPowder for injection 900mg(1.2MU)1–needle unit
3.60
GM 1,047
57,033P 900 Powder for injection 3.6 GM 1,19 84,9
BENZATHINE PHENOXYMETHYLPENICILLINP 235
4XOral suspension 250mg per 5mL 100mL
2.00
GM 113,638
1,668,431P 235
6BPaediatric oral suspension 125mg per 5mL 100mL
2.00
GM 39,174
472,769P 336
5DPaediatric oral suspension 125mg per 5mL 100mL
2.00
GM 223 2,171P 336 Oral suspension 250mg per 2.0 GM 187 2,2
BENZYLPENICILLINP 177
5KInjection 600mg (solvent required )
3.60
GM 7,022
439,554P 264
7HInjection 3g (solvent required) 3.6
0GM 1,33
0116,512P 339
8WInjection 600 mg (solvent required)
3.60
GM 130 2,344P 348
6LInjection 600mg (with sterilised water)
3.60
GM 4,881
153,081P 348 Injection 3g (solvent supplied) 3.6 GM 3,59 39,5
PHENOXYMETHYLPENICILLINP 170
3PTablet 250mg 2.0
0GM 10,65
7126,072P 170
5RCapsule 250mg 2.0
0GM 27,46
7321,178P 178
7CTablet 250mg 2.0
0GM 21,70
9248,764P 178
9ECapsule 250mg 2.0
0GM 30,82
4351,337P 296
5CCapsule 500mg 2.0
0GM 236,9
373,529,216P 302
8JTablet 500mg 2.0
0GM 111,7
351,629,524P 336
0WTablet 250mg 2.0
0GM 3,08
827,642P 336
1XTablet 500mg 2.0
0GM 4,31
245,312P 336
3BCapsule 250mg 2.0
0GM 4,13
341,264P 336 Capsule 500mg 2.0 GM 13,01 154,
PROCAINE PENICILLINP 1794K Injection 1.5g 0.6
0GM 9,19
0501,986P 3485K Injection 1.5g 3.6
0GM 21,82
81,190,434
112
J
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USEANTIBACTERIALS FOR SYSTEMIC USEBETA–LACTAM ANTIBACTERIALS,PENICILLINSBETA–LACTAMASE SENSITIVE PENICILLINS
J01CE08 BENZATHINE PENICILLIN
J01CE10
J01CE01
J01CE02
J01CE09
DICLOXACILLINP 812
1KCapsule 250mg 2.0
0GM 44,33
5530,556P 812
2LCapsule 500mg 2.0
0GM 329,7
057,120,497P 812
3MInjection 500mg (solvent required)
2.00
GM 188 3,780P 812 Injection 1g (solvent 2.0 GM 1,81 72,9
FLUCLOXACILLINP 152
4FInjection 500mg (solvent required )
2.00
GM 236 6,628P 152
5GInjection 1g (solvent required)
2.00
GM 16,266
974,215P 152
6HCapsule 250mg 2.0
0GM 58,34
8710,585P 152
7JCapsule 500mg 2.0
0GM 346,1
987,497,996P 152
8KPowder for syrup 125mg per 5mL 100mL
2.00
GM 16,528
223,967P 152
9LPowder for syrup 250mg per 5mL 100mL
2.00
GM 60,476
1,143,955A 197
42Powder for syrup 125mg per 5mL 100mL
2.00
GM 860 –P 509
1YCapsule 500mg 2.0
0GM 223 4,0
64
P 1891M
Tablet 500mg–125mg 1.00
GM
451,911
5,823,230P 189
2NPowder for syrup 125mg–31.25mg per 5mL 75mL
1.00
GM
64,687
803,400P 500
6LTablet 875mg–125mg 1.0
0GM
47,627
748,681P 500
8NTablet 500mg–125mg 1.0
0GM
11,369
142,793P 500
9PPowder for syrup 125mg–31.25mg per 5mL 75mL
1.00
GM
132
1,609P 501
1RPowder for syrup 400mg–57mg per 5mL 50mL
1.00
GM
307
4,346P 825
4KTablet 875mg–125mg 1.0
0GM
2,615,949
42,330,455P 831 Powder for syrup 400mg– 1.0 G 428,4 6,249,
TICARCILLIN with CLAVULANIC ACIDP 2179Q Injection 3g–100mg
(solvent required)15.00
GM
23,728
3,687,904P 6884H Injection 3 g–100 mg
10mL and NS15.00
GM
3,190
603,050
113
J
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USEANTIBACTERIALS FOR SYSTEMIC USEBETA–LACTAM ANTIBACTERIALS,PENICILLINSBETA–LACTAMASE RESISTANT PENICILLINS
J01CF01
J01CF05
COMBINATIONS OF PENICILLINS, INCL.BETA–LACTAMASE INHIBITORSJ01CR02 AMOXYCILLIN with CLAVULANIC ACID
J01CR03
P 3058Y
Capsule 250mg 2.00
GM
351,414
3,018,442P 309
4WGranules for syrup 125mg per 5mL 100mL
2.00
GM
143,105
1,649,175P 309
5XGranules for syrup 250mg per 5mL 100mL
2.00
GM
366,250
4,970,765P 311
9ECapsule 500mg 2.0
0GM
3,375,522
37,337,308P 331
7NCapsule 250mg 2.0
0GM
4,464
37,294P 331
8PCapsule 500mg 2.0
0GM
25,041
270,315P 331
9QGranules for syrup 125mg per 5mL 100mL
2.00
GM
292
3,316P 332
0RGranules for syrup 250mg per 5mL 100mL
2.00
GM
342
4,488J01DB0
3CEPHALOTHINP 2964B Injection 1g (solvent required)
4.00
GM
53,569
2,201,067J01DB0
4CEPHAZOLINP 1257E Injection 1g (solvent required)
3.00
GM
18,992
1,219,249
P 1169M
Tablet 375mg (sustained release)
1.00
GM 711,290
9,827,196A 198
62Tablet 375mg (sustained release)10
1.00
GM 520 –P 246
0LPowder for oral susp 125mg per 5mL 100mL
1.00
GM 146,695
2,003,208P 246
1MPowder for oral susp 250mg per 5mL 75mL
1.00
GM 318,293
4,490,337P 504
5MTablet 375mg (sustained release)
1.00
GM 645 8,752
P 1085D Injection 1g (solvent required)
4.00
GM 1,775 44,954P 1086E Injection 2g (solvent
required)4.00
GM 408 17,372
A 17175
Injection 1g (solvent required)
2.00
GM 223 –P 178
4XInjection 1g (solvent required)
2.00
GM 47,187
1,706,617P 178
5YInjection 2g (solvent required)
2.00
GM 6,011
393,619A 198
28Injection 250mg (solvent required )
2.00
GM 274 –A 198
55Injection 500mg (solvent required )
2.00
GM 176 –P 905
8RInjection 500mg (solvent required )
2.00
GM 277 2,561
114
J
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USEANTIBACTERIALS FOR SYSTEMIC USEOTHER BETA–LACTAM ANTIBACTERIALSFIRST–GENERATION CEPHALOSPORINS
J01DB01 CEFALEXIN
SECOND–GENERATION CEPHALOSPORINSJ01DC04 CEFACLOR
J01DC02 CEFUROXIMEP 8292K Tablet 250mg 14 0.50 GM 104,7361,643,820
THIRD–GENERATION CEPHALOSPORINSJ01DD01 CEFOTAXIME
J01DD02 CEFTAZIDIMEA 12747 Vial 1g 1 6.00 GM 410 –
J01DD04 CEFTRIAXONE
FOUTH–GENERATION CEPHALOSPORINSJ01DE01 CEFEPIME
P 8315P Injection 1g (solvent required)
2.00
GM 191
48,256P 8316Q Injection 2g (solvent
required)2.00
GM 201
83,337
A 19032
Tablet 500mg 3 0.30
GM
2,696
–P 411
5NTablet 500mg 0.3
0GM
5,024
248,208P 622
1KTablet 600mg 0.3
0GM
139
10,808P 820
0NTablet 500mg 0.3
0GM
57,834
1,273,502P 820
1PPowder for oral suspension 200mg per 5mL 15mL
0.30
GM
2,705
58,378P 833 Tablet 500mg 2 0.3 G 32,7 718,
CLARITHROMYCINA 164
32Liquid 250mg per 5mL 1 0.5
0Gm
443
–P 615
2TTablet 500mg 100 0.5
0GM
207
21,136P 831 Tablet 250mg 14 0.5 G 602,9 8,380,
ERYTHROMYCINP 139
7MI.V. infusion 1g (base) 1.0
0GM
734
36,799P 140
4XCapsule 250mg 1.0
0GM
135,523
1,307,730P 242
4NGranules for paediatric oral susp 200mg
1.00
GM
116,956
1,286,480P 242
8TGranules for oral susp 400mg (base) per 5mL 10
1.00
GM
173,662
2,206,418P 275
0RTablet 400mg (base) 1.0
0GM
385,520
3,576,299P 332
5BCapsule 250mg 1.0
0GM
19,314
175,694P 333
4LGranules for paediatric oral suspension 200mg
1.00
GM
263
2,892P 333
6NTablet 400mg (base) 1.0
0GM
7,812
69,956P 333 Granules for oral suspension 1.0 G 11 1,4
ROXITHROMYCINP 176
0PTablet 150mg 0.3
0GM
897,554
11,035,764P 801
6XTablet 300mg 0.3
0GM
1,327,041
16,538,159P 812
9WTablet for oral suspension 50 mg
0.30
GM
74,342
862,224
115
J
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USEANTIBACTERIALS FOR SYSTEMIC USESULFONAMIDES AND TRIMETHOPRIMTRIMETHOPRIM AND DERIVATIVES
J01EA01 TRIMETHOPRIMP 2922T Tablet 300mg 0.40 GM 748,8486,102,309
COMBINATIONS OF SULFONAMIDES AND TRIMETHOPRIM, INCL. DERIVATIVESJ01EE01 TRIMETHOPRIM with SULPHAMETHOXAZOLE
A 20264
Oral suspension 40 mg–200 mg per 5 mL, 100 mL
– – 699 –P 294
9FTablet 80mg–400mg – – 7,01
273,544P 295
1HTablet 160mg–800mg – – 338,2
293,524,117P 310
3HOral suspension 40mg–200mg per 5mL 100mL
– – 117,048
1,041,113P 339
0KTablet 160mg–800mg – – 1,12
710,248MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
MACROLIDESJ01FA10 AZITHROMYCIN
J01FA09
J01FA01
J01FA06
A 14783
Ampoule 300mg 2mL 1.80 GM 129 –A 166
44Capsule 150mg 100 1.20 GM 228 –
P 3138E
Capsule 150mg 1.20 GM 99,376
3,376,419P 505
7ECapsule 150mg 1.20 GM 32,86
2580,212
P 1208N
Tablet 250mg 1.00 GM 17,657
787,588P 120
9PTablet 500mg 1.00 GM 123,4
4310,041,412P 121
0QTablet 750mg 1.00 GM 37,4
135,209,115P 131 Tablet 250mg 1.00 GM 4,03 50,7
MOXIFLOXACINA 19908 Tablet 400mg
(base) 50.40 GM 35
9–
P 4329W Tablet 400mg 5 0.40 GM 6,22 318,NORFLOXACINA 13660 Tablet 400mg 6 0.80 GM 45,6
59–
P 3010K Tablet 400mg 0.80 GM 203,030
4,841,840
116
J
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USEANTIBACTERIALS FOR SYSTEMIC USEMACROLIDES, LINCOSAMIDES AND STREPTOGRAMINSLINCOSAMIDES
J01FF01 CLINDAMYCIN
J01FF02 LINCOMYCINP 2530E Injection 600mg in 2mL 1.80 GM 2,325 86,697
AMINOGLYCOSIDE ANTIBACTERIALSOTHER AMINOGLYCOSIDES
J01GB03 GENTAMICIN SULPHATEP 2824P Injection 80mg (base) in 2mL 0.24 GM 21,197
426,979J01GB01 TOBRAMYCIN
P 1356J Injection 80mg (base) 0.24
GM 2,354 275,751P 8872Y Injection 80mg (base) in
2mL (without preserv)0.24
GM 824 111,687QUINOLONE ANTIBACTERIALS
FLUOROQUINOLONESJ01MA02 CIPROFLOXACIN
J01MA14
J01MA06
P 2270L
Powder for injection 1 gm(1000000iu) 3
2.00
GM 486 95,077P 313
0RInjection 500mg(500000iu) (solvent required)
2.00
GM 948 78,247P 313
1TInjection 500mg(500000iu) (solvent required)
2.00
GM 29,541
5,082,038
P 1692C Capsule 50mg 0.20 GM 73,506
1,094,989P 1693D Capsule 100mg 0.20 GM 84,67
41,902,255
117
J
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USEANTIBACTERIALS FOR SYSTEMIC USEOTHER ANTIBACTERIALSGLYCOPEPTIDE ANTIBACTERIALS
J01XA01 VANCOMYCIN
STEROID ANTIBACTERIALSJ01XC01 FUSIDIC ACID
P 2312Q Tablet (sodium salt) 250mg (enteric coated) 1.50 GM 20,3783,432,717
IMIDAZOLE DERIVATIVESJ01XD01 METRONIDAZOLE
P 1638F I.V. infusion 500mg in 100mL 1.50 GM 31,928 1,350,459NITROFURAN DERIVATIVES
J01XE01 NITROFURANTOIN
OTHER ANTIBACTERIALSJ01XX05 METHENAMINE
P 3124K Tablet 1g 2.00 GM 72,431 2,612,617
P 1572R Tablet 200mg 0.20 GM 20,965
829,289P 1573T Tablet 200mg 0.20 GM 29,92
6571,956
A 14171
Capsule 150mg 1 0.20
GM 26,157
–P 147
1KCapsule 50mg 28 0.2
0GM 3,67
2566,668P 147
2LCapsule 100mg 28 0.2
0GM 9,39
72,832,676P 147
3MSolution for IV infusion 100mg in 50mL 7
0.20
GM 150 31,835P 147
4NSolution for IV infusion 200mg in 100mL 7
0.20
GM 729 405,813P 147
5PCapsule 200mg 0.2
0GM 8,15
65,114,752A 159
80Susp 50mg/5mL 35mL 0.2
0GM 133 –
A 19776
Capsule 150mg 1 0.20
GM 21,962
–A 199
01Capsule 150mg 1 0.2
0GM 7,30
4–
A 19902
Capsule 150mg 1 0.20
GM 3,853
–A 201
46Capsule 150mg 1 0.2
0GM 296 –
A 202 Capsule 150mg 1 0.2 GM 162 –ITRACONAZOLEA 148
10Capsule 100mg 0.2
0GM 1,86
0–
A 16227
Capsule 100mg 28 0.20
GM 1,765
–P 819
6JCapsule 100mg 0.2
0GM 5,67
61,707,380
118
J
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USEANTIMYCOTICS FOR SYSTEMIC USEANTIMYCOTICS FOR SYSTEMIC USEANTIBIOTICS
J02AA01 AMPHOTERICINP 1047D Injection 50mg (solvent required) 35.00 MG 135 15,014
IMIDAZOLE DERIVATIVESJ02AB02 KETOCONAZOLE
TRIAZOLE DERIVATIVESJ02AC01 FLUCONAZOLE
J02AC02
P 1981G
Capsule 150mg 0.60
GM 1,246 12,453P 198
2HCapsule 150mg 0.6
0GM 568 19,4
66P 1983J
Capsule 300mg 0.60
GM 2,254 139,307P 198
4KCapsule 300mg 0.6
0GM 8,114 117,
119PHYDRAZID
ES
8025J
Syrup 100mg per 5mL 60mL
0.60
GM 460 14,914
119
J
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USEANTIMYCOBACTERIALSDRUGS FOR TREATMENT OF TUBERCULOSISANTIBIOTICS
J04AB02 RIFAMPICIN
J04AC01 ISONIAZIDP 1554T Tablet 100mg 0.30 GM 1,217 11,761
DRUGS FOR TREATMENT OF LEPRADRUGS FOR TREATMENT OF LEPRA
J04BA02 DAPSONEP 1272Y Tablet 100mg 50.00 MG 2,638 286,
429P 8801F Tablet 25mg 50.00 MG 1,146 114,577
120
ACICLOVIRP 100
3TTablet 200mg 4.00 GM 5,37
2477,538P 100
7BTablets 200mg 90 4.00 GM 33,2
405,373,444P 105
2JTablets 800mg 35 4.00 GM 8,31
31,602,143P 823 Tablets 800mg 120 4.00 GM 21 123,
FAMCICLOVIRA 196
96Tablet 250mg 14 0.75 GM 39
0–
A 19996
Tablet 500mg 3 0.75 GM 1,806
–P 800
2ETablet 250mg 0.75 GM 45,0
926,440,727P 809
2XTablet 125mg 0.75 GM 10,2
301,397,901P 821
7LTablet 250mg 0.75 GM 60,6
7421,796,412P 889
6FTablet 500mg 56 0.75 GM 3,29
61,186,028P 889 Tablet 500mg 30 0.75 GM 2,05 417,
VALACICLOVIRP 806
4KTablet 500mg 3.00 GM 32,8
947,000,810P 813
3CTablet 500mg 3.00 GM 15,5
091,621,972P 813
4DTablet 500mg 3.00 GM 283,9
5247,523,669
J
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USEANTIVIRALS FOR SYSTEMIC USEDIRECT ACTING ANTIVIRALSNUCLEOSIDES AND NUCLEOTIDES EXCL. REVERSE TRANSCRIPTASE INHIBITORS
J05AB01
J05AB09
J05AB11
PROTEINASE INHIBITORSJ05AE08 ATAZANAVIR
P 6451M Capsule 150mg (base) 60 0.30 GM 1,649 755,867NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS
J05AF08
ADEFOVIR DIPIVOXILP 6450L Tablet 30mg 30 10.0
0MG 3,52
52,379,053J05AF0
2DIDANOSINEP 6300N Capsule 250mg (enteric coated beads)
0.40
GM 122 –P 6301P Capsule 400mg (enteric coated beads)
0.40
GM 111 26,608J05AF1
0ENTECAVIRP 9602J Tablet 0.5mg 30 0.5
0MG 4,09
81,691,517P 9603K Tablet 1mg 30 0.5
0MG 1,59
81,068,214J05AF0
5LAMIVUDINEP 6193Y Tablet 150 mg 0.3
0GM 236 14,1
04P 6257H Tablet 100mg 0.30
GM 8,692
1,397,246P 6435Q Tablet 300mg 30 0.3
0GM 347 –
J05AF04
STAVUDINEP 6190T Capsule 40mg 80.0
0MG 191 21,6
25
121
A 17034 Capsule 75mg 10 – – 32,118 –A 18057 Suspension 12mg
per ml 1– – 3,102 –
J
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USEANTIVIRALS FOR SYSTEMIC USEDIRECT ACTING ANTIVIRALSNON–NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
J05AG03 EFAVIRENZP 6356M Tablet 600mg 30 0.60 GM 188 53,964
J05AG01 NEVIRAPINEP 6215D Tablet 200mg 0.40 GM 1,613 463,702
NEURAMINIDASE INHIBITORSJ05AH02 OSELTAMIVIR
J05AH01 ZANAMIVIRA 16327 Rotadisk 5mg 20 20.00MG 2,034 –
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONJ05AR LOPINAVIR WITH RITONAVIR
P 6495W Tablet 200mg – 50mg 120 – – 1,304 927,288J05AR0
3TENOFOVIR DISOPROXIL and EMTRICITABINEP 6468K Tablet 300mg (base)–
– – 259 207,927J05AR0
4ZIDOVUDINE LAMIVUDINE and ABACAVIRP 6327B Tablet 300mg (base) 150mg–300mg 6 0
– – 243 891J05AR0
1ZIDOVUDINE and LAMIVUDINEP 6234D Tablet 150mg – 300mg – – 850 516,
350
A 17391
Vial 0.5mL 1 – – 1,113 –A 176
37Syringe 10ug per 0.5mL conjugated 1
– – 430
–A 201
45Injection 10mg per 0.5mL prefilled syringe 1
– – 111
–
P 3463G Injection 0.5mL in pre–filled syringe
– – 31,906
5,962,919P 8783G Injection 0.5mL in pre–
filled syringe– – 11,94
1641,331
J07AP01
SALMONELLA–TYPHIA 19176 Oral live attenuated capsule Typhoid
– – 5,912 –J07AP01
TYPHOID ORAL LIVE ATTENUATEDA 13158 Cap–ec 3 1 – – 37
7–
J07AP03
TYPHOID PURIFIED POLYSACCHARIDE ANTIGENA 14718 Syringe 0.5mL
– – 69,900 –A 16719 Injection 25ug – – 23,080 –
122
J
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USEVACCINESBACTERIAL VACCINESCHOLERA VACCINES
J07AE02 CHOLERA, LIVE ATTENUATEDA 18382 Oral granules Cholera, inactivated 14 – – 38,161–
HEMOPHILUS INFLUENZA B VACCINESJ07AG01 HAEMOPHILUS INFLUENZA B CONJUGATE VACCINE
A 16731 Injection 0.5mL 1 – – 149 –J07AG01 HAEMOPHILUS INFLUENZA B CONJUGATE and HEPATITIS B VACCINES
A 19684 Injection 0.5mL, 1 – – 171 –J07AG01 HAEMOPHILUS INFLUENZA B VACCINE
A 14180 Injection 0.5mL 1 – – 371 –MENINGOCOCCAL VACCINES
J07AH04 MENINGOCOCCALA 14507 Vial 0.5mL 1 – – 7,569 –
J07AH07 MENINGOCOCCAL C
PERTUSSIS VACCINESJ07AJ52 DIPHTERIA WITH TETANUS WITH PERTUSSIS PURIFIED ANTIGEN
A 17092 Injection 0.5mL 1 – – 19,183 –PNEUMOCOCCAL VACCINES
J07AL01 PNEUMOCOCCALP 1903E Injection 0.5mL (23 valent) – – 39,871 1,586,900
TETANUS VACCINESJ07AM51 TETANUS TOXOID, COMBINATIONS with DIPTHERIA
TYPHOID,VACCINES
OTHER BACTERIAL VACCINESJ07AX Q FEVER
A 15417 Vaccine 0.5mL – – 167 –
A 19065 Injection 0.25mL – – 163
–P 2852D Injection (trivalent)
0.5mL– – 848,2
1915,124,221
A 15677
Syringe 720u/0.5mL – – 13,750 –A 156
87Syringe 144u 1 – – 60,827 –
A 15770
Syringe 25u 1 – – 276
–A 157 Syringe 50u 1 – – 87 –HEPATITIS A\HEPATITIS BA 157
60Syringe 1mL – – 128,521 –
A 15917
Syringe 0.5mL – – 1,745 –A 170 Syringe 0.5mL – – 1,749 –HEPATITIS BA 129
13Vial 1mL 1 – – 5,578 –
A 12914
Vial 0.5mL 1 – – 825
–A 130
26Ampoule 20ug per mL 1 – – 61,644 –
A 13473
Ampoule 10ug per 0.5ml 1
– – 3,151 –A 157
83Vial 40ug per mL 1 – – 1,243 –
A 17628
Vial 5ug/0.5mL (paediatric) 10
– – 230
–A 176
29Vial 10ug/0.5mL (adult) 10
– – 228
–
A 14107 Injection 1mL 1 – – 2,242 –A 19166 Injection 2.5ug 1 – – 1,174 –
123
J
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USEVACCINESVIRAL VACCINESENCEPHALITIS VACCINES
J07BA02 JAPANESE ENCEPHALITIS VACCINEA 16423 Vaccine 1mL vial 3 – – 1,259 –
J07BB02 INFLUENZA VACCINE
HEPATITIS VACCINESJ07BC02 HEPATITIS A
J07BC20
J07BC01
J07BC20 SALMONELLA and HEPATITIS AA 17818 Prefilled syringe 25ug and 160 Elisa units – – 73,764
–MEASLES VACCINES
J07BD52 MEASLES with MUMPS with RUBELLA UBELLA)A 18509 Injection 0.5mL 1 – – 4,008 –
POLIOMYELITIS VACCINESJ07BF03 POLIOMYELITIS
A 16235 Injection 0.5mL – – 11,281 –RABIES VACCINES
J07BG01 RABIES INACTIVATED
ROTA VIRUS DIARRHEA VACCINESJ07BH01 ROTAVIRUS VACCINE,LIVE
A 19674 Oral liquid 2mL 1 – – 5,465 –A 19688 Oral liquid 2mL 1 – – 14,748 –
A 16723 Vaccine 0.5mL – – 15,856 –A 17821 Vaccine 0.5mL – – 82
0–
124
J
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
GENERAL ANTIINFECTIVES FOR SYSTEMIC USEVACCINESVIRAL VACCINESRUBELLA VACCINES
J07BJ01 RUBELLAA 11227 Injection 0.5mL – – 1,896 –
VARICELLA VACCINESJ07BK01 VARICELLA LIVE ATTENUATED
YELLOW FEVER VACCINESJ07BM02 VACCINE PAPILLOMAVIRUS (HUMAN TYPES 16 AND 18)
A 20142 Injection 0.5mL prefilled syringe 1 – – 885 –BACTERIAL AND VIRAL VACCINES, COMBINEDBACTERIAL AND VIRAL VACCINES, COMBINED
J07CA02 DIPHTHERIA–PERTUSSIS–POLIOMYELITIS–TETANUSA 19175 Injection 0.5mL, 1 – – 15,782 –
P 1031G
Injection 2g (solvent required)
– – 10,881
458,642P 107
9TInjection 500mg (solvent required)
– – 2,099 56,036P 108
0WInjection 1g (solvent required)
– – 6,350 176,675P 126
6PTablet 50mg – – 8,678 254,
964P 5914G
Injection 500mg (solvent required)
– – 2,380 25,847P 591
5HInjection 1g (solvent required)
– – 4,352 73,071P 591 Injection 2g (solvent – – 1,129 33,5
IFOSFAMIDEP 594
3TPowder for I.V. injection 1g – – 146 14,8
21P 5944W
Powder for I.V. injection 2g – – 230 54,898P 807
6CPowder for I.V. injection 1g – – 355 99,0
88P 8077D
Powder for I.V. injection 2g – – 723 339,278
P 5900M Powder for injection 208mg with solvent
– – 268 254,210P 8786K Powder for injection
208mg with solvent– – 631 947,
384
125
L
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTSANTINEOPLASTIC AGENTSALKYLATING AGENTSNITROGEN MUSTARD ANALOGUES
L01AA02 CHLORAMBUCILP 1163F Tablet 2mg – – 4,585 505,396
L01AA01 CYCLOPHOSPHAMIDE
L01AA06
L01AA03 MELPHALANP 2547C Tablet 2mg – – 3,239 85,469
ALKYL SULPHONATESL01AB01 BUSULPHAN
P 1128J Tablet 2mg – – 39417,254
NITROSOUREASL01AD05 FOTEMUSTINE
OTHER ALKYLATING AGENTSL01AX03
TEMOZOLOMIDEP 588
3PCapsule 100mg 15 – – 112 234,
737P 5982W
Capsule 100mg 5 – – 185 357,313P 598
3XCapsule 250mg 5 – – 131 236,
759P 8378Y
Capsule 5mg – – 172 48,481P 837
9BCapsule 20mg 5 – – 1,09
5785,041P 838
0CCapsule 100mg 5 – – 3,35
38,364,052P 838
1DCapsule 250mg 5 – – 1,38
22,756,543P 881
9ECapsule 5mg 15 – – 207 79,7
49P 8820F
Capsule 20mg 15 – – 825 834,157P 882
1GCapsule 100mg 15 – – 1,01
62,827,995
P 1622J
Tablet 2.5mg – – 83,958
1,023,476P 162
3KTablet 10mg – – 90,07
74,149,839P 239
5CInjection 50mg in 2mL – – 15,65
8552,361P 239
6DInjection 5mg in 2mL – – 1,16
985,350P 596
2TInjection 5mg in 2mL – – 351 5,4
59P 5963W
Injection 50mg in 2mL – – 557 5,960P 885
1WSolution concentrate I.V. infusion 1000mg in 10mL
– – 344 133,368P 885 Solution concentrate I.V. – – 114 115,
PEMETREXEDP 580
1HPowder for I.V. infusion 500mg (base) 2
– – 315 988,869P 588
7WPowder for I.V. infusion 500mg (base) 2
– – 168 466,924P 880
9PPowder for I.V. infusion 500mg (base) 2
– – 352 1,152,196P 971
3FPowder for I.V. infusion 500mg (base) 2
– – 1,610
5,705,758
P 8361C Tablet 150mg – – 2,028
274,428P 8362D Tablet 500mg 120 – – 20,4 15,958
CYTARABINEP 2884T Injection set containing
100mg and 5mL solvent– – 1,16
3417,558P 5918L Injection set containing – – 53 16,2
FLUOROURACILP 252
8CInjection 500mg in 10mL – – 39,1
042,256,554P 422
2FCream 50mg per g (5%) 20g – – 86,9
713,986,055P 587
2CInjection 1000mg in 20mL 5 – – 2,08
971,387P 593
5JInjection 500mg in 10mL – – 12,0
13369,525P 900 Injection 100mg in 20mL 5 – – 2,21 119,
GEMCITABINEP 593
6KPowder for I.V. infusion 200mg (base)
– – 3,001
479,357P 593
7LPowder for I.V. infusion 1gm (base)
– – 5,938
2,560,473P 804
9PPowder for I.V. infusion 200mg (base)
– – 5,354
2,173,310P 805
0QPowder for I.V. infusion 1gm (base)
– – 15,317
13,872,910
126
L
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTSANTINEOPLASTIC AGENTSANTIMETABOLITESFOLIC ACID ANALOGUES
L01BA01 METHOTREXATE
L01BA04
L01BA03 RALTITREXEDP 8284B Powder for I.V. infusion 2mg – – 201 184,354
PURINE ANALOGUESL01BB02 MERCAPTOPURINE
P 1598D Tablet 50mg – – 12,817 2,503,265L01BB03 THIOGUANINE
P 1233X Tablet 40mg – – 714 85,580PYRIMIDINE ANALOGUES
L01BC06 CAPECITABINE
L01BC01
L01BC02
L01BC05
P 2199R Injection set containing 10mg and 10mL solvent
– – 1,126
90,885P 5989F Injection set containing – – 1,05 29,0
VINCRISTINE SULPHATEP 2374Y Injection set containing
1mg and 1mL solvent– – 5,30
0656,172P 5991H Injection set containing – – 2,79 89,8
VINORELBINEP 599
2JSolution for I.V. infusion 10mg (base) in 1mL
– – 258 68,837P 599
3KSolution for I.V. infusion 50mg (base) in 5mL
– – 792 333,737P 828
0TSolution for I.V. infusion 10mg (base) in 1mL
– – 793 715,803P 828
1WSolution for I.V. infusion 50mg (base) in 5mL
– – 1,797
1,907,947P 900
9ECapsule 20 mg (base),20 – – 158 270,
699
127
L
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTSANTINEOPLASTIC AGENTSPLANT ALKALOIDS AND OTHER NATURAL PRODUCTSVINCA ALKALOIDS AND ANALOGUES
L01CA01 VINBLASTINE SULPHATE
L01CA02
L01CA04
PODOPHYLLOTOXIN DERIVATIVESL01CB01 ETOPOSIDE
P 1389D
Capsule 100 mg – – 398
164,360P 139
0ESolution for I.V. infusion 100mg in 5mL
– – 1,957
351,286P 139
6LCapsule 50mg – – 72
6340,323P 593
1ESolution for I.V. infusion 100mg in 5mL
– – 790
77,128P 593
2FPowder for I.V. infusion 113.6mg
– – 3,201
288,073P 593
3GPowder for I.V. infusion 1136mg
– – 123
36,851P 812
0JPowder for I.V. infusion 113.6mg
– – 3,564
643,644P 851
5EPowder for I.V. infusion 1136mg
– – 653
231,105P 901
0FCapsule 30 mg,16 – – 25
8521,237TAXANES
L01CD02 DOCETAXELP 592
1PInjection set containing I.V. infusion 20mg
– – 2,255
1,427,059P 592
2QInjection set containing I.V. infusion 80mg
– – 2,939
4,705,059P 807
1TInjection set containing I.V. infusion 20mg
– – 5,954
8,887,147P 807
4YInjection set containing I.V. infusion 80mg
– – 8,433
20,273,507L01CD01 PACLITAXEL
P 3017T
Solution for I.V. infusion 150mg in 25mL
– – 3,321
7,726,727P 302
6GSolution for I.V. infusion 30mg in 5mL
– – 2,679
2,918,217P 597
3JSolution for I.V. infusion 30mg in 5mL
– – 1,516
530,600P 597
4KSolution for I.V. infusion 100mg in 16.7mL
– – 1,565
1,410,195P 597
5LSolution for I.V. infusion 150mg in 25mL
– – 1,415
1,625,881P 597
6MSolution for I.V. infusion 300mg in 50mL
– – 1,189
2,131,692P 801
8BSolution for I.V. infusion 100mg in 16.7mL
– – 4,170
8,019,247P 836
0BSolution for I.V. infusion 300mg in 50mL
– – 6,675
14,433,522
P 1336H
Solution for I.V. or intravesical 10mg
– – 724 71,084P 134
0MSolution for I.V. or intravesical 20mg
– – 1,020
169,090P 134
2PSolution for I.V. or intravesical 50mg
– – 13,323
5,162,915P 587
9KSolution for I.V. or intravesical 100mg in 50mL
– – 1,181
294,638P 589
1CSolution for I.V. infusion 20mg in 10mL
– – 472 482,194P 589
2DSuspn for IV infusion 50mg in 25mL
– – 406 652,652P 592
5WSolution for I.V. or intravesical 10mg
– – 776 54,063P 592
6XSolution for I.V. or intravesical 20mg
– – 1,076
118,470P 592
7YSolution for I.V. or intravesical 50mg
– – 5,048
1,051,434P 856
9BSuspn for IV infusion 20mg in 10mL
– – 1,334
2,643,367P 857
0CSuspn for IV infusion 50mg in 25mL
– – 1,490
3,614,389P 882
7NSolution for I.V. or intravesical 100mg in 50mL
– – 1,492
505,063P 882 Solution for I.V. or intravesical – – 138 93,6
EPIRUBICIN HYDROCHLORIDEP 137
5JSolution for I.V. injection 10mg in 5mL 4
– – 489 70,519P 137
6KSolution for I.V. injection 20mg in 10mL 4
– – 517 135,892P 137
7LSolution for I.V. injection 50mg in 25mL 3
– – 5,824
4,943,590P 587
1BPowder for injection 50mg 3 – – 127 79,6
39P 5884Q
Solution for injection 200mg in 100mL
– – 219 188,320P 588
5RSolution for injection 100mg in 50mL 2
– – 589 391,977P 592
8BSolution for I.V. injection 10mg in 5mL 4
– – 429 36,802P 592
9CSolution for I.V. injection 20mg in 10mL 4
– – 581 98,585P 593
0DSolution for I.V. injection 50mg in 25mL 3
– – 2,051
1,208,525P 881
7CSolution for injection 100mg in 50mL 2
– – 1,815
1,673,772P 885
8FSolution for injection 200mg in 100mL
– – 1,787
1,823,435P 901
8PPowder for injection 50mg 3 – – 325 232,
681
P 1929M
Injection 20mg in 10mL – – 1,624 504,210P 193
0NInjection 25mg in 12.5mL
– – 1,232 472,414P 193
2QInjection 10mg in 5mL – – 357 66,7
79P 5965Y
Injection 20mg in 10mL – – 536 142,593P 596
6BInjection 25mg in 12.5mL
– – 256 83,827
P 2315W Injection 15,000 units (solvent required)
– – 1,013 301,122P 5903Q Injection 15,000 units
(solvent required)– – 1,580 147,
213
128
L
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTSANTINEOPLASTIC AGENTSCYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCESANTHRACYCLINES AND RELATED SUBSTANCES
L01DB01 DOXORUBICIN HYDROCHLORIDE
L01DB03
L01DB06 IDARUBICIN HYDROCHLORIDEP 8531B Solution for I.V. injection 10mg in 10mL – – 165
339,489L01DB07 MITOZANTRONE
OTHER CYTOTOXIC ANTIBIOTICSL01DC01 BLEOMYCIN
L01DC03 MITOMYCINA 13990 Vial 2mg 10 – – 836 –
P 1160C
Solution for I.V. injection 50mg in 5mL
– – 1,408
86,035P 116
1DSolution for I.V. injection 150mg in 15mL
– – 9,777
3,738,748P 116
2ESolution for I.V. injection 450mg in 45mL
– – 7,782
1,990,540P 590
6WSolution for I.V. injection 50mg in 5mL
– – 1,384
55,168P 590
7XSolution for I.V. injection 150mg in 15mL
– – 4,454
609,211P 590 Solution for I.V. injection – – 4,97 727,
CISPLATINP 257
8QI.V. injection 10mg in 10mL – – 24
89,072P 257
9RI.V. injection 50mg in 50mL – – 3,29
6142,304P 258
0TI.V. injection 100mg in 100mL
– – 8,805
599,193P 590
9BI.V. injection 10mg in 10mL – – 11
3786
P 5910C
I.V. injection 50mg in 50mL – – 1,368
26,702P 591 I.V. injection 100mg in – – 3,64 171,
OXALIPLATINP 587
7HSolution for I.V. infusion 50mg in 10mL
– – 2,113
874,414P 587
8JSolution for I.V. infusion 100mg in 20mL
– – 4,371
4,078,758P 599
4LPowder for I.V. infusion 50mg
– – 228
124,547P 599
5MPowder for I.V. infusion 100mg
– – 438
531,937P 853
9KPowder for I.V. infusion 50mg
– – 2,648
2,426,059P 854
0LPowder for I.V. infusion 100mg
– – 5,784
10,049,759P 884
7PSolution for I.V. infusion 50mg in 10mL
– – 3,795
4,236,403P 884
8QSolution for I.V. infusion 100mg in 20mL
– – 8,079
15,477,120
P 5896H
Solution for IV infusion 100mg\10mL
– – 2,657
2,182,543P 589
7JSolution for IV infusion 500mg\50mL
– – 2,351
5,344,289P 597
8PSolution for IV infusion 100mg\10mL
– – 3,612
3,092,954P 597
9QSolution for IV infusion 500mg\50mL
– – 3,354
7,664,448P 829
3LSolution for IV infusion 100mg\10mL
– – 9,475
11,582,372P 829
4MSolution for IV infusion 500mg\50mL
– – 9,796
24,532,701P 866
5CSolution for IV infusion 100mg\10mL
– – 9,645
11,500,093P 866
6DSolution for IV infusion 500mg\50mL
– – 9,724
24,267,035P 961
1WSolution for IV infusion 500mg\50mL
– – 255
1,144,128
129
L
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTSANTINEOPLASTIC AGENTSOTHER ANTINEOPLASTIC AGENTSPLATINUM COMPOUNDSL01XA02 CARBOPLATIN
L01XA01
L01XA03
MONOCLONAL ANTIBODIES
L01XC07 BEVACIZUMABA 19029 Soln for IV infusion 100mg/4mL – – 341 –
L01XC02 RITUXIMAB
L01XC03 TRASTUZUMABP 6497Y Powder for IV infusion 150mg – – 18,117 64,143,435
130
P 2482P
Tablet 50mg 60 – – 139
737,270P 248 Tablet 70mg 60 – – 21 1,382,
GEFITINIBP 876 Tablet 250mg 30 – – 49 1,927,IMATINIBP 644
0YTablet 100mg (base) 60 – – 67
42,381,810P 644
1BTablet 400mg (base) 30 – – 1,97
47,563,698P 644
4ETablet 100mg (base) 60 – – 3,77
314,478,215P 644
5FTablet 400mg (base) 30 – – 7,72
131,542,221P 644
6GTablet 100mg (base) 60 – – 60
12,763,247P 644
7HTablet 400mg (base) 30 – – 65
23,178,144P 911
2NTablet 400mg (base) 30 – – 16
4644,636P 911
3PTablet 100mg (base) 60 – – 15
0585,560P 911
4QTablet 400mg (base) 30 – – 25
31,039,955
P 5958N
I V injection 40mg in 2mL
– – 1,158
202,357P 595
9PI V injection 100mg in 5mL
– – 2,477
1,857,205P 841
4WI V injection 40mg in 2mL
– – 2,098
1,088,661P 841
5XI V injection 100mg in 5mL
– – 7,238
10,304,709
L
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTSANTINEOPLASTIC AGENTSOTHER ANTINEOPLASTIC AGENTSPROTEIN KINASE INHIBITORSL01XE06 DASATINIB
L01XE02
L01XE01
OTHER ANTINEOPLASTIC AGENTSL01XX05 HYDROXYUREA
P 3093T Capsule 500mg – – 32,469 2,464,019L01XX19 IRINOTECAN
L01XX17 TOPOTECANP 8199M Powder for I.V. infusion 4mg (base) – – 180
383,659
131
P 2316X
Tablet 200mg 1000.00
MG 1,691 183,557P 272
5KTablet 100mg 1000.
00MG 2,203 210,
891P 2727M
Tablet 250mg 1000.00
MG 202 26,971P 272
8NTablet 500mg 1000.
00MG 850 114,
202
P 1454M
Subcutaneous implant 3.6mg 0.13
MG 21,590
7,170,382P 809
3YSubcutaneous implant 10.8mg (base) in prefilled
0.13
MG 46,604
51,510,480P 906
4CSubcutaneous implant 3.6mg(base) in prefilled
0.13
MG 171
90,718P 906
5DSubcutaneous implant 10.8mg (base) in prefilled
0.13
MG 183
235,712P 906 Subcutaneous implant 10.8mg 0.1 MG 65 1,083,
LEUPRORELIN ACETATEA 147
27Injection 5mg 0.1
3MG 64
3–
P 8707G
Suspn subcutaneous inj(mod rel) 7.5mg inj set
0.13
MG 650
272,151P 870
8HSuspn subcutaneous inj(mod rel) 22.5mg inj set
0.13
MG 1,901
2,100,548P 870
9JSuspn subcutaneous inj(mod rel) 30mg inj set
0.13
MG 1,239
1,778,968P 885
9GSuspn subcutaneous inj(mod rel) 45mg inj set
0.13
MG 1,958
4,113,465P 887
5DI.M. injection (modified release) 7.5mg diluent
0.13
MG 5,025
2,106,832P 887
6EI.M. injection (modified release) 22.5mg diluent
0.13
MG 13,302
14,702,667P 887
7FI.M. injection (modified release) 30mg diluent
0.13
MG 9,470
13,590,294
L
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTSENDOCRINE THERAPYHORMONES AND RELATED AGENTSPROGESTOGENS
L02AB02 MEDROXYPROGESTERONE
L02AB01 MEGESTROLP 2734X Tablet 160mg 160.00 MG 1,486 107,714
GONADOTROPHIN RELEASING HORMONE ANALOGUESL02AE03 GOSERELIN
L02AE02
P 2109B
Tablet 10mg (base) 60
20.00
MG 5,082
236,006P 211
0CTablet 20mg (base) 60
20.00
MG 135,671
10,404,706L02BA0
2TOREMIFENE
P Tablet 60mg (base) 60.00
MG 3,377
229,333
L02BB03
BICALUTAMIDEP 8094B Tablet 50mg 50.00 MG 34,85
47,750,574L02BB0
1FLUTAMIDEP 1417N Tablet 250mg 750.00 MG 3,37
3728,439L02BB0
2NILUTAMIDEP 8131Y Tablet 150mg 30.00 MG 4,92
01,128,243
132
L
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTSENDOCRINE THERAPYHORMONE ANTAGONISTS AND RELATED AGENTSANTI–ESTROGENS
L02BA01 TAMOXIFEN
ANTI–ANDROGENS
ENZYME INHIBITORSL02BG01
AMINOGLUTETHIMIDEP 1036M Tablet 250mg 1000.
00MG 49
378,337L02BG0
3ANASTROZOLEP 8179L Tablet 1mg 1.00 MG 167,4
2531,277,431L02BG0
6EXEMESTANEP 8506Q Tablet 25mg 30
25.00 MG 14,002
2,613,220L02BG0
4LETROZOLEP 8245Y Tablet 2.5mg 2.50 MG 66,8
9312,490,623
P 6291D Injection 300ug in 0.5mL syringe
0.35
MG 1,745
3,433,036P 6292E Injection 480ug in
0.5mL syringe0.35
MG 788 3,611,767
P 8289G
Inj. set 1 vial powder dose 30ug(6000000 i.u.)
4.30
UG 3,634
3,833,505P 840
3GInj. 44ug (12000000iu)in 0.5 mL single syringe
4.30
UG 17,539
18,498,378P 880
5KInj. 30ug (6000000iu) in 0.5mL single syringe
4.30
UG 15,857
16,735,123L03AB0
8INTERFERON BETA–1bP 8101J
Injection set 1 vial powder dose ME 34,5
5040,558,217L03AB0
4INTERFERON–ALFA–2aP 8180M Solution for injection 3000000iu in 0.5mL
ME 1,723
952,780P 8181N Solution for injection
3000000iu in 0.5mLME 16
587,253P 8551C Injection 45000000iu in 0.5mL
syringeME 12
788,710L03AB0
5INTERFERON–ALFA–2bP 6255F Solution for injection 60000000iu in 1.2mL mult
ME 116
306,711P 8348J
Soln for inj.18000000iu in 1.2mL multi–ME 45
9279,034L03AB1
1PEGINTERFERON ALFA–2aP 6449K Prefilled syringe 180ug/0.5mL, 4 26.00
UG 931
1,305,476L03AB6
0PEGINTERFERON ALFA–2b COMBINATIONSP 6394M 112 ribavirin tabs 200mg +4 syrngs PEG–IFN alfa–2b –
– 645
1,181,375P 6395N 140 ribavirin tabs 200mg +4
syrngs PEG–IFN alfa–2b –– 75
81,458,260P 6396P 168 ribavirin tabs 200mg +4
syrngs PEG–IFN alfa–2b –– 82
31,690,464P 6405D 112 ribavirin 200mg/4 single
use injection pens –– 49
9880,922P 6407F 140 ribavirin 200mg/4 single
use injection pens –– 38
6780,025P 6410J168 ribavirin 200mg/4 single use
injection pens –– 29
6687,660
P 1131M
Vial powder for intravesical admin. 5x108 CFU
– – 1,223 657,879P 114
0BInjection set 1 vial Powder – – 1,117 463,
987P 5901N
Injection set 1 vial Powder – – 437 102,870P 590
2PAmpoule containing powder 5x10<^> 8<D>CFU
– – 169 37,731
133
L
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTSIMMUNOSTIMULANTSCYTOKINES AND IMMUNOMODULATORSCOLONY STIMULATING FACTORS
L03AA02 FILGRASTIM
L03AA13 PEGFILGRASTIMP 6363X Injection 6mg in 0.6mL single use syringe 0.30 MG 11,961
25,629,526INTERFERONS
L03AB07 INTERFERON BETA–1a
OTHER IMMUNOSTIMULANTS
L03AX03 BCG VACCINE
L03AX13 GLATIRAMER ACETATEP 8726G Inj 20mg in 1mL single dose prefilled syringe 20.00 MG 17,664
19,249,091
134
L
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTSIMMUNOSUPPRESSANTSIMMUNOSUPPRESSANTSSELECTIVE IMMUNOSUPPRESSANTSL04AA21 EFALIZUMAB
P 9000Q Inj set 4 vials pdr 125 mg and 4 pre filled syring
10.00
MG 1,253
1,313,200P 9001R Inj set 4 vials pdr 125 mg
and 4 pre filled syring10.00
MG 3,635
3,899,394L04AA1
8EVEROLIMUSP 8841H Tablet 0.5 mg 60 1.5
0MG 13
292,560L04AA1
3LEFLUNOMIDEP 8374R Tablet 10mg 30 20.0
0MG 34,9
403,445,309P 8375T Tablet 20mg 30 20.0
0MG 110,3
7015,930,303L04AA0
6MYCOPHENOLIC ACIDP 6208R Capsule 250mg 2.0
0GM 21
098,631P 6209T Tablet 500mg 2.0
0GM 1,17
2852,065P 8649F Capsule 250mg 300 2.0
0GM 93
3570,392P 8650G Capsule 500mg 150 2.0
0GM 4,79
93,080,072P 8652J Tablet (enteric coated)
180mg 1202.00
GM 165
46,285P 8653K Tablet (enteric coated)
360mg 1202.00
GM 678
340,346L04AA1
0SIROLIMUSP 8724E Tablet 1mg 100 3.0
0MG 42
3399,193P 8833X Tablet 2mg 100 3.0
0MG 17
9280,272
P 8737W
Injection 40mg in 0.8mL prefilled syringe
2.90
MG 5,153
8,989,574P 874
1CInjection 40mg in 0.8mL prefilled syringe
2.90
MG 19,664
34,313,610P 903
3KInjection 40mg in 0.8mL prefilled syringe
2.90
MG 1,160
2,022,542P 903
4LInjection 40mg in 0.8mL prefilled syringe
2.90
MG 1,767
3,082,736P 907
7RInjection 40mg in 0.8mL prefilled syringe 2
2.90
MG 974
1,703,388P 907
8TInjection 40mg in 0.8mL prefilled syringe 2
2.90
MG 576
1,006,417P 909
9XInjection 40mg in 0.8mL prefilled syringe
2.90
MG 623
1,086,778P 910
0YInjection 40mg in 0.8mL prefilled syringe 2
2.90
MG 964
1,682,522P 910
1BInjection 40mg in 0.8mL prefilled syringe 2
2.90
MG 163
284,497P 910
2CInjection 40mg in 0.8mL prefilled syringe 2
2.90
MG 121
211,191P 910 Injection 40mg in 0.8mL 2.9 MG 23 405,
ETANERCEPTP 636
7DInjection set vial pdr 25mg and syringe solvent 4
7.00
MG 1,472
2,461,233P 863
7NInjection set vial pdr 25mg and syringe solvent 4
7.00
MG 584
1,050,070P 863
8PInjection set vial pdr 25mg and syringe solvent 4
7.00
MG 5,978
10,734,990P 877
8BInjection set vial pdr 25mg and syringe solvent 4
7.00
MG 351
715,316P 877
9CInjection set vial pdr 25mg and syringe solvent 4
7.00
MG 4,112
7,402,287P 886
1JInjection set vial pdr 50mg and syringe solvent 4
7.00
MG 2,743
4,785,970P 886
2KInjct set 4 vials pdr 50mg and 4 pre–filled syr
7.00
MG 13,075
22,821,898P 903
5MInjct set 4 vials pdr 25mg & 4 prefilled syr solv
7.00
MG 558
1,003,304P 903
6NInjection set 4 vials pdr 25mg and 4 syringe solv
7.00
MG 1,236
2,222,153P 903
7PInjection set 4 vials pdr 25mg and 4 syringe solv
7.00
MG 165
290,906P 903
8QInjct set 4 vials pdr 50mg & 4 prefilled syr solv
7.00
MG 538
945,488P 908
1YInjct set 4 vials pdr 50mg and 4 pre–filled syr
7.00
MG 143
260,220P 908
2BInjct set 4 vials pdr 50mg & 4 prefilled syr solv
7.00
MG 460
806,804P 908
3CInjct set 4 vials pdr 50mg & 4 prefilled syr solv
7.00
MG 115
200,708P 908
4DInjct set 4 vials pdr 50mg & 4 prefilled syr solv
7.00
MG 469
819,238P 908
5EInjection 50mg in 1mL single use refilled syr 4 1
7.00
MG 522
911,353P 908
6FInjection 50mg in 1mL single use refilled syr 4 1
7.00
MG 1,529
2,668,605P 908
7GInjection 50mg in 1mL single use refilled syr 4 1
7.00
MG 260
453,800P 908
8HInjection 50mg in 1mL single use refilled syr 4 1
7.00
MG 512
893,832P 908
9JInjection 50mg in 1mL single use refilled syr 4 1
7.00
MG 1,558
2,719,284P 909
0KInjection 50mg in 1mL single use refilled syr 4 1
7.00
MG 4,837
8,443,038P 909 Injection 50mg in 1mL single 7.0 MG 13 236,
INFLIXIMABP 639
7QPowder for I.V. infusion 100mg 1
3.75
MG 1,794
4,402,517P 644
8JPowder for I.V. infusion 100mg 1
3.75
MG 3,414
13,044,090P 649
6XPowder for I.V. infusion 100mg 1
3.75
MG 369
1,436,920P 961
3YPowder for I.V. infusion 100mg 1
3.75
MG 314
960,293
135
L
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTSIMMUNOSUPPRESSANTSIMMUNOSUPPRESSANTSTUMOR NECROSIS FACTOR ALPHA INHIBITORS
L04AB04 ADALIMUMAB
L04AB01
L04AB02
P 6232B
Capsule 10mg (with microemulsion pre–
0.25
GM 201 16,058P 635
2HCapsule 25mg 30 0.2
5GM 1,92
1406,918P 635
3JCapsule 50mg 30 0.2
5GM 1,44
8366,739P 635
4KCapsule 100mg 30 0.2
5GM 2,13
81,055,126P 865
7PCapsule 10mg 120 0.2
5GM 770 77,8
35P 8658Q
Capsule 25mg 60 0.25
GM 6,779
948,034P 865
9RCapsule 50mg 60 0.2
5GM 8,98
22,057,746P 866
0TCapsule 100mg 60 0.2
5GM 9,29
74,258,253P 866 Oral liquid 100mg per mL 0.2 GM 221 138,
TACROLIMUSP 621
6ECapsule 1mg 5.0
0MG 658 537,
511P 6328C
Capsule 500ug 100 5.00
MG 170 43,800P 864
6CCapsule 500ug 100 5.0
0MG 1,50
2346,173P 864
7DCapsule 1mg 100 5.0
0MG 5,92
73,724,883P 864
8ECapsule 5mg 100 5.0
0MG 313 499,
264
P 2687K Tablet 50mg 0.15 GM 113,268
8,221,765P 2688L Tablet 25mg 0.15 GM 13,40
2592,685
136
L
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTSIMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS INTERLEUKIN
INHIBITORS L04AC03 ANAKINRA
P 8774T Injection 100mg in 0.67mL pre–filled syringe 280.10 GM 279377,040
CALCINEURIN INHIBITORS
L04AD01 CYCLOSPORIN
L04AD02
OTHER IMMUNOSUPPRESSANTSL04AX01 AZATHIOPRINE
L04AX02 THALIDOMIDEP 6469L Capsules 50mg 28 0.10 GM 1,944 2,291,084
P 1299J
Tablet 25mg (enteric coated)
0.10
GM
84,071
1,127,359P 130
0KTablet 50mg (enteric coated) 50
0.10
GM
1,068,974
11,948,847P 130
2MSuppository 100mg 40 0.1
0GM
17,768
392,744A 169
18Tablet 25mg 20 0.1
0GM
21,968
–A 169
71Tablet 25mg 10 0.1
0GM
6,315
–A 174
54Tablet 25mg 30 0.1
0GM
25,805
–A 185
67Tablet 50mg 20 0.1
0GM
118,288
–A 187
26Suppository 50mg 10 0.1
0GM
524
–P 507
6ETablet 25mg (enteric coated)
0.10
GM
187
1,840P 507
7FTablet 50mg (enteric coated)
0.10
GM
2,087
21,050P 536
2FTablet 50mg (enteric coated) 50
0.10
GM
2,842
50,735P 536
4HTablet 25mg (enteric coated) 100
0.10
GM
179
42P 536
5JTablet 50mg (enteric coated) 50
0.10
GM
1,982
35,969
P 2454E
Capsule 25mg 0.10 GM 322,233
3,373,096P 275
7DSuppository 100mg 0.10 GM 64,04
81,285,451P 537
7BCapsule 25mg 100 0.10 GM 1,25
918,048P 537
8CSuppository 100mg 40 0.10 GM 449 14,2
17P 5379D
Capsule 25mg 100 0.10 GM 1,517
22,447P 538 Suppository 100mg 40 0.10 GM 297 2,9
KETOROLACA 13986 Ampoule 30mg per
1mL 530.00
MG 4,481
–A 14188 Tablet 10mg 30 30.0 MG 2,11 –SULINDACP 2047R Tablet 100mg 0.40 GM 4,56
866,631P 2048T Tablet 200mg 0.40 GM 13,74
5189,896
137
M
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
MUSCULO–SKELETAL SYSTEMANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTSANTIINFLAMMATORY/ANTIRHEUMATIC PRODDUCTS,NON–STEROIDSACETIC ACID DERIVATIVES AND RELATED SUBSTANCESM01AB05 DICLOFENAC
M01AB55 DICLOFENAC WITH MISOPROSTOLP 4190M Tablet 50mg 200ug 60 – – 2,872 105,545
M01AB01 INDOMETHACIN
M01AB15
M01AB02
MELOXICAMP 856
1NTablet 7.5mg 15.0
0MG
455,995
9,968,544P 856
2PTablet 15mg 15.0
0MG
1,161,710
34,154,470P 888
7RCapsule 7.5mg 30 15.0
0MG
214,148
4,616,947P 888 Capsule 15mg 30 15.0 M 343,5 9,914,
PIROXICAMP 189
5RDispersible tablet 10mg 50
20.00
MG
14,834
192,909P 189
6TDispersible tablet 20mg 25
20.00
MG
96,561
1,221,775P 189
7WCapsule 10mg 20.0
0MG
33,059
430,262P 189
8XCapsule 20mg 20.0
0MG
163,247
2,065,470P 520
1RDispersible tablet 10mg 20.0
0MG
342
4,296P 520
2TDispersible tablet 20mg 20.0
0MG
336
2,398P 520
3WCapsule 10mg 20.0
0MG
934
11,343
A 13267
Tablet 200mg 12 1.20
GM 411 –A 132
68Tablet 200mg 24 1.2
0GM 4,52
0–
A 13372
Tablet 200mg 48 1.20
GM 1,913
–A 154
01Susp 0.1/5mL 100mL 1.2
0GM 1,31
9–
A 16004
Tablet 200mg 24 1.20
GM 150 –P 319
0XTablet 400mg 1.2
0GM 230,7
542,998,304P 319
2BTablet 400mg 30 1.2
0GM 195,0
491,553,372P 319
8HTablet 200mg 1.2
0GM 18,79
8191,312P 512
1MTablet 200mg 1.2
0GM 607 5,0
95P 5123P
Tablet 400mg 1.20
GM 778 7,572P 512
4QTablet 400mg 30 1.2
0GM 6,95
955,227P 536
8MTablet 400mg 100 1.2
0GM 564 8,7
92P 537 Tablet 400mg 100 1.2 GM 307 4,9IBUPROFEN with CODEINEA 177
16Tablet 200mg 12.8mg 48 – – 40,20
6–
A 18882
Tablet 200mg 12.8mg 48 – – 27,281
–A 188
87Tablet 200mg 12.8mg 48 – – 110 –
A 197 Tablet 200mg 12.8mg 75 – – 9,30 –KETOPROFENP 158
8NSuppository 100mg 0.1
5GM 2,85
860,878P 159
0QCapsules 200mg (sustained release) 28
0.15
GM 195,867
3,046,073P 513
6HCapsule 200mg (sustained release)
0.15
GM 127 1,591
138
M
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
MUSCULO–SKELETAL SYSTEMANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTSANTIINFLAMMATORY/ANTIRHEUMATIC PRODDUCTS,NON–STEROIDSOXICAMS
M01AC06
M01AC01
PROPIONIC ACID DERIVATIVESM01AE01 IBUPROFEN
M01AE51
M01AE03
A 11401
Tablet 275mg 12 0.50
GM 354 –P 161
4YTablet 750mg (sustained release) 28
0.50
GM 99,674
1,282,285P 161
5BTablet 1g (sustained release) 28
0.50
GM 253,652
3,907,725P 165
8GOral suspension 125mg per 5mL 474mL
0.50
GM 565 45,948P 165
9HTablet 500mg 0.5
0GM 209,3
222,832,946P 167
4DTablet 250mg 0.5
0GM 51,84
3713,051P 179
5LTablet 550mg 50 0.5
0GM 46,00
8634,794P 517
6KTablet 250mg 0.5
0GM 203 2,0
09P 5177L
Tablet 500mg 0.50
GM 136 1,563P 517
9NTablet 1g (sustained release)
0.50
GM 118 1,449P 534
5HTablet 250mg 100 0.5
0GM 134 59
P 5346J
Tablet 500mg 50 0.50
GM 767 9,920P 534
7KTablet 750mg (sustained release) 28
0.50
GM 282 4,403P 534
8LTablet 1g (sustained release) 28
0.50
GM 1,096
17,995P 534
9MTablet 250mg 100 0.5
0GM 205 1,1
04P 5350N
Tablet 500mg 50 0.50
GM 773 20,887P 535
1PTablet 750mg (sustained release) 28
0.50
GM 156 2,698P 535
2QTablet 1g (sustained release) 28
0.50
GM 247 4,379P 535
3RTablet 550mg 50 0.5
0GM 149 3,2
44P 5354T
Tablet 550mg 50 0.50
GM 135 –
A 11611 Capsule 250mg 20
1.00 GM 606 –P 1824B Capsule 250mg 1.00 GM 43,94
8723,791
A 17093
Capsule 200mg 10 0.20 GM
3,343
–P 843
9ECapsule 100mg 60 0.20 G
M226,948
6,802,110P 844 Capsule 200mg 60 0.20 G 1,436, 44,405
LUMIRACOXIBA 187
36Tablet 400mg 5 0.10 G
M7,975
–A 201
35Tablet 200mg 30 0.10 G
M9,963
–P 226
1BTablet 100mg 30 0.10 G
M425
30P 903
2JTablet 200mg 30 0.10 G
M433,611
12,965,476
139
M
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
MUSCULO–SKELETAL SYSTEMANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTSANTIINFLAMMATORY/ANTIRHEUMATIC PRODDUCTS,NON–STEROIDSPROPIONIC ACID DERIVATIVES
M01AE02 NAPROXEN
M01AE11 TIAPROFENIC ACIDP 2103Q Tablet 300mg 600.00 MG 15,690
250,061FENAMATES
M01AG01 MEFENAMIC ACID
COXIBSM01AH01 CELECOXIB
M01AH06
OTHER ANTIINFL./ANTIRHEUMATIC AGENTS, NON–STEROIDSM01AX12 PENTOSAN–POLY SULFATE SODIUM
A 14955 Capsule 100mg 100 – – 1,103 –
140
P 2016D
Injection 10mg 2.40 MG 184 9,550P 201
7EInjection 20mg 2.40 MG 336 26,6
41P 2018F
Injection 50mg 2.40 MG 2,104 259,911
M
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
MUSCULO–SKELETAL SYSTEMANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTSSPECIFIC ANTIRHEUMATIC AGENTSGOLD PREPARATIONS
M01CB03 AURANOFINP 1095P Tablet 3mg 6.00 MG 3,627 231,167
M01CB01 SODIUM AUROTHIOMALATE
PENICILLAMINEM01CC01 PENICILLAMINE
P 2721F Tablet 125mg 0.50 GM 469 16,954P 2838JTablet 250mg 0.50 GM 4,608 213,
076
141
DICLOFENACA 148
60Gel 50g 1 – – 4,069 –
A 14861
Gel 100g 1 – – 13,455 –A 149
79Gel 20g 1 – – 2,881 –
A 201 Gel 3% 25g 1 – – 98 –KETOPROFENA 14948 Gel 2.5% 30g 1 – – 12
4–
A 14949 Gel 2.5% 60g 1 – – 88 –PIROXICAMA 15090 Gel 0.5% 25g 1 – – 73
1–
A 15091 Gel 0.5% 50g 1 – – 574
–
A 10653
Cream 50g 1 – – 175 –A 129
31Cream 100g 1 – – 6,001 –
P 4022Q
Compound Cream APF 100gm
– – 2,982 37,523P 402
3ROintment BP 100gm – – 1,971 21,1
47P 4025W
Compound ointment APF 1934 100gm
– – 484 4,573P 402
6XLiniment APF 100gm – – 2,306 19,6
99P 402 Compound liniment APF – – 323 3,3METHYL SALICYLATE with MENTHOL with EUCALYPTUS OILA 11224 Cream 125g 1 – – 2,740 –A 12943 Cream 50g 1 – – 468 –
M
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
MUSCULO–SKELETAL SYSTEMTOPICAL PRODUCTS FOR JOINT and MUSCULAR PAINTOPICAL PRODUCTS FOR JOINT and MUSCULAR PAINANTIINFL. PREP., NON–STEROIDS FOR TOPICAL USE
M02AA15
M02AA10
M02AA07
CAPSAICIN and SIMILAR AGENTSM02AB CAPSAICIN
A 15579 Cream 0.025% 45g – – 191 –PREPARATIONS with SALICYLIC ACID DERIVATIVES
M02AC METHYL SALICYLATE
M02AC
142
M
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
MUSCULO–SKELETAL SYSTEMMUSCLE RELAXANTSMUSCLE RELAXANTS, CENTRALLY ACTING AGENTSETHERS, CHEMICALLY CLOSE TO ANTIHISTAMINES
M03BC01 ORPHENADRINE CITRATEA 11353 Tablet 100mg 100 0.12 GM 6,043 –
M03BC51 ORPHENADRINE CITRATE with PARACETAMOLA 11354 Tablet 100 0.12 GM 2,955 –
OTHER CENTRALLY ACTING AGENTSM03BX01 BACLOFEN
P 2729P
Tablet 10mg 50.00
MG 88,823
3,624,808P 273
0QTablet 25mg 50.0
0MG 47,62
13,895,815P 628
4RIntrathecal injection 10mg in 5mL
0.55
MG 588 319,148MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS
DANTROLENE AND DERIVATIVESM03CA01 DANTROLENE SODIUM
P 1779P Capsule 25mg 0.10 GM 4,517 267,230P 1780Q Capsule 50mg 0.10 GM 2,639 178,723
P 2600W Tablet 100mg 0.40 GM 261,609
3,598,765P 2604C Tablet 300mg 0.40 GM 930,2
359,642,543
143
M
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
MUSCULO–SKELETAL SYSTEMANTIGOUT PREPARATIONSANTIGOUT PREPARATIONSPREPARATIONS INHIBITING URIC ACID PRODUCTIONM04AA01 ALLOPURINOL
PREPARATIONS INCREASING URIC ACID EXCRETIONM04AB01 PROBENECID
P 1940D Tablet 500mg 1.00 GM 18,603 1,272,907PREPARATIONS WITH NO EFFECT ON URIC ACID METABOLISM
M04AC01 COLCHICINEP 1227N Tablet 500ug 1.00 MG 261,9122,537,863
P 8090T Tablet 40mg 10.00
MG
18,217
2,874,820P 8511Y Tablet 70mg alendronic 10.0 M 1,727, 89,109
CLODRONIC ACIDP 8132B Capsule equivalent to
400mg sodium clodronate1.60
GM
876
296,446P 8265B Capsule equivalent to
800mg sodium clodronate1.60
GM
16,986
6,633,071
P 6223M
Vial pdr for IV infuse 90mg amp solvent 10mL
MG 2,366
1,073,952P 627
9L2 vials pdr for IV infuse 30mg 2 amp solvent 10mL 60.00
MG 153
43,876P 628
9BConcentrated injection 90mg in 10mL
MG 498
208,896P 820
9C2 vials pdr for IV infuse 30mg 2 amp solvent 10mL 60.00
MG 782
240,837P 846 Concentrated injection 60mg in MG 16 44,0
RISEDRONIC ACIDP 444
3WTablet 5mg 28 5.00 MG 89
546,731P 444
4XTablet 35mg 4 5.00 MG 29,5
741,545,411P 848
1JTablet 5mg 28 5.00 MG 15,8
32826,102P 848
2KTablet 30mg 28 5.00 MG 4,00
71,214,732P 862
1RTablet 35mg 5.00 MG 526,4
7527,461,047
144
M
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
MUSCULO–SKELETAL SYSTEMDRUGS FOR TREATMENT OF BONE DISEASESDRUGS AFFECTING BONE STRUCTURE AND MINERALIZATIONBISPHOSPHONATES
M05BA04 ALENDRONIC ACID
M05BA02
M05BA01 DISODIUM ETIDRONATEP 2920Q Tablet 200mg 0.40 GM 409 61,184
M05BA03 DISODIUM PAMIDRONATE
M05BA07
M05BA05 TILUDRONIC ACIDP 8267D Tablet 200mg 0.40 MG 796 241,578
M05BA08 ZOLEDRONIC ACIDP 6371H Injection concentrate I.V. infusion 4mg (
as monohydrate) in 5mL 4.00 MG 21,271 10,223,633BISPHOSPHONATES AND CALCIUMM05BB03 ALENDRONIC ACID and COLECALCIFEROL
P 9012H Tablet equiv to 70mg alendronic with 70ug Colecal – –645,318 33,132,593
M05BB01 ETIDRONIC ACID AND CALCIUMP 8056B 28 tabs 200mg and 76 tabs calcium (equiv 500mg) – –
14,589 1,014,573M05BB02 RISEDRONIC SODIUM with CALCIUM CARBONATE
P 8899J Pack containing 4 tablets 35mg and 24 tabs 1.25g – – 625,245 32,637,998
BISPHOSPHONATES AND CALCIUMM05BX03 STRONTIUM RANELATE
P 3036T Granules for oral suspension 2g, 28 Sachets 2.00 GM 50,4242,583,943
145
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMANAESTHETICSANAESTHETICS, GENERALOPIOID ANAESTHETICSN01AH01 FENTANYL
A 14186 Ampoule 100ug/2 5 – – 209 –ANAESTHETICS, LOCALAMIDES
N01BB01
BUPIVACAINEA 11219 Vial 0.5% 20mL 5 – – 167 –
N01BB02
LIGNOCAINE HYDROCHLORIDEA 15896 Ampoule 1%2mL 50 – – 172 –A 15901 Ampoule 2% 5mL 50 – – 159 –A 17544 Ampoule 1% 5mL 50 – – 514 –
N01BB52
LIGNOCAINE with ADRENALINEA 15905 Vial 2% 20mL 5 – – 537 –A 16268 Ampoule 1% 5mL 50 – – 340 –
N01BB52
PRILOCAINE with LIGNOCAINEA 14984 Patch 1 g – – 386 –
N01BB09
ROPIVACAINEA 15645 Injection 10mL 10mg/mL 5
– – 751 –
CODEINE with ASPIRINA 100
90Tablet soluble 8mg – 300mg 20
– – 439
–A 100
91Tablet soluble 8mg – 300mg 100
– – 14,444
–A 104
65Tablet soluble 8mg– 500mg 50
– – 566
–A 121
69Tablet 8mg – 325mg 100 – – 93
1–
P 406 Tablet soluble 8mg– – – 5,63 67,7CODEINE with PARACETAMOLA 105
27Tablet 8mg – 500mg 100 – – 88
6–
A 11705
Capsule 8mg – 500mg 50 – – 14,371
–A 117
06Tablet 8mg – 500mg 100 – – 38,3
61–
A 11755
Tablet soluble 8mg – 500mg 24
– – 373
–P 121
5YTablet 30mg–500mg 20 – – 3,120,
54027,078,006A 126
70Tablet 8mg – 500mg 20 – – 26
3–
A 12692
Tablet 8mg – 500mg 100 – – 657
–A 127
36Tablet 30mg–500mg 50 – – 4,42
9–
A 14215
Tablet 8mg – 500mg 50 – – 267
–A 147
88Tablet 8mg–500mg 100 – – 1,86
7–
A 14978
Caplet 15mg – 500mg 50 – – 365
–A 159
94Tablet 8mg – 500mg 50 – – 52
3–
A 17212
Tablet 9.6mg–500mg 48 – – 6,624
–A 172
67Caplet 8mg–500mg 48 – – 8,47
4–
A 17820
Tablet 8mg–500mg 48 – – 2,208
–A 183
74Tablet 8mg – 500mg 48 – – 2,82
0–
A 18375
Tablet 8mg – 500mg 50 – – 167
–A 183
76Tablet 8mg – 500mg 96 – – 15,4
35–
A 18377
Tablet 8mg – 500mg 100 – – 1,399
–A 183
79Tabsule 8mg – 500mg 48 – – 31
6–
A 18380
Tabsule 8mg – 500mg 96 – – 619
–A 187
34Tablet 15mg–500mg 12 – – 91,8
98–
A 19039
Caplet 8mg/500mg 24 – – 859
–A 190
41Tablet 8mg/500mg 24 – – 3,44
5–
P 3316M
Tablet 30mg–500mg 20 – – 128,683
954,109P 417
0LTablet 15mg–500mg 20 – – 19,4
80204,147P 417
1MTablet 8mg–500mg – – 32,1
94370,112P 878
5JTablet 30mg–500mg 60 – – 644,5
3212,770,515
146
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMANALGESICSOPIOIDSNATURAL OPIUM ALKALOIDS
N02AA59
N02AA59
DIHYDROCODEINEA 11785 Linctus 200mL 1 – – 21,20
7–
A 12825 Linctus 100mL 1 – – 8,859 –HYDROMORPHONEP 842
0EInjection 2mg in 1mL 5 4.0
0MG 1,791 32,2
95P 8421F
Injection 10mg in 1mL 5 4.00
MG 2,242 127,701P 842
2GInjection 50mg in 5mL 5 4.0
0MG 2,183 288,
183P 8423H
Injection 500mg in 50mL 4.00
MG 371 79,456P 842
4JOral liquid 1mg per mL 473mL
20.00
MG 2,353 138,066P 854
1MTablet 2mg 20 20.0
0MG 742 14,3
73P 8542N
Tablet 4mg 20.00
MG 847 35,828P 854
3PTablet 8mg 20.0
0MG 1,313 105,
778
147
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMANALGESICSOPIOIDSNATURAL OPIUM ALKALOIDS
N02AA08
N02AA03
148
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMANALGESICSOPIOIDSNATURAL OPIUM ALKALOIDS
N02AA01 MORPHINEA 149
31Capsule 20mg (sustained release)
100.00
MG 347 –A 149
35Capsule 100mg (sustained release)
100.00
MG 128 –A 154
15Mixture 200mL 1mg per mL 100.
00MG 267 –
P 1607N
Injection 120mg in 1.5mL 30.00
MG 3,186
292,837P 164
4MInjection 10mg in 1mL 30.0
0MG 47,34
4767,770P 164
5NInjection 15mg in 1mL 30.0
0MG 15,24
3315,429P 164
6PTablet 30mg 100.
00MG 14,40
9281,362P 164
7QInjection 30mg in 1mL 30.0
0MG 28,14
7928,439P 165
3BTablet 10mg (controlled release)
100.00
MG 95,392
2,394,108P 165
4CTablet 30mg (controlled release)
100.00
MG 95,527
4,605,707P 165
5DTablet 60mg (controlled release)
100.00
MG 71,956
5,619,454P 165
6ETablet 100mg (controlled release)
100.00
MG 67,910
7,915,666A 196
08Injection 10mg in 1mL 30.0
0MG 336 –
A 19620
Injection 15mg in 1mL 30.00
MG 527 –P 212
2QOral solution 2mg per mL 200mL
100.00
MG 20,190
355,519P 212
3ROral solution 5mg per mL 200mL
100.00
MG 33,554
697,715P 212
4TOral solution 10mg per mL 200mL
100.00
MG 36,886
1,109,201P 283
9KCapsule 20mg (sustained release)
100.00
MG 63,003
2,354,041P 284
0LCapsule 50mg (sustained release)
100.00
MG 50,673
3,091,155P 284
1MCapsule 100mg (sustained release)
100.00
MG 39,448
4,906,226P 347
9DInjection 15mg in 1mL 30.0
0MG 11,00
3142,413P 348
0EInjection 30mg in 1mL 30.0
0MG 4,93
070,607P 434
9XTablet 200mg (controlled release)
100.00
MG 211 35,811P 803
5XTablet 5mg (controlled release)
100.00
MG 37,852
684,449P 814
6RSachet 30mg (controlled release)
100.00
MG 1,210
48,487P 830
5DSachet 60mg granules for oral suspension
100.00
MG 706 51,468P 830
6ESachet 100mg granules for oral suspension
100.00
MG 447 53,070P 834
9KCapsule 10mg (sustained release) 20
100.00
MG 27,463
588,651P 845
3XTablet 200mg (controlled release)
100.00
MG 1,068
394,748P 848
9TTablet 15mg (controlled release) 20
100.00
MG 41,884
1,172,126P 849
0WSachet 20mg granules for oral suspension 20
100.00
MG 2,712
80,583P 849
1XCapsule 30mg (controlled release) 10
100.00
MG 2,630
67,904P 849
2YCapsule 60mg (controlled release) 10
100.00
MG 3,871
154,201P 849
3BCapsule 90mg (controlled release) 10
100.00
MG 2,523
158,723P 849
4CCapsule 120mg (controlled release) 10
100.00
MG 4,288
432,885P 866
9GTablet 10mg 20 100.
00MG 1,19
017,712P 867
0HTablet 20mg 20 100.
00MG 1,22
422,565
A 16418
Tablet 40mg (controlled release) 60
75.00
MG 116
–P 248
1NSuppository 30mg 30.0
0MG 12,7
40852,183P 262
2BTablet 5mg 75.0
0MG 604,8
647,919,365P 519
5KTablet 5mg 75.0
0MG 79
68,588P 838
5HTablet 10mg (controlled release) 20
75.00
MG 304,662
8,330,223P 838
6JTablet 20mg (controlled release) 20
75.00
MG 285,152
13,008,016P 838
7KTablet 40mg (controlled release) 20
75.00
MG 177,717
12,877,798P 838
8LTablet 80mg (controlled release) 20
75.00
MG 99,462
12,979,003P 846
4LCapsule 5mg 20 75.0
0MG 78,8
31988,428P 850
1KCapsule 10mg 20 75.0
0MG 77,0
051,424,342P 850
2LCapsule 20mg 20 75.0
0MG 57,8
451,892,848P 864
4YOral solution 5mg per 5mL 250mL
75.00
MG 6,727
154,507P 868
1XTablet 5mg (controlled release) 20
75.00
MG 121,280
2,945,617
A 17987
Lozenge 200ug 3 – – 399 –P 887
8GTransdermal patch 2.1mg(12 ug per hour) 5
1.20
MG 51,819
2,594,206P 889
1YTransdermal patch 4.2mg (25 ug per hour) 5
1.20
MG 72,768
4,516,625P 889
2BTransdermal patch 8.4mg (50 ug per hour) 5
1.20
MG 49,651
5,488,891P 889
3CTransdermal patch 12.6mg (75 ug per hour) 5
1.20
MG 24,350
3,737,817P 889 Transdermal patch 16.8mg 1.2 MG 28,40 6,225,
PETHIDINE HYDROCHLORIDEA 158
88Injection 100mg in 2mL 10 0.4
0GM 680 –
P 1829G
Injection 100mg in 2mL 5 0.40
GM 6,939
76,709A 189
90Injection 100mg in 2mL 0.4
0GM 7,49
5–
A 19593
Injection 50mg in 1mL 0.40
GM 2,173
–A 199
82Injection 100mg in 2mL 5 0.4
0GM 27,45
1–
A 16347
Capsule 32.5mg 325mg 20
– – 146,820 –A 164
44Tablet 32.5mg 325mg 20
– – 433,975 –A 166
50Tablet 32.5mg 325mg 20
– – 27,141 –
149
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMANALGESICSOPIOIDSNATURAL OPIUM ALKALOIDSN02AA05 OXYCODONE
PHENYLPIPERIDINE DERIVATIVESN02AB03 FENTANYL
N02AB02
DIPHENYLPROPYLAMINE DERIVATIVESN02AC04 DEXTROPROPOXYPHENE NAPSYLATE
P 4081T Capsule 100mg 0.30 GM 25,702 512,536N02AC54 DEXTROPROPOXYPHENE with PARACETAMOL
ORIPAVINE DERIVATIVESN02AE01 BUPRENORPHINE
A 15207
Tablets 2 mg (slow release) 1.20
MG 1,409
–P 886
5NTransdermal patch 5mg (releasing ~5ug/hour) 2
1.20
MG 184,873
5,176,187P 886
6PTransdermal patch 10mg (releasing ~10ug/hour)
1.20
MG 169,246
7,134,058P 886
7QTransdermal patch 20mg (releasing ~20ug/hour)
1.20
MG 93,852
6,659,651
150
A 18386
Tablet 5mg/500mg 24 – – 1,266
–A 190
53Tablet 5mg/500mg 8 – – 4,81
8–
A 195 Capsule 5mg/500mg 10 – – 4,81 –PARACETAMOLA 115
11Elixir 120mg/5 1 3.0
0GM
124
–A 115
12Elixir 200mL 1 3.0
0GM
257
–A 115
15Tablet 500mg 50 3.0
0GM
2,859
–A 115
16Tablet 500mg 100 3.0
0GM
1,401
–A 115
17Tab–sol 500mg 24 3.0
0GM
1,334
–A 115
19Drop 20mL 1 3.0
0GM
968
–A 116
99Suppositories 250mg 20 3.0
0GM
152
–P 174
6XTablet 500mg 3.0
0GM
1,564,418
12,233,046P 174
7YMixture 120mg per 5mL 100mL
3.00
GM
23,917
194,237P 177
0EElixir 240mg per 5mL 200mL
3.00
GM
143,688
1,501,521P 519
6LTablet 500mg 3.0
0GM
245
1,845P 531
9YSuppositories 500mg 24 3.0
0GM
3,149
154,307P 532
0BSuppositories 500mg 24 3.0
0GM
1,136
40,035P 534
3FTablet 665mg (modified release) 9 6
3.00
GM
1,090
13,091P 534
4GTablet 665mg (modified release) 9 6
3.00
GM
249
2,805P 878
4HTablet 500mg 300 3.0
0GM
1,424,486
18,319,103P 881
4XTablet 665mg (modified release) 1 92
3.00
GM
638,383
7,508,721
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMANALGESICSOPIOIDSOTHER OPIOIDS
N02AX02 TRAMADOLA 179
88Capsule 50mg 50 0.3
0GM 11
6–
P 2527B
Tablet 50mg (twice daily sustained release) 20
0.30
GM 45,604
732,050P 348
4JInjection 100mg in 2mL 5 0.3
0GM 17,5
56187,124P 523
2JCapsule 50mg 20 0.3
0GM 89
37,828P 523
4LTablet 100mg (twice daily sustained release) 20
0.30
GM 237
3,414P 845
5BCapsule 50mg 20 0.3
0GM 189,0
771,659,431P 852
3NTablet 100mg (twice daily sustained release) 20
0.30
GM 451,282
10,355,546P 852
4PTablet 150mg (twice daily sustained release) 20
0.30
GM 221,322
6,803,360P 852
5QTablet 200mg (twice daily sustained release) 20
0.30
GM 365,699
13,710,014P 858
2QInjection 100mg in 2mL 5 0.3
0GM 10,4
55110,946P 861
1FCapsule 50mg 20 0.3
0GM 908,3
418,006,293P 884
3KOral drops 100mg per mL 10mL
0.30
GM 2,494
28,747OTHER ANALGESICS AND ANTIPYRETICS
SALICYLIC ACID DERIVATIVESN02BA01 ASPIRIN
P 1010E Tablet 300mg (dispersible) 3.00 GM 198,4061,480,326ANILIDES
N02BE51 METOCLOPRAMIDE and PARACETAMOL
N02BE01
151
PARACETAMOL with CODEINE with DOXYLAMINEA 108
70Tablet 24 – – 29,039 –
A 12600
Tablet 20 – – 173,229 –A 129
32Capsule 24 – – 6,004 –
A 13102
Tablet 20 – – 164,281 –A 132
00Capsule 20 – – 21
3–
A 13823
Capsule 20 – – 3,661 –A 152
86Tablet 24 – – 99
0–
A 15650
Caplet 500mg–8mg–5mg – – 22,917 –A 172
68Tablet 500mg–9.6mg–5.1mg 20
– – 10,827 –A 183
72Cap 500mg–9.6mg–5.1mg 10 + cap500mg–9.6mg 200
– – 176 –A 183 Tablet 20 – – 16 –PARACETAMOL with PROMETHAZINE with CODEINEA 14779 Syrup 200mL 1 – – 11,445 –A 18358 Syrup 120mg–6.5mg–
5mg in 5mL 100mL– – 6,256 –
P 1323P Injection 1mg in 1mL
4.00 MG 1,532 34,404P 3460D Injection 1mg in
1mL4.00 MG 6,279 97,0
79
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMANALGESICSOTHER ANALGESICS AND ANTIPYRETICSANILIDESN02BE51
N02BE51
ANTIMIGRAINE PREPARATIONSERGOT ALKALOIDS
N02CA01 DIHYDROERGOTAMINE
N02CA52 ERGOTAMINE TARTRATE with CAFFEINEA 18569 Suppositories 2mg–100 mg 5 – – 19,708 –
N02CA52 ERGOTAMINE with CAFFEINEA 13550 Tablet 20 – – 84,788 –
N02CA04 METHYSERGIDEP 2826R Tablet 1mg 4.00 MG 8,891 393,545
NARATRIPTANA 161
35Tablet 2.5mg 4 2.5
0MG 27,24
1–
A 20036
Tablet 2.5mg (base) 2 2.50
MG 854 –P 829
8RTablet 2.5mg (base) 4 (2 upto Feb 06)
2.50
MG 75,642
1,867,249P 973 Tablet 2.5mg (base) 4 2.5 MG 8,09 213,
SUMATRIPTANA 141
81Tablet 100mg 50.0
0MG 29,13
6–
A 15210
Tablet 50mg 50.00
MG 128,746
–A 159
87Nasal Spray 10mg per dose 2
20.00
MG 3,239
–A 167
20Injection 6mg in 0.5mL refill 6.0
0MG 2,64
2–
A 16730
Injection 6mg in 0.5mL 6.00
MG 254 –A 174
55Tablet 50mg (base) 4 50.0
0MG 3,32
0–
A 17456
Tablet 100mg 2 50.00
MG 1,532
–A 196
39Tablet 50mg 2 (Fast disintegrating)
50.00
MG 898 –A 196
40Tablet 100mg 2 50.0
0MG 129 –
A 19997
Tablet 50mg 50.00
MG 478 –A 199
98Tablet 100mg 2 50.0
0MG 151 –
P 8144P
Tablet 50mg (base) 4 (2 upto 4 Feb 06)
50.00
MG 239,731
5,828,053P 834
1BNasal Spray 20mg per dose 2
20.00
MG 96,449
1,526,151P 888 Tablet 50mg (base) (fast 50.0 MG 17,82 428,
ZOLMITRIPTANA 200
37Tablet 2.5mg 2 2.5
0MG 1,46
0–
P 8266C
Tablet 2.5mg 4 (2 upto Feb06)
2.50
MG 144,849
3,536,479P 973
6KTablet 2.5mg 4 2.5
0MG 10,59
2274,599
152
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMANALGESICSANTIMIGRAINE PREPARATIONSSELECTIVE 5HT RECEPTOR AGONISTSN02CC02
N02CC01
N02CC03
OTHER ANTIMIGRAINE PREPARATIONSN02CX01 PIZOTIFEN MALATE
P 3074T Tablet 500ug (base) 1.50 MG 138,7752,875,266
P 1850J
Tablet 30mg 0.10 GM 16,379
173,707P 185
3MInjection 200mg in 1mL
0.10 GM 146 6,113A 187
51Elixir 15mg/5mL 100mL
100.00
MG 296 –
P 1249R
Tablet 50mg 0.30
GM 7,640
214,959P 187
3NCapsule 30mg 0.3
0GM 21,25
3572,015P 187
4PCapsule 100mg 0.3
0GM 170,1
004,731,623P 269
2QPaediatric oral suspension 30mg per 5mL 500mL
0.30
GM 10,161
257,293
P 1413JCapsule 250mg 1.25
GM 2,464 130,454P 1414K Paediatric syrup 250mg
per 5mL 250mL1.25
GM 3,065 96,872
P 1805B
Tablet 500ug 8.00
MG 35,132
792,980P 180
6CTablet 2mg 8.0
0MG 22,13
7839,317P 180
7DInjection 1mg in 2mL (set containing solution)
8.00
MG 2,663 64,681P 180
8EPaediatric oral drops 2.5mg in 1mL 10mL
8.00
MG 3,704 59,584P 533
7XTablet 500ug 8.0
0MG 26,14
7498,049P 533
8YTablet 2mg 8.0
0MG 12,82
2446,996P 533
9BOral liquid 2.5mg per mL 10mL
8.00
MG 3,626 52,230P 534
0CTablet 500ug 8.0
0MG 11,54
6245,139P 534
1DTablet 2mg 8.0
0MG 5,516 192,
318P 5342E
Oral liquid 2.5mg per mL 10mL
8.00
MG 516 8,804
P 2419H
Tablet 200mg 1.00
GM 142,432
5,064,367P 242
2LTablet 100mg 1.0
0GM 56,48
81,208,375P 242
6QTablet 200mg (controlled release)
1.00
GM 73,964
2,674,199P 242
7ROral suspension 100mg per 5mL 300mL
1.00
GM 26,168
690,744P 243 Tablet 400mg (controlled 1.0 GM 52,72 3,367,
OXCARBAZEPINEP 858
4TTablet 150mg 100 1.0
0GM 1,62
5133,710P 858
5WTablet 300mg 100 1.0
0GM 5,50
6764,494P 858
6XTablet 600mg 100 1.0
0GM 3,32
0677,274P 858
8BOral suspension 60mg per mL 250mL
1.00
GM 674 91,199
153
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMANTIEPILEPTICSANTIEPILEPTICSBARBITURATES AND DERIVATIVES
N03AA02 PHENOBARBITONE
N03AA03 PRIMIDONEP 1939C Tablet 250mg 1.25 GM 16,775 854,255
HYDANTOIN DERIVATIVESN03AB02 PHENYTOIN
SUCCINIMIDE DERIVATIVESN03AD01 ETHOSUXIMIDE
BENZODIAZEPINE DERIVATIVESN03AE01 CLONAZEPAM
CARBOXAMIDE DERIVATIVESN03AF01 CARBAMAZEPINE
N03AF02
P 2289L
Tablet 200mg (enteric coated) 20 0
1.50
GM 268,309
9,060,557P 229
0MTablet 500mg (enteric coated) 20 0
1.50
GM 297,187
18,157,915P 229
3QOral liquid 200mg per 5mL 300 mL
1.50
GM 51,768
1,878,547P 229
4RCrushable tablet 100mg 1.5
0GM 52,6
561,622,878P 229 Syrup 200mg per 5mL 1.5 GM 18,1 662,
TIAGABINEP 822
1QTablet 5mg (base) 30.0
0MG 99
097,794P 822
2RTablet 10mg (base) 30.0
0MG 1,06
6180,391P 822 Tablet 15mg (base) 30.0 MG 35 72,3
VIGABATRINP 2667JTablet 500mg 120 2.0
0GM 8,65
11,147,201P 2668K Oral powder sachet
500mg2.00
GM 2,039
187,011
P 1834M
Capsule 300mg 100 1.80 GM 51,329
5,114,446P 183
5NCapsule 400mg 100 1.80 GM 15,8
432,320,461P 459
1PCapsule 100mg 100 1.80 GM 7,60
9233,581P 459
2QCapsule 300mg 100 1.80 GM 28,7
722,578,320P 459
3RCapsule 400mg 100 1.80 GM 4,33
8550,322P 459
4TTablet 600mg 100 1.80 GM 4,31
6812,508P 459
5WTablet 800mg 100 1.80 GM 2,20
1521,009P 838
9MTablet 800mg 100 1.80 GM 9,98
72,543,263P 850
5PCapsule 100mg 100 1.80 GM 12,2
66377,751P 855 Tablet 600mg 100 1.80 GM 12,5 2,394,
LAMOTRIGINEP 284
8XTablet 25mg 0.30 GM 39,5
021,829,523P 284
9YTablet 50mg 0.30 GM 68,5
294,487,563P 285
0BTablet 100mg 0.30 GM 111,2
7411,611,174P 285
1CTablet 200mg 0.30 GM 94,4
4115,331,238P 806 Tablet 5mg 0.30 GM 5,97 183,
LEVETIRACETAMP 865
4LTablet 250mg 60 1.50 GM 6,18
4427,988P 865
5MTablet 500mg 60 1.50 GM 16,2
181,808,431P 865
6NTablet 1gm 60 1.50 GM 5,56
3899,363P 970
8YTablet 250mg 60 1.50 GM 16,0
691,370,071P 970
9BTablet 500mg 60 1.50 GM 49,3
827,083,720P 971
0CTablet 1gm 60 1.50 GM 28,3
865,447,698
154
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMANTIEPILEPTICSANTIEPILEPTICSFATTY ACID DERIVATIVES
N03AG01 SODIUM VALPROATE
N03AG06
N03AG04
OTHER ANTIEPILEPTICSN03AX12 GABAPENTIN
N03AX09
N03AX14
A 19043
Capsules 75mg 56 0.30 GM 44,348
–A 190
44Capsules 150mg 56 0.30 GM 23,32
6–
A 190 Capsules 300mg 56 0.30 GM 8,00 –SULTHIAMEP 2099L Tablet 50mg 0.40 GM 1,37
251,908P 2100M Tablet 200mg 0.40 GM 1,60 137,
TOPIRAMATEA 195
61Tablet 25mg 60 0.30 GM 168 –
A 20252
Tablet 50mg 60 0.30 GM 165 –A 202
53Tablet 100mg 60 0.30 GM 225 –
A 20254
Tablet 200mg 60 0.30 GM 184 –P 816
3PTablet 25mg 0.30 GM 16,46
4844,833P 816
4QTablet 50mg 0.30 GM 19,44
61,416,397P 816
5RTablet 100mg 0.30 GM 17,13
01,938,008P 816
6TTablet 200mg 0.30 GM 10,04
81,933,295P 837
1NCapsule 15mg 0.30 GM 554 29,0
52P 8372P
Capsule 25mg 0.30 GM 676 36,648P 852
0KCapsule 50mg 0.30 GM 847 73,6
04P 9701N
Capsule 15mg 60 0.30 GM 781 44,166P 970
2PCapsule 25mg 60 0.30 GM 952 60,8
64P 9703Q
Capsule 50mg 60 0.30 GM 1,071
107,938P 970
4RTablet 25mg 60 0.30 GM 8,70
8515,141P 970
5TTablet 50mg 60 0.30 GM 11,45
8923,190P 970
6WTablet 100mg 60 0.30 GM 12,95
81,565,050P 970
7XTablet 200mg 60 0.30 GM 7,85
41,612,062
155
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMANTIEPILEPTICSANTIEPILEPTICSOTHER ANTIEPILEPTICS
N03AX16 PREGABALIN
N03AX03
N03AX11
P 1109JTablet 2mg 10.00 MG 12,379
151,113P 1110K Tablet 5mg 10.00 MG 5,721 83,346
P 2225D
Capsule 100mg–25mg 0.60
GM 36,020
1,377,511P 222
6ECapsule 200mg–50mg 0.6
0GM 18,29
9949,738P 222
7FCapsule 50mg–12.5mg 0.6
0GM 23,10
8501,896P 222
8GTablet 200mg–50mg 0.6
0GM 37,79
72,024,194P 222
9HTablet 100mg–25mg 0.6
0GM 52,57
92,060,043P 223
1KCapsule 100mg–25mg (sustained release)
0.60
GM 12,155
506,081P 821
8MDispersible tablet 50mg 12.5mg
0.60
GM 6,900
157,819P 821 Dispersible tablet 100mg 0.6 GM 7,95 335,
LEVODOPA with CARBIDOPAP 124
2JTablet 100mg–25mg 0.6
0GM 183,1
077,745,781P 124
5MTablet 250mg–25mg 0.6
0GM 45,35
12,198,225P 125 Tablet 200mg–50mg 100 0.6 GM 29,70 2,211,
LEVODOPA,DECARBOXYLASE INHIBITOR and COMT INHIBITORP 879
7BTablet 50mg–12.5mg–200mg
0.45
GM 1,512
477,516P 879
8CTablet 100mg–25mg–200mg 0.4
5GM 9,78
73,365,214P 879
9DTablet 150mg–37.5mg–200mg
0.45
GM 8,528
3,178,210
156
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMANTI–PARKINSON DRUGSANTICHOLINERGIC AGENTSTERTIARY AMINES WITH CARBON CHAIN
N04AA01 BENZHEXOL HYDROCHLORIDE
N04AA02 BIPERIDEN HYDROCHLORIDEP 2544X Tablet 2mg 10.00MG 14,289 265,730
ETHERS OF TROPINE OR TROPINE DERIVATIVESN04AC01 BENZTROPINE MESYLATE
P 2362H
Tablet 2mg 60 2.00 MG 61,843
696,024P 303
8XInjection 2mg in 2mL 2.00 MG 1,210 28,2
92P 3457Y
Injection 2mg in 2mL 2.00 MG 5,152 107,874DOPAMINERGIC AGENTS
DOPA AND DOPA DERIVATIVESN04BA02 LEVODOPA with BENSERAZIDE
N04BA02
N04BA03
ADAMANTANE DERIVATIVESN04BB01 AMANTADINE HYDROCHLORIDE
P 3016R Capsule 100mg 0.20 GM 15,496 650,564
P 6104G Injection 10mg in 1 mL
20.00
MG 200 228,048P 9607P Injection 20mg in 2 20.0 MG 156 239,
BROMOCRIPTINE MESYLATEP 144
3YCapsule 2.5mg (base) 40.0
0MG 12,31
2438,374P 144
5CCapsule 10mg 40.0
0MG 1,32
1270,562P 144 Capsule 5mg 40.0 MG 5,28 357,
CABERGOLINEP 839
3RTablet 1mg 30 3.00 MG 34,80
02,595,317P 839
4TTablet 2mg 30 3.00 MG 31,28
53,096,322P 839 Tablet 4mg 30 3.00 MG 24,17 2,931,
PERGOLIDEP 280
8TTablet 50ug (base) 3.00 MG 1,45
384,512P 280
9WTablet 250ug (base) 3.00 MG 4,90
2342,606P 281 Tablet 1mg (base) 3.00 MG 2,64 671,
ROPINIROLEA 18889 Tablet 0.5mg 28 6.00 MG 6,73
0–
A 18890 Tablet 2mg 28 6.00 MG 3,000
–
157
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMANTI–PARKINSON DRUGSDOPAMINERGIC AGENTSDOPAMINE AGONISTS
N04BC07 APOMORPHINE
N04BC01
N04BC06
N04BC02
N04BC04
MONOAMINE OXIDASE TYPE B INHIBITORSN04BD01 SELEGILINE HYDROCHLORIDE
P 1973W Tablet 5mg 100 5.00 MG 6,975 386,543OTHER DOPAMINERGIC AGENTS
N04BX02 ENTACAPONEP 8367J Tablet 200mg 1.00 GM 17,651
4,998,415
P 1195X
Injection 50mg in 2 mL 0.10
GM 892 13,331P 119
6YTablet 10mg 0.3
0GM 9,589 79,7
67P 1197B
Tablet 25mg 0.30
GM 42,695
417,607P 119
9DTablet 100mg 0.3
0GM 27,84
7377,977P 120
1FMixture 25mg per 5mL 100mL
0.30
GM 4,929 72,478P 345
5WInjection 50mg in 2mL 0.1
0GM 3,980 56,2
99
P 1001Q
Injection 50mg in 2mL 1.00 MG 4,322
153,263P 104
6CInjection 12.5mg in 0.5mL
1.00 MG 2,287
40,032P 309 Injection 25mg in 1mL 1.00 MG 4,86 118,
PROCHLORPERAZINEP 236
9QInjection 12.5mg in 1mL
50.00
MG 7,443
114,669P 289
3GTablet 5mg 100.
00MG 810,8
536,694,103P 289
4HSuppositories 5mg 5 100.
00MG 5,29
294,932P 289
5JSuppositories 25mg 5 100.
00MG 20,87
9436,306P 347 Injection 12.5mg in 50.0 MG 12,02 172,
TRIFLUOPERAZINE HYDROCHLORIDEP 218
5BTablet 1mg (base) 20.0
0MG 15,38
6153,282P 218
6CTablet 5mg (base) 20.0
0MG 17,20
3197,684P 238
6NTablet 2mg (base) 20.0
0MG 7,17
276,187
P 3052P Tablet 2.5mg 50.00 MG 42,567
379,491P 3053Q Tablet 10mg 50.00 MG 17,01 221,
THIORIDAZINE HYDROCHLORIDEA 202
85Tablet 50mg 100 0.30 GM 119 –
P 2163W
Tablet 10mg 0.30 GM 2,648 25,186P 216
4XTablet 50mg 0.30 GM 5,130 76,7
02P 2165Y
Tablet 100mg 0.30 GM 4,556 106,106P 235
9ETablet 25mg 0.30 GM 5,237 59,6
85
158
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMPSYCHOLEPTICSANTIPSYCHOTICSPHENOTHIAZINE WITH DIMETHYLAMINOPROPYL GROUP
N05AA01 CHLORPROMAZINE HYDROCHLORIDE
PHENOTHIAZINE WITH PIPERAZINE STRUCTUREN05AB02 FLUPHENAZINE DECANOATE
N05AB04
N05AB06
PHENOTHIAZINE WITH PIPERIDINE STRUCTUREN05AC01 PERICYAZINE
N05AC02
BUTYROPHENONE DERIVATIVESN05AD01 HALOPERIDOL
P 2761H
Tablet 500ug 100 8.00
MG 49,476
432,823P 276
3KOral liquid 2mg per mL 100 mL
8.00
MG 1,868 28,258P 276
5MI.M. injection equivalent to 50mg haloperidol
3.30
MG 2,098 51,058P 276
6NI.M. injection equivalent to 150mg haloperidol
3.30
MG 1,888 81,848P 276
7PTablet 1.5mg 8.0
0MG 15,62
4143,779P 276
8QInjection 5mg in 1mL 8.0
0MG 6,893 148,
479P 2770T
Tablet 5mg 8.00
MG 21,349
213,054
159
P 3456X
Injection 5mg in 1mL 8.00
MG 4,055 82,044
159
A 19954
Capsule 20mg 60 80.00 MG 13,879
–P 907
0JCapsule 20mg 60 80.00 MG 1,67
7179,223P 907
1KCapsule 40mg 60 80.00 MG 2,98
6583,105P 907
2LCapsule 60mg 60 80.00 MG 663 187,
670P 9073M
Capsule 80mg 60 80.00 MG 3,874
1,397,948
P 2255Q
Injection oily I.M. 20mg in 1mL
4.00
MG 5,485 96,026P 225
6RInjection oily I.M. 40mg in 1mL
4.00
MG 3,208 76,920P 225
7TInjection oily I.M. 100mg in 1mL
4.00
MG 4,932 208,458
P 6101D
Tablet 25mg 0.30 GM 4,832
312,634P 610
2ETablet 100mg 0.30 GM 23,6
968,064,709P 641
7RTablet 50mg 100 0.30 GM 1,18
5114,987P 641 Tablet 200mg 100 0.30 GM 3,65 1,644,
OLANZAPINEA 183
56Vial 10mg (solvent required)
10.00
MG 110
–P 817
0BTablet 2.5mg 30 10.0
0MG 144,4
099,558,904P 818
5TTablet 5mg 30 10.0
0MG 238,5
2830,597,762P 818
6WTablet 7.5mg 30 10.0
0MG 60,2
3212,648,687P 818
7XTablet 10mg 30 10.0
0MG 297,3
9994,749,622P 843
3WWafer 5mg 28 10.0
0MG 45,4
025,675,765P 843 Wafer 10mg 28 10.0 MG 49,1 15,329
QUETIAPINEP 845
6CTablet 25mg (base) 60 0.40 GM 106,9
157,021,166P 845
7DTablet 100mg (base) 90 0.40 GM 74,2
2111,401,643P 845
8ETablet 200mg (base) 60 0.40 GM 88,6
8923,583,161P 858
0NTablet 300mg (base) 60 0.40 GM 57,2
0019,998,318
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMPSYCHOLEPTICSANTIPSYCHOTICSINDOLE DERIVATIVES
N05AE04 ZIPRASIDONE
THIOXANTHENE DERIVATIVES
N05AF01 FLUPENTHIXOL
N05AF05 ZUCLOPENTHIXOLP 8097E Oily I.M. injection 200mg in 1mL 15.00MG 23,033
537,680DIPHENYLBUTYLPIPERIDINE DERIVATIVES
N05AG02 PIMOZIDEA 11421 Tablet 2mg 50 4.00 MG 549 –
DIAZEPINES, OXAZEPINES AND THIAZEPINESN05AH02 CLOZAPINE
N05AH03
N05AH04
160
P 8594H
Tablet 100mg 30 0.40
GM 20,771
1,022,775P 859
5JTablet 200mg 60 0.4
0GM 29,58
64,523,501P 859
6KTablet 400mg 60 0.4
0GM 34,12
89,360,042P 873
6TOral solution 100mg per mL 60mL 2
0.40
GM 237 45,530
P 3059B Tablet 250mg 200 889.00
MG 101,870
1,407,118P 8290H Tablet 450mg (slow
release) 200889.00
MG 31,646
934,344
P 8717T
Tablet 10mg 30 15.00
MG 28,753
5,004,557P 871
8WTablet 15mg 30 15.0
0MG 31,3
137,803,957P 871
9XTablet 20mg 30 15.0
0MG 12,8
343,664,520P 872 Tablet 30mg 30 15.0 MG 19,7 6,877,
RISPERIDONEP 316
9TTablet 1mg 5.0
0MG 91,6
897,090,793P 317
0WTablet 2mg 5.0
0MG 65,9
039,770,422P 317
1XTablet 3mg 5.0
0MG 32,3
846,788,075P 317
2YTablet 4mg 5.0
0MG 27,0
347,506,111P 810
0HOral solution 1mg per mL 100mL
5.00
MG 4,628
612,731P 878
0DPdr for I.M. injection 25mg/2mL diluent syringe
1.80
MG 34,171
10,862,832P 878
1EPdr for I.M. injection 37.5mg/2mL diluent syringe
1.80
MG 31,562
13,938,062P 878
2FPdr for I.M. injection 50mg/2mL diluent syringe
1.80
MG 38,721
19,524,308P 878
7LTablet 0.5mg 60 5.0
0MG 68,4
882,733,921P 878
8MTablet 0.5mg (orally disintegrating)56
5.00
MG 12,137
463,859P 878
9NTablet 1mg 60 5.0
0MG 53,7
444,040,691P 879
0PTablet 1mg (orally disintegrating) 56
5.00
MG 4,583
326,077P 879
1QOral solution 1mg per mL 30mL
5.00
MG 6,672
321,340P 879
2RTablet 1mg (orally disintegrating) 56
5.00
MG 5,056
358,419P 879
4WTablet 2mg (orally disintegrating) 56
5.00
MG 5,378
728,415P 886
9TTablet 0.5mg 60 5.0
0MG 29,6
231,176,166P 887
0WTablet 0.5mg (orally disintegrating) 56
5.00
MG 5,185
196,292P 907
5PTablet 3mg (orally disintegrating) 56
5.00
MG 778
134,492P 907
6QTablet 4mg (orally disintegrating) 56
5.00
MG 572
127,322P 907
9WTablet 2mg 60 5.0
0MG 8,44
41,172,277P 908
0XTablet 2mg (orally disintegrating) 56
5.00
MG 914
111,417
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMPSYCHOLEPTICSANTIPSYCHOTICSBENZAMIDES
N05AL05 AMISULPRIDE
LITHIUMN05AN01 LITHIUM CARBONATE
OTHER ANTIPSYCHOTICSN05AX12 ARIPIPRAZOLE
N05AX08
161
P 2130D
Tablet 250ug 1.00 MG 79,777
830,460P 213
1ETablet 500ug 1.00 MG 187,6
702,603,803P 213
2FTablet 1mg 1.00 MG 217,2
884,633,665P 811 Tablet 2mg 1.00 MG 131,7 4,048,
BROMAZEPAMP 4150K Tablet 3mg 10.00 MG 18,30
2472,984P 4151L Tablet 6mg 10.00 MG 27,60
2867,908
A 13803
Injection 10mg in 2mL 10.00
MG
224
–A 154
50Elixir 0.1% 100mL 10.0
0MG
3,604
–P 255
8PInjection 10mg in 2mL 10.0
0MG
5,018
59,008P 316
1JTablet 2mg 10.0
0MG
245,749
1,782,981P 316
2KTablet 5mg 10.0
0MG
1,896,974
14,197,205P 345
8BInjection 10mg in 2mL 10.0
0MG
11,541
125,564P 507
1XTablet 2mg 10.0
0MG
578
3,987P 507
2YTablet 5mg 10.0
0MG
3,771
25,730P 535
5WTablet 2mg 50 10.0
0MG
548
4,578P 535
6XTablet 5mg 50 10.0
0MG
3,738
34,720P 535
7YTablet 2mg 50 10.0
0MG
217
1,915P 535 Tablet 5mg 50 10.0 M 1,95 21,2
LORAZEPAMA 138
07Tablet 1mg 50 2.50 M
G76,084
–A 138 Tablet 2.5mg 50 2.50 M 33,1 –OXAZEPAMP 313
2WTablet 15mg 50.0
0MG
216,232
1,411,632P 313
3XTablet 30mg 50.0
0MG
1,146,504
7,717,366P 313
4YTablet 15mg 50.0
0MG
10,100
83,288P 313
5BTablet 30mg 50.0
0MG
14,296
121,747P 519
3HTablet 30mg 50.0
0MG
217
1,431P 537
1QTablet 15mg 50 50.0
0MG
564
4,538P 537
2RTablet 30mg 50 50.0
0MG
1,375
11,511P 537
3TTablet 15mg 50 50.0
0MG
171
1,606P 537
4WTablet 30mg 50 50.0
0MG
880
9,176
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMPSYCHOLEPTICSANXIOLYTICSBENZODIAZEPINE DERIVATIVES
N05BA12 ALPRAZOLAM
N05BA08
N05BA09 CLOBAZAMA 10898 Tablet 10mg 50 20.00MG 22,762 –
N05BA01 DIAZEPAM
N05BA06
N05BA04
AZASPIRODECANEDIONE DERIVATIVESN05BE01 BUSPIRONE HYDROCHLORIDE
P 4144D Tablet 5mg 50 30.00 MG 2,692 127,241P 4145E Tablet 10mg 50 30.00 MG 3,771 282,817
A 11021
Ampoule 15mg/3mL 5 15.00
MG
307
–A 126
45Ampoule 5mg/mL 10 15.0
0MG
6,515
–A 137
71Ampoule 5mg/mL 10 15.0
0MG
1,731
–A 168
38Ampoule 5mg/5mL 5 15.0
0MG
249
–A 179
73Ampoule 5mg/mL 5 15.0
0MG
253
–A 185
05Ampoule 5mg/mL 10 15.0
0MG
581
–A 185 Ampoule 5mg/5mL 10 15.0 M 25 –NITRAZEPAMP 272
3HTablet 5mg 25 5.00 M
G630,276
4,510,215P 273
2TTablet 5mg 50 5.00 M
G13,504
129,742P 535
9CTablet 5mg 50 5.00 M
G1,361
12,338P 536 Tablet 5mg 50 5.00 M 57 7,0
TEMAZEPAMA 183
40Capsule 10mg 20.0
0MG
118
–A 185
87Capsule 10mg 25 20.0
0MG
882
–P 208
8XTablet 10mg 20.0
0MG
78,712
723,505P 208
9YTablet 10mg 25 20.0
0MG
2,706,112
19,366,662P 522
1TTablet 10mg 20.0
0MG
1,124
7,785P 537
5XTablet 10mg 50 20.0
0MG
5,694
52,746P 537 Tablet 10mg 50 20.0 M 1,95 21,0
TRIAZOLAM
162
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMPSYCHOLEPTICSHYPNOTICS AND SEDATIVESALDEHYDES AND DERIVATIVES
N05CC01 CHLORAL HYDRATEA 18744 Syrup 1g/10mL 200mL 1.00 GM 1,743 –
BENZODIAZEPINE DERIVATIVESN05CD03 FLUNITRAZEPAM
P 4216X Tablet 1mg 30 1.00 MG 53,124 901,222N05CD08 MIDAZOLAM
N05CD02
N05CD07
N05CD05A 13374 Tablet 0.125mg 50 0.25 MG 4,986 –
ZOLPIDEMA 168
09Tablet 10mg 7 10.00 MG 26,46
6–
A 17644
Tablet 10mg 20 10.00 MG 299,817
–A 197
63Tablet 6.25mg 21 10.00 MG 20,30
5–
A 19764
Tablet 12.5mg 7 10.00 MG 419 –A 197
65Tablet 12.5mg 21 10.00 MG 165,0
75–
A 19787
Tablet 10mg 20 10.00 MG 16,422
–A 198
03Tablet 10mg 7 10.00 MG 933 –
A 19804
Tablet 10mg 20 10.00 MG 44,627
–A 198
17Tablet 10mg 7 10.00 MG 4,24
0–
A 19818
Tablet 10mg 20 10.00 MG 103,107
–A 198
93Tablet 10mg 20 10.00 MG 13,80
9–
A 19899
Tablet 10mg 20 10.00 MG 8,860
–A 199
74Tablet 10mg 20 10.00 MG 2,18
7–
A 201 Tablet 10mg 20 10.00 MG 430 –ZOPICLONEA 14925 Tablet 7.5mg 10 7.50 MG 6,11
1–
P 4522B Tablet 7.5mg 7.50 MG 88,668
2,011,769
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMPSYCHOLEPTICSHYPNOTICS AND SEDATIVESBENZODIAZEPINE RELATED DRUGS
N05CF02
N05CF01
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMPSYCHOANALEPTICSANTIDEPRESSANTSNON SELECTIVE MONOAMINE REUPTAKE INHIBITORS
N06AA09 AMITRIPTYLINE HYDROCHLORIDEA 197
35Tablet 25mg 75.0
0MG 375 –
P 2417F
Tablet 10mg 50 75.00
MG 374,719
2,718,127P 241
8GTablet 25mg 50 75.0
0MG 534,7
233,923,180P 242
9WTablet 50mg 50 75.0
0MG 401,7
033,231,304N06AA0
4CLOMIPRAMINE HYDROCHLORIDEP 1561E Tablet 25mg 50 100.
00MG 65,63
12,415,115N06AA1
6DOTHIEPIN HYDROCHLORIDEP 1357K Capsule 25mg 50 150.
00MG 262,3
922,167,485P 1358L Tablet 75mg 50 150.
00MG 359,3
753,306,524N06AA1
2DOXEPIN HYDROCHLORIDEP 1011F Capsule 10mg (base)50
100.00
MG 68,841
534,978P 1012G Tablet 50mg (base)
50100.00
MG 144,990
1,327,955P 1013H Capsule 25mg
(base)50100.00
MG 171,966
1,461,743A 14246 Tablet 75mg 30 100.
00MG 124 –
N06AA02
IMIPRAMINE HYDROCHLORIDEP 2420J Tablet 10mg 50 100.
00MG 45,77
2333,718P 2421K Tablet 25mg 50 100.
00MG 129,4
371,061,558N06AA1
0NORTRIPTYLINE HYDROCHLORIDEP 2522R Tablet 10mg (base) 50
75.00
MG 20,202
246,352P 2523T Tablet 25mg (base)
5075.00
MG 62,625
1,110,750N06AA0
6TRIMIPRAMINE MALEATEA 14531 Tablet 25mg (base) 150.
00MG 2,10
8–
A 16468 Capsule 50mg 50 150.00
MG 11,297
–
CITALOPRAMP 822
0PTablet 20mg (base) 28 20.0
0MG
1,560,358
52,018,615P 870
2BTablet 10mg (base) 28 20.0
0MG
24,684
479,366P 870 Tablet 40mg (base) 28 20.0 M 92,7 3,953,
ESCITALOPRAMP 870
0XTablet 10mg (base) 28 10.0
0MG
773,655
22,498,361P 870
1YTablet 20mg (base) 28 10.0
0MG
543,459
21,622,540P 884
9ROral solution 10mg (base) per mL 28mL
10.00
MG
1,714
64,998P 970 Oral solution 10mg (base) 10.0 M 27 16,5
FLUOXETINE HYDROCHLORIDEP 1434L Capsule 20mg
(base)2820.00
MG
850,812
29,179,103P 8270G Tablet 20mg (base) 20.0 M 257,9 7,941,
FLUVOXAMINEP 8174F Tablet 100mg 30 0.1
0GM
329,922
13,572,744P 8512B Tablet 50mg 30 0.1
0GM
131,329
3,202,951
P 2236Q
Tablet 50mg (base) 30 50.00
MG
1,356,188
40,211,141P 223
7RTablet 100mg (base) 30
50.00
MG
1,306,731
46,066,364P 883
6CTablet 50mg (base) 30 50.0
0MG
91,865
2,674,539P 883
7DTablet 100mg (base) 30
50.00
MG
86,185
2,760,876
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMPSYCHOANALEPTICSANTIDEPRESSANTSSELECTIVE SEROTONIN REUPTAKE INHIBITORS
N06AB04
N06AB10
N06AB03
N06AB08
N06AB05 PAROXETINEP 2242B Tablet 20mg (base) 30 20.00MG 1,127,052 42,901,897
N06AB06 SERTRALINE
MONOAMINE OXIDASE INHIBITORS, NON–SELECTIVEN06AF03 PHENELZINE SULPHATE
P 2856H Tablet 15mg (base) 100 60.00MG 7,082 884,140N06AF04 TRANYLCYPROMINE SULPHATE
P 2444P Tablet 10mg (base) 50 10.00MG 17,682 950,886MONOAMINE OXIDASE TYPE A INHIBITORS
N06AG02 MOCLOBEMIDEP 190
0BTablet 150mg 60 0.30 GM 51,71
61,114,715A 202
58Tablet 150mg 60 0.30 GM 563 –
A 20259
Tablet 300mg 60 0.30 GM 176 –P 800
3FTablet 300mg 60 0.30 GM 133,2
905,123,770
BUPROPIONP 8465M Tablet 150mg
(sustained release)0.30
GM 58,333
4,538,214P 8710K Tablet 150mg 0.3 GM 35,3 6,011,
MIANSERIN HYDROCHLORIDEP 1627P Tablet 10mg 50 60.0
0MG 21,6
58327,700P 1628Q Tablet 20mg 50 60.0 MG 46,4 1,638,
MIRTAZAPINEP 851
3CTablet 30mg 30 30.0
0MG 871,8
0531,837,846P 885
5CTablet 15mg (orally disintegrating) 30
30.00
MG 50,666
1,178,110P 885
6DTablet 30mg (orally disintegrating) 30
30.00
MG 47,210
1,647,735P 885
7ETablet 45mg (orally disintegrating) 30
30.00
MG 16,709
868,195P 888
3MTablet 45mg 30 30.0
0MG 73,7
093,796,800
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMPSYCHOANALEPTICSANTIDEPRESSANTSOTHER ANTIDEPRESSANTS
N06AX12
N06AX03
N06AX11
N06AX18 REBOXETINEP 8583R Tablet 4mg (base) 60 8.00 MG 97,094 3,762,542
N06AX16 VENLAFAXINEA 196
00Tablet 75mg (base) 100.
00MG
333
–P 830
1XCapsule 75mg (base) modified release 28
100.00
MG
1,162,077
54,115,527P 830
2YCapsule 150mg (base) modified release 28
100.00
MG
1,266,494
80,059,487P 886
8RTablet 37.5mg (base) (modified release) 28
100.00
MG
140,888
3,749,150
A 18484
Capsule 18mg 28 80.00
MG 875 –A 184
86Capsule 25mg 28 80.0
0MG 1,773 –
A 18488
Capsule 40mg 28 80.00
MG 3,885 –A 184
90Capsule 60mg 28 80.0
0MG 6,513 –
P 9092M
Capsule 10mg base 56
80.00
MG 751 170,680P 909
3NCapsule 18mg base 56
80.00
MG 968 208,639P 909
4PCapsule 25mg base 56
80.00
MG 1,912 417,474P 909
5QCapsule 40mg base 56
80.00
MG 3,198 699,735P 909
6RCapsule 60mg base 56
80.00
MG 2,678 578,419
A 17704
Capsule controlled release 20mg
30.00
MG 23,196
–A 177
05Capsule controlled release 30mg
30.00
MG 24,299
–A 177
06Capsule controlled release 40mg
30.00
MG 25,907
–P 217
2HTablet CR 27mg 30 30.0
0MG 4,44
9324,083P 238
7PTablet C R 18mg 30 30.0
0MG 22,90
01,327,226P 238
8QTablet C R 36mg 30 30.0
0MG 59,78
74,109,965P 243
2BTablet C R 54mg 30 30.0
0MG 45,81
33,598,283P 883 Tablet 10mg 100 30.0 MG 112,5 2,052,
MODAFINILA 176
24Tablet 100mg 30 0.3
0GM 3,95
4–
A 17626
Tablet 100mg 90 0.30
GM 209 –P 881
6BTablet 100mg 120 0.3
0GM 2,45
6771,899
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMPSYCHOANALEPTICSPSYCHOSTIMULANTS AND NOOTROPICSCENTRALLY ACTING SYMPATHOMIMETICS
N06BA09 ATOMOXETINE
N06BA02 DEXAMPHETAMINE SULPHATEP 1165H Tablet 5mg 15.00MG 257,6415,828,619
N06BA04 METHYLPHENIDATE
N06BA07
DONEPEZILP 8495D Tablet 5mg 28 7.5
0MG 61,1
779,672,208P 8496E Tablet 10mg 28 7.5 MG 173,8 26,882
GALANTAMINEP 877
0NTablet 8mg (base) (prolonged release) 28
16.00
MG 25,396
3,544,393P 877
1PTablet 16mg (base) (prolonged release) 28
16.00
MG 73,670
11,626,427P 877 Tablet 24mg (base) 16.0 MG 15,6 2,926,
RIVASTIGMINEP 849
7FCapsule 1.5mg 56 9.0
0MG 3,04
0490,029P 849
8GCapsule 3mg 56 9.0
0MG 5,41
3859,396P 849
9HCapsule 4.5mg 56 9.0
0MG 2,75
8428,933P 850
0JCapsule 6mg 56 9.0
0MG 3,64
5565,130P 856
3QOral solution 2mg (base) per mL 120mL
9.00
MG 658
109,283
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMPSYCHOANALEPTICSANTI–DEMENTIA DRUGSANTICHOLINESTERASES
N06DA02
N06DA04
N06DA03
OTHER ANTI–DEMENTIA DRUGS N06DX01 MEMANTINE HYDROCHLORIDE
A 18031 Tablet 10mg 56 – – 13,984 –
P 1959D
Tablet 60mg 180.00
MG 11,285
655,364P 260
8GTablet 180mg (sustained release)
180.00
MG 2,076 239,819P 272
4JTablet 10mg 180.
00MG 2,827 74,7
28
P 4571N
Transdermal patch 7 cm releasing ~7mg/24hr 7
MG 407 28,798P 457
2PTransdermal patch 14 cm releasing ~14mg/24hr 7 14.00
MG 852 60,405P 457
3QTransdermal patch 21 cm releasing ~21mg/24hr 7 14.00
MG 3,053 215,733P 457
6WTransdermal patch releasing 5mg/16hr 7
MG 272 13,405P 457
7XTransdermal patch releasing 10mg/16hr 7
MG 517 27,505P 457
8YTransdermal patch releasing 15mg/16hr 7
MG 711 42,038
N07BB03
ACAMPROSATEP 8357W Tablet 333mg (enteric coated)
2.00
GM 27,760
4,577,664N07BB0
1DISULFIRAMA 16345 Effervescent Tablet 200mg 30
– – 3,909
–N07BB04
NALTREXONEP 8370M Tablet 50mg 30 50.0
0MG 19,78
93,179,676
P 6307Y
Sublingual tablet 0.4mg (base)
8.00
MG 1,189
–P 630
8BSublingual tablet 2mg (base) 8.0
0MG 2,07
4–
P 630 Sublingual tablet 8mg (base) 8.0 MG 9,80 –BUPRENORPHINE HYDROCHLORIDE with NALOXONE HYDROCHLORIDEP 6470M Sublingual tablet 2mg
(base) – 0.5mg (base) 28– – 6,59
3–
P 6471N Sublingual tablet 8mg – – 9,37 –METHADONE HYDROCHLORIDEP 160
6MInjection 10mg in 1mL 25.0
0MG 549 85,6
52P 1609Q
Tablet 10mg 25.00
MG 92,532
3,099,129A 175
13Syrup 25mg per 5mL 200mL 25.0
0MG 49,04
1–
P 5399E
Syrup 25mg per 5mL 200mL 75.00
MG 1,054
23,538P 540
0FSyrup 25mg per 5mL 200mL 75.0
0MG 733 19,7
19P 6171T
Syrup 25mg per 5mL 200mL 25.00
MG 8,340
–P 617
2WSyrup 25mg per 5mL 1 L 25.0
0MG 1,80
8–
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMOTHER NERVOUS SYSTEM DRUGSPARASYMPATHOMIMETICSANTICHOLINESTERASES
N07AA02 PYRIDOSTIGMINE BROMIDE
CHOLINE ESTERSN07AB02 BETHANECHOL
CHLORIDEP 1062X Tablet 10mg 45.00MG 6,235 135,226
DRUGS USED IN ADDICTIVE DISORDERSDRUGS USED IN NICOTINE DEPENDENCE
N07BA01 NICOTINE
DRUGS USED IN ALCOHOL DEPENDENCE
DRUGS USED IN OPIOID DEPENDENCEN07BC01 BUPRENORPHINE
N07BC51
N07BC02
170
N
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
NERVOUS SYSTEMOTHER NERVOUS SYSTEM DRUGSANTIVERTIGO PREPARATIONSANTIVERTIGO PREPARATIONSN07CA01 BETAHISTINE
A 16064 Tablet 16mg 25 24.00 MG 160,406 –A 18064 Tablet 16mg 10 24.00 MG 27
7–
OTHER NERVOUS SYSTEM DRUGSOTHER NERVOUS SYSTEM DRUGS
N07XX02 RILUZOLEP 8664B Tablet 50mg 56 0.10 MG 6,375 4,333,764
N07XX06 TETRABENAZINEP 1330B Tablet 25mg 0.10 GM 5,018 1,845,730
171
P 1621H
Tablet 400mg 2.00
GM 354,244
3,513,135P 162
6NTablet 400mg 2.0
0GM 1,72
513,460P 163
0TOral suspension 320mg per 5mL
2.00
GM 29,570
440,246P 163
6DTablet 200mg 2.0
0GM 135,1
57984,765P 164
2KSuppositories 500mg 10 2.0
0GM 1,42
136,036P 333
9RTablet 200mg 2.0
0GM 68,66
7498,661P 334
1WOral suspension 320mg per 5mL
2.00
GM 867 12,560P 515
5HTablet 400mg 2.0
0GM 58,55
5576,705P 515
9MTablet 400mg 2.0
0GM 130 924
P01BA01 CHLOROQUINEA 15137 Tablet equivalent to 150mg (approx.)
0.50
GM 4,490
–P01BA02 HYDROXYCHLOROQUINE SULPHATE
P 1512N Tablet 200mg 0.52
GM 147,464
5,170,920BIGUANIDES
P01BB51 ATOVAQUONE with PROGUANILA 16050 Tablet 12 – – 21,79
7–
A 18864 Tablet 12 – – 1,481
–
A 14495
Tablet 250mg 8 1.00 GM 15,572
–QUININEP 197
2TTablet 300mg 1.50 GM 55,03
8597,036P 197
5YTablet 300mg 1.50 GM 134,9
831,474,737
P
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLANTSANTIPROTOZOALSAGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASESNITROIMIDAZOLE DERIVATIVES
P01AB01 METRONIDAZOLE
P01AB02 TINIDAZOLE
P 1465D Tablet 500mg 2.00 GM 138,0171,145,747ANTIMALARIALSQUINOLINE DERIVATIVES
P01BB01 PROGUANILA 15224 Tablet 100mg 0.20 GM 451 –
METHANOLQUINOLINESP01BC02 MEFLOQUINE
P01BC01
DIAMINOPYRIMIDINESP01BD01 PYRIMETHAMINE
P 1966L Tablet 25mg – – 305 3,913
P 8459F
Tablet 400mg 4.00 GM 536 92,468P 850
3MTablet 200mg 6 0.40 GM 1,664 53,9
87P 9047E
Tablet 200mg 6 0.40 GM 639 20,230
P 3047JTablet 125mg (base) 0.75 GM 649 4,452P 3048K Tablet 250mg
(base)0.75 GM 3,183 26,1
51
172
P
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLANTSANTHELMINTICSANTITREMATODALSQUINOLINE DERIVATIVES
P02BA01 PRAZIQUANTEL
A 13814 Tablet 600mg 8 3.00 GM 360 –ANTINEMATODAL AGENTSBENZIMIDAZOLE DERIVATIVESP02CA03 ALBENDAZOLE
P02CA01 MEBENDAZOLEP 4325P Tablet 100mg 0.20 GM 174 3,167
TETRAHYDROPYRIMIDINE DERIVATIVESP02CC01 PYRANTEL EMBONATE
AVERMECTINESP02CF01 IVERMECTIN
P 8359Y Tablet 3mg 4 12.00MG 4,604 182,494
173
P
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLANTSECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLANTSECTOPARASITICIDES, INCL. SCABICIDESPYRETHRINES, INCL. SYNTHETIC COMPOUNDS
P03AC04 PERMETHRINP 3054R Cream 50mg per g (5%) 30g – – 53,805 817,475
OTHER ECTOPARASITICIDES, INCL. SCABICIDESP03AX01 BENZYL BENZOATE
A 13227 Lotion 25% 200mL 1
– – 486 –A 19826 Lotion 25% 200mL
1– – 241 –
A 10690
Nasal spray pump 15mL 1 0.40
MG 269 –P 437
7JNasal drops 500ug per mL (0.05%) 15 mL
0.40
MG 138 2,075P 437
8KNasal spray 500ug per mL (0.05%) 15 mL
0.40
MG 2,400 36,246P 437
9LNasal spray 500ug per mL (0.05%) 18 mL
0.40
MG 377 6,030
R01AD01
BECLOMETHASONE DIPROPIONATEA 17056 Aqueous nasal spray 50ug per dose 200 dose 0.40
MG 4,536
–R01AD05
BUDESONIDEA 17200 Nasal spray aqueous(pump) 32ug per dose 60 doses 0.30
MG 783 –A 17201 Nasal spray aqueous(pump) 32ug per dose 120 doses 0.30
MG 954 –A 17850 Nasal spray aqueous(pump) 64ug per dose 240 doses 0.30
MG 96,934
–A 17952 Nasal spray aqueous(pump) 64ug per dose 120 doses 0.30
MG 155,037
–P 4092JNasal spray aqueous(pump) 64ug per dose 120 doses 0.30
MG 46,178
1,230,119R01AD0
8FLUTICASONEA 17840 Aqueous Nasal unit dose instillation 400ug 28 0.20
MG 802 –R01AD09
MOMETASONE FUROATEA 16441 Aqueous Nasal spray 50ug per dose 0.20
MG 451,319
–A 18043 Aqueous Nasal spray 50ug per dose 65 doses 0.20
MG 28,497
–
174
R
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
RESPIRATORY SYSTEMNASAL PREPARATIONSDECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USESYMPATHOMIMETICS, PLAIN
R01AA05 OXYMETAZOLINE
R01AA07 XYLOMETAZOLINEA 11436 Nasal spray 15mL 1 0.80 MG 1,142 –
ANTIALLERGIC AGENTS,EXCL.CORTICOSTEROIDSR01AC02 LEVOCABASTINE
P 4311X Nasal spray 500ug per mL (0.05) 10mL 0.60 MG 2,966 49,317R01AC01 SODIUM CROMOGLYCATE
P 4468E Nasal spray metered dose pump 20mg per mL (2%) 40.00 MG965 17,979
CORTICOSTEROIDS
OTHER NASAL PREPARATIONSR01AX03 IPRATROPIUM BROMIDE
A 16829
Aqueous nasal spray(pump pack) 42ug per dose 10mL
0.24
MG 222 –P 408
9FAqueous nasal spray(pump pack) 21ug per dose
0.24
MG 10,369
214,043P 409
0GAqueous nasal spray(pump pack) 42ug per dose
0.24
MG 10,783
289,507
R01BA52
BROMHEXINE with GUAIPHENESIN with PSEUDOEPHEDRINEA 19678 Liquid 100mL 1 – –
1,342 –R01BA52
BROMHEXINE with PSEUDOEPHEDRINEA 19485 Liquid 200mL – – 73
6–
R01BA52
CHLORPHENIRAMINE with DEXTROMETHORPHAN with PARACETAMOL with PSEUDOEPHERINEA 19965 Tablets 2mg chlor/500mg pseud 6+
– –322
–
175
R
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
RESPIRATORY SYSTEMNASAL PREPARATIONSNASAL DECONGESTANTS FOR SYSTEMIC USESYMPATHOMIMETICS
R01BA52 BROMHEXINE with PSEUDOEPHEDRINEA 19651 Liquid 200mL 1 – – 2,931 –
R01BA52 CHLORPHENIRAMINE with DEXTROMETHORPHAN with PSEUDOEPHEDRINEA 19681 Mixture 100mL 1 – – 361 –
R01BA52 CHLORPHENIRAMINE with PARACETAMOL with CODEINE PSEUDOEPHERINEA 19971 Tab2mg chlor/500mg para/
30mg pseud8+/9mg codeine – – 4,634 –R01BA52 CHLORPHENIRAMINE with PSEUDOEPHEDRINE with PARACETEMOL
A 19538 Tablet 24 – – 2,460 –R01BA52 CODEINE with PARRACETAMOL with PSEUDOEPHEDRINE with TRIPROLIDINE
A 19481 Tablet 24 – – 73,120 –R01BA52 DEXTROMETHORPHAN with
DOXYLAMINE with PARACETAMOL with PSEUDOEPHEDRINEA 19483 Capsule 24 – – 31,100 –A 19484 Capsule 20 – – 2,466 –
R01BA52 DEXTROMETHORPHAN with PARACETAMOL with PSEUDOEPHEDRINEA 19482 Capsule 24 – – 2,168 –A 19503 Tablet 24 – – 1,333 –
R01BA52 DEXTROMETHORPHAN with PARACETAMOLE with PSEUDOEPHEDRINEA 19541 Tablet 24 – – 1,102 –
R01BA52 DEXTROMETHORPHAN with PSEUDOEPHEDRINEA 19511 Syrup 100mL – – 2,204 –A 19533 Tablet 6 – – 40,929 –A 19922 Capsules 10mg/30mg 24 – – 543 –
R01BA52 IBUPROFEN WITH PSEUDOEPHEDRINEA 19663 Tablets 20 – – 618 –
R01BA52 IBUPROFEN with PSEUDOEPHEDRINEA 19513 Tablet 24 – – 2,563 –
R01BA52 IBUPROFEN with PSEUDOEPHEDRINE with PSEUDOEPHEDRINEA 19492 Tablet 24 – – 12,540 –
R01BA52 LORATADINE with PSEUDOEPHEDRINEA 19534 Tablet 6 – – 23,272 –
A 11894
Tablet 10 – – 4,849 –A 190
49Sachet, 10 – – 62
4–
A 19478
Tablet 24 – – 2,484 –A 195
04Tablet 24 – – 11,764 –
A 19515
Tablet 24 – – 6,857 –
176
R
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
RESPIRATORY SYSTEMNASAL PREPARATIONSNASAL DECONGESTANTS FOR SYSTEMIC USESYMPATHOMIMETICS
R01BA52 PARACETAMOL with PSEUDOEPHEDRINE
R01BA52 PARACETAMOL with PSEUDOEPHEDRINE with CHLORPHENIRAMINEA 11897 Tablet 10 – – 6,148 –
R01BA52 PARACETAMOL with PSEUDOEPHEDRINE with TRIPROLIDINEA 19514 Tablet 24 – – 7,412 –A 19516 Tablet 20 – – 4,725 –
R01BA52 PSEUDEPHEDRINE with FEXOFENADINEA 19052 Tablet 120mg–60mg 10 – – 535 –A 19644 Tablet 120mg–60mg 6 – – 17,373 –
R01BA02 PSEUDOEPHEDRINEA 11948 Elixir 30mg/5mL 1 0.24 GM 2,260 –A 17458 Tablet 60mg 60 0.24 GM 309 –A 18518 Tablet 60mg 30 0.24 GM 167 –A 19683 Tablets 60mg 12 – – 4,478 –A 19962 Tablets substained release 120mg 6 0.24 GM 8,427
–P 4420P Tablet 60mg 0.24 GM 16,612 245,654
R01BA52 PSEUDOEPHEDRINE with GUAIPHENESINA 19921 Capsules 30mg/100mg 24 – – 1,224 –
P 8136F
Capsule contain powder oral inhalation 12ug
24.00
UG
17,466
640,478P 823
9PPowder oral inhalation breath actuated 6ug
24.00
UG
11,974
293,916P 824 Powder oral inhalation breath 24.0 U 70,9 2,574,
R03AC02 SALBUTAMOLP 109
9WCapsule 200 ug (base) (oral inhalation)
0.80
MG
4,033
82,755A 162
97Oral pressurised inhalation 100 ug per
0.80
MG
181
–P 200
0GNebuliser solution single dose 2.5mg(base)
10.00
MG
107,284
2,497,019P 200
1HNebuliser solution single dose 5mg(base)
10.00
MG
501,984
12,513,099P 200
3KNebuliser solution 5mg (base) per mL(0.5%)
10.00
MG
237
3,307P 349
5YOral pressurised inhalant 100ug (base) CFC-free
0.80
MG
17,987
203,353P 349
6BNebuliser solution single dose 2.5mg(base)
10.00
MG
6,367
95,642P 349
7CNebuliser solution single dose 5mg(base)
10.00
MG
9,815
152,807P 828
8FOral pressurised inhalant 100ug (base) CFC-free
0.80
MG
3,021,120
49,707,716P 835
4QOral pressurised inhalant breath actuated 100ug
0.80
MG
86,740
3,109,081R03AC1
2SALMETEROLP 3027H Oral pressurised inhalation 25ug (base) 0.10
MG
59,716
2,038,373P 8141L Powder inhal in breath actu
dev 50ug/dose 60 doses 0.10MG
24,180
842,139R03AC0
3TERBUTALINE SULPHATEP 1251W Nebuliser solution single dose 5mg in 2mL
MG
3,005
87,462P 1252X Pdr for inhalation in breath
actu dev 500ug/doseMG
348,232
5,636,436
A 18544
Pdr oral inhal in breath actu dev400ug–12ug/dose 60 – – 37
8–
P 8625Y
Pdr oral inhal in breath actu dev200ug–6ug/dose 120 – – 559,7
8632,263,855P 875
0MPdr oral inhal in breath actu dev400ug–12ug/dose 60 – – 291,7
4825,048,040P 879
6YPdr oral inhal in breath actu dev6ug–100ug/dose 120 – – 27,1
911,446,475
177
R
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
RESPIRATORY SYSTEMDRUGS FOR OBSTRUCTIVE AIRWAY DISEASESADRENERGICS, INHALANTSSELECTIVE BETA–2–ADRENOCEPTOR AGONISTS
R03AC13 EFORMOTEROL
ADRENERGICS AND OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASESR03AK07 EFORMOTEROL with BUDESONIDE
R03AK04 SALBUTAMOL with IPRATROPIUM BROMIDEP 4283K Oral press inhal 20ug (anhydrous)–100 ug per dose – –
482 22,365R03AK06 SALMETEROL and FLUTICASONE
P 8430Q
Pdr oral inhal in breath actu dev 50ug/100ug 60
– – 89,037
4,025,332P 843
1RPdr oral inhal in breath actu dev 50ug/250ug 60
– – 715,271
41,707,903P 843
2TPdr oral inhal in breath actu dev 50ug/500ug 60
– – 681,127
53,605,189P 851
7GOral Press inhal 25ug–50ug 120
– – 96,142
4,343,619P 851
8HOral Press inhal 25ug–125ug 120
– – 272,428
15,842,251
178
P 8519J
Oral Press inhal 25ug–250ug 120
– – 984,510
76,516,504
P 8406K
Oral press inhal 50ug/dose(200 doses) CFC free
0.80
MG 13,612
238,869P 840
7LOral press inhal 100ug/dose(200 doses)CFC
0.80
MG 73,299
2,283,786P 840
8MOral press inhal in breath actv dev 50ug CFC free
0.80
MG 3,051
78,605P 840 Oral press inhal in breath actu 0.8 MG 30,27 1,107,
BUDESONIDEP 206
5QNebuliser suspn single dose units 500ug in 2mL 30
1.50
MG 6,237
331,149P 206
6RNebuliser suspn single dose units 1mg in 2mL 30
1.50
MG 14,741
1,098,212P 207
0YPder for oral inhal in breath actu dev 100ug/dose
0.80
MG 10,589
226,802P 207
1BPder oral inhal in breath actu dev 200ug/dose
0.80
MG 70,590
2,035,202P 207 Pder oral inhal in breath actu 0.8 MG 149,0 6,507,
CICLESONIDEP 8853Y Oral pressurised inhalation
80ug/dose 120 doses0.16
MG 10,266
244,635P 8854B Oral pressurised inhalation 0.1 MG 46,65 1,840,
FLUTICASONEA 173
14Oral pressurised inhalation 50ug/dose 120 doses
0.60
MG 182 –P 814
7TPowder for oral inhalation 100ug/dose 60 doses
0.60
MG 11,442
177,495P 814
8WPowder for oral inhalation 250ug/dose 60 doses
0.60
MG 60,019
1,719,488P 814
9XPowder for oral inhalation 500ug/dose 60 doses
0.60
MG 20,355
1,022,983P 834
5FOral pressurised inhalation 125ug/dose 120 doses
0.60
MG 128,628
3,661,274P 834
6GOral pressurised inhalation 250ug/dose 120 doses
0.60
MG 132,653
6,407,293P 851
6FOral pressurised inhalation 50ug/dose 120 doses
0.60
MG 128,882
1,993,512
P 1541D
Nebuliser solution 250ug per mL (0.025%)
0.30
MG 957
18,983P 154
2ENebuliser solution single dose 250ug/mL 30
0.30
MG 46,697
2,083,457P 823
8NNebuliser solution single dose 500ug in 1mL 30
0.30
MG 245,186
12,895,779P 867
1JOral pressurised inhalation 21ug/dose 200 doses
0.12
MG 116,178
4,565,928
179
R
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
RESPIRATORY SYSTEMDRUGS FOR OBSTRUCTIVE AIRWAY DISEASESOTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES,INHALANTSGLUCOCORTICOIDS
R03BA01 BECLOMETHASONE DIPROPIONATE
R03BA02
R03BA08
R03BA05
ANTICHOLINERGICSR03BB01 IPRATROPIUM BROMIDE
R03BB04 TIOTROPIUM BROMIDEP 8626B Capsule 18ug (base)(oral inhalation) 3018.00 UG 1,376,925 104,392,442
ANTIALLERGIC AGENTS, EXCL. CORTICOSTEROIDSR03BC03 NEDOCROMIL
P 8365G Oral pressurised inhalation 2mg/dose 112 doses 8.00 MG63,961 2,150,084
R03BC01 SODIUM CROMOGLYCATEP 112
4ENebuliser solution ampoule 20mg/2ml
80.00
MG 1,250
71,762A 200
17Nebuliser solution 20 mg per 2 mL, ampoule
80.00
MG 153 –P 287
2EOral pressurised inhalation 1mg/dose 200 doses
40.00
MG 537 14,970P 287
8LCapsule 20mg (oral inhalation)
80.00
MG 2,560
82,776P 833
4POral pressurised inhalation 5mg/dose 112 doses
40.00
MG 36,666
1,240,028
180
P 8767K
Oral pressurised inhalation 1mg/dose 200 doses
40.00
MG 5,921
166,311
R03DA02
CHOLINE THEOPHYLLINATEA 16083 Elixir 50mg per 5mL 500mL
0.60
GM 5,578 –R03DA54
CHOLINE THEOPHYLLINATE with GUAIPHENESINA 10362 Expectorant 500mL 1
– – 10,743
–R03DA04
THEOPHYLLINEP 2614N Syrup 80mg per 15mL 500mL
0.40
GM 14,386
136,848P 2634P Tablet 250mg (sustained
release)0.40
GM 21,856
258,988P 8230E Tablet 200mg (sustained
release)0.20
GM 16,957
181,442P 8231F Tablet 300mg (sustained
release)0.40
GM 16,925
223,545
A 16115
Chewable tablet 10mg 28
10.00
MG 42,841
–P 862
7CChewable tablet 4mg (base) 28
10.00
MG 63,007
2,897,244P 862
8DChewable tablet 5mg (base) 28
10.00
MG 84,530
3,889,233
181
R
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
RESPIRATORY SYSTEMDRUGS FOR OBSTRUCTIVE AIRWAY DISEASESADRENERGICS FOR SYSTEMIC USESELECTIVE BETA–2–ADRENOCEPTOR AGONISTS
R03CC02 SALBUTAMOLP 1103C Syrup 2mg (base) per 5mL 300mL 12.00 MG 49,692
619,464R03CC03 TERBUTALINE SULPHATE
P 1034K
Injection 500ug in 1mL
15.00
MG 144 34,198A 172
36Elixir 0.3mg/mL 300mL
2.00 MG 29,795
–P 349
1RInjection 500ug in 1mL
15.00
MG 3,832 108,798OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
XANTHINES
LEUKOTRIENERECEPTOR ANTAGONISTSR03DC03 MONTELUKAST
R03DC01 ZAFIRLUKASTA 16282 Tablet 20mg 56 40.00MG 886 –
180
R05CA CAMPHOR COMPOUNDA 15831 Linctus 100mL – – 532 –
R05CA10 GUAIPHENESIN with PSEUDOEPHEDRINE
A 13545 Syrup sf100m– – 2,675 –
A 19461 Syrup 100m 1 – – 2,741 –R05CA10 SENEGA and AMMONIA
A 19447 Mixture 200mL – – 2,428 –P 4074K Mixture 200mL – – 12,06
796,378MUCOLYTICS
P 1214X
Tablet 30mg 100.00
MG 68,433
1,190,383A 128
17Linctus 0.5% 100mL 1
100.00
MG 1,559
–A 165 Tablet 30mg 100 100. MG 725 –CODEINE with PARACETAMOL with PSEUDOEPHEDRINEA 10584 Tablet 24 – – 37,26
9–
A 19469 Tablet 24 – – 21,963
–
A 14751 Elixir sugar free 200mL
– – 202
–A 17186 Elixir sugar and colour – – 2,875 –DEXTROMETHORPHAN with DIPHENHHYDRAMINEA 18877 Linctus 100mL 1 – – 78
8–
A 18878 Linctus 200mL 1 – – 55 –DEXTROMETHORPHAN with DIPHENHHYDRAMINE with PSEUDOEPHEDRINE
R
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
RESPIRATORY SYSTEMCOUGH AND COLD PREPARATIONSEXPECTORANTS,EXCL COMBINATIONS WITH ANTITUSSIVESEXPECTORANTS
R05CB01 ACETYLCYSTEINEP 8747J Sterile inhalation solution 200mg per mL(20%) 5mL 1.60 GM 6,887 934,187
R05CB02 BROMHEXINE HYDROCHLORIDEA 10212 Elx 4mg/5mL 1 24.00 MG 10,741 –A 13662 Tablet 8mg 100 24.00 MG 3,234 –
COUGH SUPPRESSANTS, EXCL.COMBINATIONS WITH EXPECTORANTSOPIUM ALKALOIDS AND DERIVATIVES
R05DA04 CODEINE
R05DA20
R05DA20 CODEINE with PSEUDOEPHEDRINEA 12608 Linct 100mL 1 100.00 MG 291 –
R05DA20 CODEINE with PSEUDOEPHEDRINE with PHENYLEPHRINEA 19650 Mixture 100mL 1 – – 2,407 –
R05DA20 DEXTROMETHORPHAN with BROMPHENIRAMINE with PHENYLEPHRINE
R05DA20
R05DA20A 19463 Syrup 100mL – – 1,565 –
181
A 10723
Linctus 200mL 1 50.00
MG 1,996 –A 126
11Linctus 200mL 1 50.0
0MG 705 –
A 12921
Expectorant 200mL 1 50.00
MG 650 –A 138
09Linctus 1mg per mL (0.1%) 100mL
50.00
MG 1,402 –P 407
1GLinctus 1mg per mL (0.1%) 100mL
50.00
MG 7,951 97,628
R
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
RESPIRATORY SYSTEMCOUGH AND COLD PREPARATIONSCOUGH SUPPRESSANTS, EXCL.COMBINATIONS WITH EXPECTORANTSOPIUM ALKALOIDS AND DERIVATIVES
R05DA08 PHOLCODINE
R05DA20 PHOLCODINE with PSEUDOEPHEDRINEA 13367 Mixture 200mL 1 50.00MG 1,699 –
COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONSOPIUM DERIVATIVES AND EXPECTORANTS
R05FA02 AMMONIA with CODEINE with GUAIPHNESIN with PHENYLEPHRINE with PSEUDOEPHEDRINEA 19682 Mixture 100mL – – 210 –
R06AA02
DIMENHYDRINATEA 10684 Syrup 2.5mg/mL 50mL 300.
00MG 55
3–
R06AA02
DIPHENHYDRAMINEA 15912 Capsule 50mg 8 200.
00MG 4,914 –
R06AA52
DIPHENHYDRAMINE with AMMONIUM CHLORIDEA 10194 Mixture 100mL 1
– – 3,470 –A 10196 Mixture 500mL 1 – – 21
7–
A 13099 Mixture 200mL 1 – – 4,691 –R06AA52
DIPHENHYDRAMINE with PHENYLEPHA 11694 200mL 1 – – 1,109 –
R06AA09
DOXYLAMINEA 13003 Tablet 25mg 20 – – 32,840 –A 14123 Capsule 25mg 20 – – 14,349 –
R06AB01
BROMPHENIRAMINEA 16130 Drops 50mL 1 – – 9,499 –
R06AB51
BROMPHENIRAMINE COMBINATIONSA 10665 Drop 30mL 1 24.0
0MG 9,860 –
A 10713 Elixir 200mL 1 24.00
MG 280
–A 14816 Drop 50mL – – 2,014 –
182
R
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
RESPIRATORY SYSTEMANTIHISTAMINES FOR SYSTEMIC USEANTIHISTAMINES FOR SYSTEMIC USEAMINOALKYL ETHERS
SUBSTITUTED ALKYLAMINES
R06AB54 CHLORPHENIRAMINE with CODEINE with PARACETAMOL with PSEUDOEPHRINEA 19679 Tablets 24 – – 49,621
– R06AB54 CHLORPHENIRAMINE with CODINE with PARACETAMOL WITH PSEUDOEPHEDRINE A 19479 Tablet 24 – –
7,164 –A 19480 Capsule 24 – – 14,825 –
R06AB54 CHLORPHENIRAMINE with DEXTROMETHORPHAN WITH PARACETAMOL WITH PSEUDOEPHEDRINEA 19486 Sachets 10 – – 1,227 –A 19489 Tablets 24 – – 1,024 –
R06AB54 CHLORPHENIRAMINE with DEXTROMETHORPHAN with PARACETAMOL with PSEUDOEPHRINEA 19547 Capsules 24 – – 1,354 –
R06AB54 CHLORPHENIRAMINE with PARACETAMOLA 18516 Tablets 2mg/500mg 24 – – 1,960 –
R06AB54 CHLORPHENIRAMINE with PARACETAMOL with PSEUDOEPHEDRINEA 19475 Tablet 24 – – 4,408 –A 19502 Tablets 24 – – 249 –A 19506 Tablets 24 – – 2,111 –
R06AB54 CHLORPHENIRAMINE with PHENYLEPHRINEA 106
04Syrup 100mL 1 – – 22
0–
A 10605
Syrup 200mL 1 – – 279
–A 160
69Syrup 100mL 1 – – 53
1–
A 160 Syrup Infant 50mL 1 – – 24,586 –R06AB54 CHLORPHENIRAMINE with PHOLCODEINE with PSEUDOEPHRINE
A 19542 Syrup 100mL – – 213
–A 19543 Syrup 200mL – – 35
8–
R06AB54
CHLORPHENIRAMINE with PSEUDOEPHEDRINEA 13477 Syrup infant 50mL 1
– – 10,992 –R06AB54
CHLORPHENIRAMINE with PSEUDOEPHRINEA 19532 Tablets 12
– – 43,544 –R06AB02
DEXCHLORPHENIRAMINEA 11602 Syrup 2mg/5mL 1 6.0
0MG 16,257 –
A 12592 Tablet 6mg 20 6.00
MG 12,928 –A 12822 Tablet 2mg 50 6.0
0MG 18,281 –
A 19058 Tablet 2mg 25 6.00
MG 26,427 –A 19059 Tablet 6mg 40 6.0
0MG 5,174 –
R06AB52
DEXCHLORPHENIRAMINE with PHENYLEPHRINEA 10608 Tablet 18
– – 299
–R06AB05
PHENIRAMINEA 10066 Tablet 50mg 10 75.0
0MG 97
2–
A 13917 Tablet 50mg 75.00
MG 4,380 –
183
R
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
RESPIRATORY SYSTEMANTIHISTAMINES FOR SYSTEMIC USEANTIHISTAMINES FOR SYSTEMIC USESUBSTITUTED ALKYLAMINES
PHENOTHIAZINE DERIVATIVES
R06AD02 PROMETHAZINE
A 12553
Elixir 100mL 1 25.00
MG 502 –A 158
10Tablet 25mg 30 25.0
0MG 3,963 –
P 1948M
Injection 50mg in 2mL 25.00
MG 11,669
265,204P 348
8NInjection 50mg in 2mL 25.0
0MG 13,74
7259,568P 407
2HTablet 10mg 25.0
0MG 36,30
8476,088P 407
3JTablet 25mg 25.0
0MG 56,53
6854,269P 532
5GTablet 10mg 50 25.0
0MG 2,730 39,6
78P 5326H
Tablet 25mg 50 25.00
MG 3,758 63,481P 532
7JOral liquid 5mg per 5mL 100mL
25.00
MG 26,464
483,609P 532
8KTablet 10mg 50 25.0
0MG 1,204 15,7
85P 5329L
Tablet 25mg 50 25.00
MG 1,937 35,326P 533
0MOral liquid 5mg per 5mL 100mL
25.00
MG 11,000
7,765R06AD5
2PROMETHAZINE with PHOLCODINEA 12066 Linctus 100mL 1 – – 1,986 –
184
R06AD01
TRIMEPRAZINEA 12156 Syrup 7.5mg/5 1 30.0
0MG 3,631 –
A 12157 Syrup 30mg/5 1 30.00
MG 2,437 –
A 14363
Tablet 10mg 10.00
MG 6,682 –A 161
21Oral drops 10mg per mL 20mL
10.00
MG 284 –A 161
22Oral solution 1mg/mL 75mL
10.00
MG 2,589 –P 417
5RTablet 10mg 30 10.0
0MG 16,47
9614,165
185
R
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
RESPIRATORY SYSTEMANTIHISTAMINES FOR SYSTEMIC USEANTIHISTAMINES FOR SYSTEMIC USEPIPERAZINE DERIVATIVESR06AE07 CETIRIZINE
R06AE CETIRIZINE AND PSEUDOEPHEDRINEA 19920 Tablet 6 – – 1,383 –
OTHER ANTIHISTAMINES FOR SYSTEMIC USER06AX02
CYPROHEPTADINE HYDROCHLORIDEP 1798P Tablet 4mg 12.0
0MG 83,13
51,028,587R06AX2
7DESLORATADINEA 18720 Tablet 5mg 28 5.0
0MG 133 –
A 18721 Tablet 5mg 7 5.00
MG 420 –R06AX26
FEXOFENADINEA 161
41Tablet 120mg 10 0.1
2GM 368 –
A 16142
Tablet 180mg 10 0.12
GM 2,539
–A 162
66Tablet 180mg 30 0.1
2GM 1,35
7–
A 18893
Tablet 120mg 10 0.12
GM 257 –A 188
94Tablet 180mg 10 0.1
2GM 433 –
A 18895
Tablet 180mg 30 0.12
GM 176 –P 423
7BCapsule 60mg 0.1
2GM 6,11
7279,000P 423
8CTablet 120mg 0.1
2GM 13,01
6507,795R06AX13 LORATADINE
A 13978
Tablet 10mg 10.00
MG 10,052
–A 145
13Syrup 100mL 10.0
0MG 3,30
5–
A 18283
Tablet 10mg 50 10.00
MG 457 –A 196
85Tablet 10mg 10.0
0MG 713 –
A 19687
Tablet 10mg 50 10.00
MG 113 –P 431
3BTablet 10mg 10.0
0MG 41,65
11,774,907R06AX13 LORATADINE with PSEUDOEPHEDRINE
A 15405 Tablet 10 10.00
MG 161 –A 16281 Tablet 10 10.0
0MG 134 –
P 1171P
Eye ointment 10mg per g (1%) 4g
– – 551,521
4,694,520A 146
70Eye drops Minims 0.5% 20 – – 160 –
P 2360F
Eye drops 5mg per mL (0.5%) 10mL
– – 1,171,383
9,455,863P 505
5CEye drops 5mg per mL (0.5%) 10mL
– – 218 1,158S01AA1
1GENTAMICIN SULPHATEP 1441W Eye drops 3mg (base) per mL (0.3%) 5mL
– – 12,424
217,168S01AA1
2TOBRAMYCINP 2328M Eye drops 3mg per mL (0.3%) 5mL
– – 72,113
1,257,644P 2329N Eye ointment 3mg per g
(0.3%) 3.5g– – 19,58
7394,835
P 1217C
Eye drops 3mg per mL (0.3%) 5mL
– – 15,786
449,630A 173
03Eye drops 3mg per mL (0.3%) 5mL
– – 336 –A 173
04Eye drops 3mg per mL (0.3%) 5mL
– – 209 –
S01BA01
DEXAMETHASONEP 1288T Eye drops 1mg per mL (0.1%) 5mL
– – 190,934
1,760,640S01BA0
7FLUOROMETHOLONEP 1204J Eye drops 1mg per mL (0.1%) 5mL
– – 264,340
2,436,603P 1438Q Eye drops 1mg per mL
(0.1%) 5mL– – 59,13
5545,882S01BA0
2HYDROCORTISONEP 1497T Eye ointment 5mg per g (0.5%) 5g
– – 21,469
226,351A 19589 Eye drops 10mg per
mL (1%) 10mL– – 212 –
P 2441L Eye ointment 10mg per g (1%) 5g
– – 44,308
475,383S01BA0
4PREDNISOLONEA 14678 Minims 0.5% 20 – – 2,71
7–
186
S
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
SENSORY ORGANSOPHTHALMOLOGICALSANTIINFECTIVESANTIBIOTICS
S01AA01 CHLORAMPHENICOL
SULFONAMIDESS01AB04 SULPHACETAMIDE
P 2063N Eye drops 100mg per mL (10%) 15mL – – 23,142278,460
ANTIVIRALSS01AD03 ACICLOVIR
P 1002R Eye ointment 30mg per g (3%) 4.5g – – 42,3831,300,521
OTHER ANTIINFECTIVESS01AX13 CIPROFLOXACIN
S01AX11 OFLOXACINP 8383F Eye drops 3mg per mL (0.3%) 5mL – – 15,481
409,123ANTIINFLAMMATORY AGENTSCORTICOSTEROIDS, PLAIN
CORTICOSTEROIDS AND SYMPATHOMIMETICS IN COMBS01BB02 PREDNISOLONE ACETATE with PHENYLEPHRINE HYDROCHLORIDE
187
P 3112T Eye drops 10mg–1.2mg per mL (1%–0.12%) 10mL – –265,476 5,717,102
S01EA03
APRACLONIDINEP 8083K Eye drops 5mg (base) per mL (0.5%) 10mL
1.50
MG 6,745
251,079S01EA0
5BRIMONIDINEP 8351M Eye drops 2mg per mL (0.2%) 5mL
0.40
MG 196,963
3,836,979S01EA0
2DIPIVEFRINEP 1351D Eye drops 1mg per mL (0.1%) 10mL
0.20
MG 8,355
176,842
A 19844
Eye drops 30mg per mL (3%) 15mL
12.00
MG 343 –A 198
45Eye drops 30mg per mL (3%) 15mL
12.00
MG 333 –A 202
75Eye drops 5mg per mL (0.5%) 15mL
2.00
MG 168 –P 259
5NEye drops 10mg per mL (1%) 15mL
4.00
MG 13,038
148,951P 259
6PEye drops 20mg per mL (2%) 15mL
8.00
MG 32,729
414,315P 259
8REye drops 40mg per mL (4%) 15mL
16.00
MG 28,554
444,133P 277
8FEye drops 5mg per mL (0.5%) 15mL
2.00
MG 4,174 47,359P 277
9GEye drops 60mg per mL (6%) 15mL
24.00
MG 4,131 82,764
188
S
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
SENSORY ORGANSOPHTHALMOLOGICALSANTIINFLAMMATORY AGENTSANTIINFLAMMATORY AGENTS, NON–STEROIDS
S01BC03 DICLOFENACA 15226 Eye drops 0.1% – – 546 –A 19829 Eye drops 5mg/5mL (0.1%)
1 .3mL, 5– – 19,81
6–
S01BC04
FLURBIPROFENP 8699W Eye drops 300ug per mL(0.03%) single dose 0.4mL 5
– – 2,261 31,635S01BC0
5KETOROLAC TROMETAMOLA 16800 Eye drops 0.5% 5mL – – 37,02
6–
ANTIGLAUCOMA PREPARATIONS AND MIOTICSSYMPATHOMIMETICS IN GLAUCOMA THERAPY
PARASYMPATHOMIMETICS
S01EB01 PILOCARPINE
CARBONIC ANHYDRASE INHIBITORSS01EC01
ACETAZOLAMIDEP 1004W Tablet 250mg 0.7
5GM 33,97
6659,862S01EC0
4BRINZOLAMIDEP 8483L Eye drops 10mg per mL (1%) 5mL
2.00
MG 155,860
3,043,552S01EC0
3DORZOLAMIDEP 8488R Eye drops 20mg per mL (2%) 5mL
6.00
MG 56,593
1,105,122
P 2811Y Eye drops 2.5mg (base) per mL(0.25%) 5mL
0.50 MG 94,580
1,246,650P 2825Q Eye drops 5mg (base)
per mL (0.5%) 5mL1.00 MG 47,7
72629,890S01ED5
1BRIMONIDINE TARTRATE with TIMOLOL MALEATEP 8826M Eye drops 2mg–5mg (base) per
– 101,825
2,789,545S01ED5
1LATANOPROST with TIMOLOL MALEATEP 8895E Eye drops 50ug 5mg per mL (0.005%–0.5%), 2.5 mL –
– 281,277
12,196,961S01ED0
3LEVOBUNOLOLP 1819R Eye drops 2.5mg per mL (0.25%) 5mL 0.50
MG 25,119
304,407S01ED0
1TIMOLOL MALEATEP 1278G Eye drops 2.5mg (base) per mL (0.25%) 5mL 0.50
MG 48,728
590,309P 1279H Eye drops 5mg (base) per mL
(0.5% ) 5mL 1.00MG 302,3
293,980,377P 1925H Eye drops (gellan gum solution)
2.5mg (base) 0.50MG 25,3
81308,273P 1926J Eye
drops (gellan gum solution) 5mg (base) 1.00MG 156,6
342,066,923P 8803H Eye gel 1mg (base) per g
(0.1%) 5g –– 57,9
61703,542S01ED5
1TIMOLOL MALEATE with PILOCARPINE HYDROCHLORIDEP 8567X Eye drops 5mg–20mg per mL
– 264,414
7,257,633S01ED5
1TRAVAPROST WITH TIMOLOL
S01FA01
ATROPINE SULPHATEP 1093M Eye drops 10mg per mL (1%) 15mL
– – 17,959
176,886S01FA0
4CYCLOPENTOLATEA 10596 Eye drops 1%15mL 1 – – 140 –
S01FA05
HOMATROPINE HYDROBROMIDEA 19627 Eye drops 50mg per mL (5%) 15mL
– – 122 –P 2541R Eye drops 20mg per mL (2%) 15mL
– – 13,300
211,910S01FA0
6TROPICAMIDEA 11192 Eye drops 0.5% 1 – – 251 –A 11193 Eye drops 1% 1 – – 127 –
189
S
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
SENSORY ORGANSOPHTHALMOLOGICALSANTIGLAUCOMA PREPARATIONS AND MIOTICSBETA BLOCKING AGENTS
S01ED02 BETAXOLOL HYDROCHLORIDE
P 9057Q Eye drops 0.04–5mg (base) per mL(0.004–0.5%)2.5mL – – 45,663 1,980,356
PROSTAGLANDIN ANALOGUESS01EE03
BIMATOPROSTP 8620Q Eye drops 300ug per mL (0.03%) 3mL
30.00
UG
283,503
10,347,374S01EE0
1LATANOPROSTP 8243W Eye drops 50ug per mL (0.005%) 2.5mL
5.00
UG
1,485,055
54,193,542S01EE0
4TRAVOPROSTP 8597L Eye drops 0.040mg per mL (0.004%)
– – 137,801
5,026,522MYDRIATICS AND CYCLOPLEGICS
ANTICHOLINERGICS
SYMPATHOMIMETICS EXCL. ANTIGLAUCOMA PREPARATIONS S01FB01 PHENYLEPHRINE
190
A 13252 Eye drops 0.12% 1 – – 165 –
188
P 4031E Eye drops 5mg (sulphate)–250ug (nitrate)
– – 4,222 52,426P 4032F Eye drops 5mg
(phosphate)–500ug– – 120 1,4
84S01GA01
NAPHAZOLINEP 4035J Eye drops 1mg per mL (0.1%) 15mL
– – 2,353 28,774S01GA5
1NAPHAZOLINE COMBINATIONSP 4355F Eye drops 250ug–3mgper mL (0.025%–0.3%) 15mL
– – 3,277 41,524
P 1371E Solution for intravitreal injection 3mg in 0.3mL
– – 7,726
15,944,397P 1382R Solution for intravitreal
injection 3mg in 0.3mL– – 9,94
220,425,802
S
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
SENSORY ORGANSOPHTHALMOLOGICALSDECONGESTANTS AND ANTIALLERGICSSYMPATHOMIMETICS USED AS DECONGESTANTS
S01GA51 ANTAZOLINE with NAPHAZOLINE
S01GA55 PHENYLEPHRINE HYDROCHLORIDE with ZINC SULPHATEP 4034H Eye drops 2.5mg–1.2mg per mL (0.25%–0.12%) 15mL – –
675 7,843OTHER ANTIALLERGICS
S01GX08 KETOTIFENA 187
22Eye drops 250mg (base) per mL 2.5mL
– – 1,087 –A 187
23Eye drops 250mg (base) per mL 5mL
– – 5,149 –A 197
91Eye drops 250mg (base) per mL 2.5mL
– – 7,366 –A 197
92Eye drops 250mg (base) per mL 2.5mL
– – 263 –S01GX02
LEVOCABASTINEP 4310W Eye drops 500ug per mL (0.05%) 4mL
– – 3,848 63,882S01GX0
5LODOXAMIDEA 19726 Eye drops 0.1% 10mL – – 653 –
S01GX01
SODIUM CROMOGLYCATEP 1127H Eye drops 20mg per mL (2%) 10mL
– – 32,691
440,593OCULAR VASCULAR DISORDER AGENTS
ANTINEOVASCULARISATION AGENTSS01LA04 RANIBIZUMAB
S01LA01 VERTEPORFINP 1349B Powder for I.V. infusion 15mg– – 234 532,600
189
P 8564R Ocular lubricating gel 2mg–3mg per g (0.2%–0.3%)
– – 108,407
1,012,602P 8676P Eye drops 4mg–3mg per mL – – 374,3 3,476,
CARBOMER 940P 8384G Ocular lubricating gel 2mg
per g (0.2%) 10g– – 171,7
021,612,313P 8514D Ocular lubricating gel 3mg
per g (0.3%) 30– – 18,75
0652,571
S
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
SENSORY ORGANSOPHTHALMOLOGICALSOTHER OPHTHALMOLOGICALSOTHER OPHTHALMOLOGICALS
S01XA20 ARTIFICIAL TEARS and OTHER INDIFFERENT PREPARATIONS
S01XA20
S01XA20 CARBOMER 980P 8578L Eye drops 2mg per g (0.2%) single dose units – – 5,287
185,949S01XA20 CARMELLOSE SODIUM
P 2324H
Eye drops 10mg per mL (1%) single dose units
– – 17,063
602,928P 233
8CEye drops 5mg per mL (0.5%) single dose units
– – 86,114
3,031,258P 854
8XEye drops 5mg per mL (0.5%) 15mL
– – 445,524
4,138,618P 859
3GEye drops 10mg per mL (1%) 15mL
– – 132,812
1,233,567P 882
3JEye drops 2.5mg per mL (0.25%) single dose 0.6mL
– – 6,255
243,126P 882
4KOcular lub gel 10mg per mL (1%) single unit 0.6mL
– – 2,003
64,377S01XA20 HYPROMELLOSE
P 1509K
Eye drops 3mg–1mg per mL (0.3%–0.1%) 15mL
– – 570,706
5,313,244P 295
6NEye drops 5mg per mL (0.5%) 15mL
– – 25,538
236,834P 828
7EEye drops 3mg–1mg per mL (0.3%) 15mL
– – 166,042
1,541,920S01XA2
0HYPROMELLOSE with DEXTRANP 8299T Eye drops (0.3%–0.1%) single dose 0.4mL 28
– – 53,123
1,846,260S01XA2
0PARAFFINP 1750D Compound eye ointment 7g – – 151,9
973,083,839P 1754H Compound eye ointment
3.5g– – 20,93
6406,192S01XA2
0POLYVINYL ALCOHOLP 2681D Eye drops 30mg per mL (3%) 15mL
– – 27,252
253,484P 2682E Eye drops 14mg per mL
(1.4%) 15mL– – 116,2
911,080,608P 8831T Eye drops 14mg per mL
(1.4%) 15mL– – 1,81
716,567P 8832W Eye drops 30mg per mL
(3%) 15mL– – 1,05
29,784
190
S
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
SENSORY ORGANSOTOLOGICALSANTIINFECTIVESANTIINFECTIVES
S02AA10
ACETIC ACIDA 10103 Ear drops 35mL 1 – – 196 –
S02AA01
CHLORAMPHENICOLP 1172Q Ear drops (aqueous) 5mg per mL (0.5%) 5mL
– – 17,890
174,318S02AA1
5CIPROFLOXACINP 2480M Eye drops 3mg per mL (0.3%) 5mL 1
– – 16,200
298,073S02AA3
0NEOMYCIN UNDECENOATE with BACITRACIN ZINCP 2296W Ear ointment 12mg (3.5mg
– – 123,194
917,192CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION
CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATIONS02CA06
DEXAMETHASONE with FRAMYCETIN SULPHATE and GRAMICIDINP 2781J Ear drops
4,117,965S02CA0
2FLUMETHASONE PIVALATE with CLIOQUINOLA 15097 Ear drops 200ug–10mg per mL (0.02%–1%)
– – 51,603–
S02CA03
HYDROCORTISONE with CIPROFLOXACINP 4528H Ear drops 2mg/10mg per mL(0.2–1%) 10mL
– – 106,2842,959,733S02CA0
4TRIAMCINOLONE ACETONIDE with NEOMYCIN SULPHATE GRAMICIDINand NYSTATINP 2971J Ear drops 1mg–2.5mg (base)–250ug–per mL – –
1,042,015P 2974M Ear ointment 1mg–2.5mg (base)–250ug– per
mL – – 340,3962,419,311OTHER OTOLOGICALS
ANALGESICS AND ANESTHETICSS02DA PHENAZONE with BENZOCAINE
A 10094 Ear drops 10mL 1 – – 1,782 –INDIFFERENT PREPARATIONS
S02DC
S02DCA 10803 Ear drops non–nhs 15mLCARBAMIDE PEROXIDE
– – 156 –
P 4176T Ear drops 65mg per mL (6.5%) 10mL
– – 4,446 57,246S02DC DICHLOROBENZENE CHLORBUTOL and
TURPENTINEP 4180B Ear drops 20mg–
50mg–0.1mL per mL (2%–
OIL
– – 5,498 69,464S02DC DOCUSATE SODIUM
P 4199B Ear drops 50mg per mL (5%) 10mL
– – 11,911
154,720
191
S
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
SENSORY ORGANSOPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONSANTIINFECTIVESANTIINFECTIVES
S03AA FRAMYCETIN SULPHATEP 1440T Eye and ear drops 5mg per mL (0.5%) 8 mL – – 69,769
564,744
192
V
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
VARIOUSALLERGENSALLERGENSALLERGEN EXTRACTS
V01AA07 INSECT ALLERGEN EXTRACT –HONEY BEE VENOMP 2886X Injection set containing 550ug – – 2,738 557,477
V01AA07 INSECT ALLERGEN EXTRACT –PAPER WASP VENOMP 2918N Injection set containing 550ug – – 430 87,763
P 1753G
Injection 2mg in 5mL – – 209 8,120P 348
1FInjection 800ug in 2mL – – 2,187 212,
876P 3482G
Injection 2mg in 5mL – – 5,650 359,401
P 6500D Tablet 250mg (dispersible) 28
– – 254 235,720P 9600G Tablet 500mg
(dispersible) 28– – 954 1,786,
577
P 2308L
Tablet 15mg 60.00
MG 6,464
710,623P 587
0YInjection equiv to 300mg folinic acid in 30mL
60.00
MG 411 91,765P 588
6TInjection equiv to 100mg folinic acid in 10mL
60.00
MG 2,561
374,437P 589
0BInjection equiv to 50mg folinic acid in 5mL
60.00
MG 5,224
410,036P 874
0BInjection equiv to 50mg folinic acid in 5mL
60.00
MG 12,722
1,974,877P 881
2TInjection equiv to 100mg folinic acid in 10mL
60.00
MG 6,060
1,643,077P 904 Injection equiv to 300mg 60.0 MG 237 61,1
MESNAP 596
1RSolution for I.V. injection 1g in 10mL
– – 295 13,112P 807
8ESolution for I.V. injection 400mg in 4mL
– – 152 9,216P 807
9FSolution for I.V. injection 1g in 10mL
– – 1,205
173,382
193
V
2007atc ItEM tYPE codE forM and strEngth ddd unIts scrIPts
cost($)
VARIOUSALL OTHER THERAPEUTIC PRODUCTSALL OTHER THERAPEUTIC PRODUCTSANTIDOTES
V03AB15 NALOXONE HYDROCHLORIDE
IRON CHELATING AGENTSV03AC03 DEFERASIROX
V03AC01 DESFERRIOXAMINEP 6113R Powder for injection 500mg vial – – 112 32,513
DRUGS FOR TREATMENT OF HYPERKALEMIAV03AE02 SEVELAMER
P 2142R Sevelamer hydrochloride tablet 800mg 180 6.40 GM 556201,314
V03AE01 SODIUM POLYSTYRENE SULPHONATEP 4470G Oral powder 454g – – 4,344 287,712
DETOXIFYING AGENTS FOR CYTOSTATIC TREATMENTV03AF03 CALCIUM FOLINATE
V03AF01
DRUGS FOR TREATMENT OF HYPERCALCEMIAV03AG SODIUM ACID PHOSPHATE
P 2946C Tablet containing 500mgP–469mgNa–123mgK – – 3,392301,085